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Summary
In spite of major developments in insulin production and methods of delivery, problems remain in 
the day to day management of insulin treated diabetes. One striking difference between currently 
available insulin treatments is the relative difference in weight gain and hypoglycaemia frequency. 
With the use of stable isotope technology the differential effects of 0.5units/kg of subcutaneous 
insulin detemir and NPH insulin on glucose flux, lipid metabolism and brain function during 
hyperglycaemia were investigated. Two protocols were designed, a protocol to look at the action of 
insulin following a period of insulin withdrawal and a second protocol using the gold standard 
euglycaemic and hyperglycaemic hyperinsulinaemic clamp methodology.
Following a period of insulin withdrawal, suppression of endogenous glucose production (glucose 
Ra) was similar with subcutaneous insulin detemir and NPH insulin treatment. With glucose 
concentration decreasing from 9 to 6mmol/l, glucose Ra decreased from 8.2±0.9 to 5.8±0.5 and 
8.2±0.5 to 6.3±0.6pmol/kg/min respectively. However, peripheral glucose uptake (glucose Rd) was 
greater with NPH insulin when compared with insulin detemir at the same glucose concentration. 
With glucose concentration decreasing from 9 to 6mmol/l, insulin detemir was consistently lower at 
11.0±0.6 to 9.5±0.7 and 11.5±0.6 to 11.4±0.4pmol/kg/min with NPH insulin. Suppression of 
lipolysis was delayed with insulin detemir compared to NPH insulin. While eliciting comparable 
effects on glucose flux and lipolysis during the clamp study, insulin detemir compared with NPH 
insulin showed a distinct negative shift in EEG DC-potentials. (ANOVA P=0.03)
Insulin detemir had a lesser effect on peripheral glucose uptake and delayed suppression of lipolysis 
when compared to NPH insulin. Insulin detemir may also affect brain fiinction to a greater extent 
than NPH insulin suggesting that enhanced insulin signalling to the brain may be an important 
mechanism behind the limitation of weight gain observed in people with type 1 diabetes receiving 
subcutaneous detemir treatment.
statement of originality
This thesis and the work to which it refers are the results of my own efforts. Any ideas, data, images 
or text resulting from the work of others (whether published or unpublished) are fully identified as 
such within the work and attributed to their originator in the text or bibliography. This thesis has not 
been submitted in whole or in part for any other academic degree or professional qualification. I 
agree that the University of Surrey has the right to submit my work to the plagiarism detection 
service TumitinUK for originality checks. Whether or not drafts have been assessed, the University 
reserves the right to require an electronic version of the final document (as submitted) for 
assessment as above.
Contents
List of figures............................................................................................................................................. 7
List of tables................................................................................................................................................9
List of abbreviations................................................................................................................................. 10
Chapter 1. Introduction............................................................................................................................ 13
1.1. Diabetes Mellitus..........................................................................................................................13
1.1.1 Definition of diabetes mellitus.......................................................................................... 13
1.1.2. Diagnosis of diabetes mellitus......................................................................................... 16
1.1.3. Epidemiology of type 1 diabetes...................................................................................... 18
1.1.4 Pathophysiology of type 1 diabetes................................................................................19
1.2. Insulin............................................................................................................................................ 22
1.2.1 The insulin molecule..........................................................................................................22
1.2.2. Biosynthesis of insulin......................................................................................................24
1.2.3. The insulin receptor (IR).................................................................................................. 26
1.2.4. Ligand/receptor-binding affinity......................................................................................28
1.2.5. The evolution of insulin....................................................................................................30
1.3. Normal insulin physiology...........................................................................................................33
1.3.1. Endogenous glucose production...................................................................................... 33
1.3.2. Glucose transport and glucose uptake into muscle and adipose tissue......................... 36
1.3.4. Fat and lipid metabolism...................................................................................................37
1.3.5. Lipolysis in adipose tissue................................................................................................38
1.4. Insulin in diabetes.........................................................................................................................39
1.4.1. Hyperglycaemia................................................................................................................ 39
1.4.2. Importance of portal insulin............................................................................................. 43
1.4.3. Challenges of peripheral insulin delivery....................................................................... 44
1.4.4. The endothelial barrier....................... 46
1.4.5. Therapeutic hepatoselective insulins: size matters.........................................................47
1.4.6. Insulin and hypoglycaemia...............................................................................................50
1.4.7. Insulin and weight gain..................................................................................................... 51
1.4.8. Insulin and cancer............................................................................................................. 51
1.5. Using isotopes to measure metabolic flux................................................................................... 53
1.5.1. Isotope dilution technique...............................................................................................53
1.6. Brain function............................................................................................................................... 54
1.7. Hypothesis................................................................................................................  56
4
1.7.1. Aims................................................................................................................................... 57
Chapter 2. Clinical Methodology............................................................................................................58
2.1. Participants and informed ethical consent..................................................................................58
2.2. Study protocol...............................................................................................................................59
2.2.1. Metabolic study preparation for both protocols..............................................................59
2.2.2. Insulin withdrawal protocol............................................................................................. 62
2.2.3. Euglycaemic / hyperglycaemic clamp protocol...............................................................65
Chapter 3. Analytical methods................................................................................................................ 70
3.1. Gas-chromatography mass spectrometry (GC-MS)................................................................... 70
3.2. Experimental protocols................................................................................................................ 70
3.3. Data analysis................................................................................................................................. 77
3.3.1. The Steele Equation..........................................................................................................78
3.4. Statistical analysis.........................................................................................................................80
3.4.1. Power calculation.............................................................................................................. 80
Chapter 4. Results for the insulin withdrawal protocol........................................................................ 82
4.1. Participant characteristics............................................................................................................ 82
4.2. Plasma glucose concentration.....................................................................................................83
4.3. Glucose metabolism.....................................................................................................................85
4.4. Glycerol metabolism................................................................................................................... 95
4.5. Non esterified fatty acids (NEFA)............................................................................................. 97
Chapter 5. Discussion of insulin withdrawal protocol.......................................................................... 99
5.1. Summary of main findings.......................................................................................................... 99
5.2. Factors influencing the results.....................................................................................................99
5.3. Discussion of insulin withdrawal results.................................................................................. 101
5.4. Comparison with similar work.................................................................................................. 107
5.5. Directions for the future............................................................................................................ 110
Chapter 6. Results for euglycaemic / hyperglycaemic clamp protocol...............................................112
6.1. Participant characteristics............................................................................................................ 112
6.2. Plasma glucose concentration................................................................................................... 113
6.3. Glucose metabolism...................................................................................................................115
6.4. Non esterified fatty acids (NEFA)............................................................................................119
6.5. Electroencephalograph (EEG)................................................................................................... 120
6.5.1. DC-potential.....................................................................................................................120
6.5.2. AC-potential.....................................................................................................................125
Chapter 7. Discussion of euglycaemic / hyperglycaemic clamp protocol......................................... 128
5
7.1. Summary of main findings........................................................................................................ 128
7.2. Factors influencing results........................................................................................................ 128
7.3. Discussion of clamp protocol results....................................................................................... 128
7.4. Comparison with similar work..................................................................................................131
7.5. Directions for the future............................................................................................................ 134
Chapter 8. Conclusion............................................................................................................................ 135
Chapter 9. References....................................................................................................   136
Appendix 1: Abstracts............................................................................................................................ 153
Oral presentation Diabetes UK APC Manchester 14th March 2013..................................... 153
Poster Presentation. American Diabetes Association. Chicago. June 2013............................. 154
Appendix 2: Publications.......................................................................................................................155
Herring, R. H. Jones, D. L. Russell-Jones 2013. Hepatoselectivity and the evolution of 
insulin. Diabetes, Obesity and Metabolism. DOT: 10.111 l/dom .l2117..................................155
List of figures
Figure 1. Worldwide comparative prevalence (%) of diabetes in 20 - 70 year age group________ 18
Figure 2. Pathogenesis of type 1 diabetes.______________________________________________21
Figure 3. The amino acid sequence of bovine insulin_____________________________________ 23
Figure 4. The insulin hexamer._____________________  23
Figure 5. Cleavage of proinsulin and C-peptide in the beta cell.____________________________ 25
Figure 6. The normal physiological insulin profile of insulin secretion.______________________26
Figure 7. The insulin receptor________________________________________________________ 27
Figure 8. A typical phylogenetic tree of the animal kingdom.______________________________ 30
Figure 9. The molecular evolution of insulin.____________________________________________32
Figure 10. The avian circulation._____________________________________________________ 33
Figure 11. Insulin concentration before and after glucose load in the hepatic vein, portal vein and
hepatic artery in normal dogs.________________________________________________________ 35
Figure 12. Action of insulin to stimulate glucose uptake. _________________________________ 37
Figure 13. Regulation of lipolysis in adipocytes.________________________________________ 39
Figure 14. The response to incremental doses of intravenous insulin of a patient admitted in diabetis
ketoacidosis.______________________________________________________________________41
Figure 15. Mean rates of appearance and disappearance of glucose for 6 patients during saline
infusion and low-dose and high-dose prandial insulin infusion. ____________________________ 42
Figure 16. Insulin analogues using single letter coding for amino acids.______________________45
Figure 17. The single pool concept in tracer dilution studies.______________________________ 53
Figure 18. A schematic diagram of the endothelial cells that form the blood-brain barrier.______ 54
Figure 19. Screening, Randomization, and Metabolic Studies of Study Participants ___________ 60
Figure 20. Insulin withdrawal protocol.________________________________________________ 63
Figure 21. Euglycaemic / hyperglycaemic hyperinsulinaemic clamp protocol_________________66
Figure 22. EEG electrode positions for AC and DC potential recordings. ____________________ 69
Figure 23. MOX-TMS derivative of glucose.____________________________________________72
Figure 24. MOX-TMS derivative of [6,62H2] glucose.___________________________________ 72
Figure 25. Selected ion chromatograms for m/z 319 and m/z 321 in a plasma sample.__________ 73
Figure 26. Glucose enrichment calibration curves.________________________________________74
Figure 27. Glycerol enrichment calibration curve.________________________________________77
Figure 28. EEG DC potential recordings._______________________________________________ 79
Figure 29. Plasma glucose concentration plotted against time in the insulin withdrawal protocol. 84 
Figure 30. Glucose rate of appearance (Ra) plotted against time from subcutaneous injection in the
insulin withdrawal protocol._________________________________________________________ 86
7
Figure 31. Glucose rate of disappearance (Rd) plotted against time from subcutaneous injection in
the insulin withdrawal protocol.______________________________________________________ 87
Figure 32. Plasma glucose Ra and Rd in the detemir group plotted against time in the insulin
withdrawal protocol._______________________________________________________________ 88
Figure 33. Plasma glucose Ra and Rd in the NPH group plotted against time in the insulin
withdrawal protocol_______________________________________________________________ 89
Figure 34. Glucose rate of appearance (Ra) at each glucose concentration as the plasma glucose
concentration decreased in the insulin withdrawal protocol._______________________________ 92
Figure 35. Glucose rate of disappearance (Rd) at each glucose concentration as the plasma glucose
concentration decreased in the insulin withdrawal protocol._______________________________ 93
Figure 36. Metabolic clearance rate of glucose at each glucose concentration in the insulin
withdrawal protocol._______________________________________________________________ 94
Figure 37. Plasma glycerol concentration plotted against time in the insulin withdrawal protocol in
the insulin withdrawal protocol.______________________________________________________ 95
Figure 38. Glycerol Ra % change from subcutaneous insulin injection in the insulin withdrawal
protocol. _________________________________________________________________________96
Figure 39. NEFA concentrations plotted against time in the insulin withdrawal protocol._______ 97
Figure 40. Plasma glucose concentration plotted against time in the clamp protocol.__________ 114
Figure 41. Glucose infusion rates plotted against time in the clamp protocol._________________114
Figure 42. Glucose rate of appearance (Ra) plotted against time in the clamp protocol.________ 115
Figure 43. Plasma glucose rate of disappearance (Rd) against time in the clamp protocol.______ 116
Figure 44. Metabolic rate of clearance (MCR(s)) in the clamp period.______________________ 117
Figure 45. Plasma NEFA concentration plotted against time in the clamp protocol.___________ 119
Figure 46. The mean DC-potential for all subjects and all electrodes plotted against time from
subcutaneous injection.____________________________________________________________ 120
Figure 47. Mean DC potentials for each individual frontal electrode following subcutaneous
injection.________________________________________________________________________ 122
Figure 48. Mean DC potentials for each individual central electrode following subcutaneous
injection.________________________________________________________________________ 123
Figure 49. Mean DC potentials for each individual central electrode following subcutaneous 
injection.________________________________________________________________________ 124
8
List of tables
Table 1. Classification of Diabetes Mellitus_____________________________________________13
Table 2. Blood sampling scheme for the insulin withdrawal protocol ______  64
Table 3. Blood sampling scheme for the euglycaemic hyperglycaemic clamp protocol_________ 67
Table 4. Insulin withdrawal subject characteristics.______________________________________ 82
Table 5. Time in mins to reach a blood glucose concentration of >7mmol/l following intravenous
insulin withdrawal.________________________________________________________________ 83
Table 6. Time in mins to reach the defined end-point for each metabolic study._______________ 85
Table 7. A summary of the glucose measurements plotted against time before and after
subcutaneous injection of insulin detemir and NPH insulin.  _____________________________ 90
Table 8. The number of participant observation for glucose Ra and Rd at each glucose
concentration._____________________________________________________________________91
Table 9. The effect of detemir and NPH on glycerol Ra metabolism. 97
Table 10. Participant characteristics in the euglycaemic and hyperglycaemic hyperinsulinaemic
clamp protocol.___________________________________________________________________112
Table 11. A summary of the effect of insulin detemir and NPH insulin on glucose metabolism in the
euglycaemic and hyperglycaemic hyperinsulinaemic clamp protocol. ______________________ 118
Table 12. Mean DC potentials for each electrode during the euglycaemic period.____________ 121
Table 13. Mean DC potentials for each electrode during the hyperglycaemic period.__________ 121
Table 14. EGG AC potential band frequencies._________________________________________125
Table 15. Comparison between treatment and mean spectral power (uV2 per Hz) at each band
fi*equency during the eyes open period.  ______________________________________________ 126
Table 16. Comparison between treatment and mean spectral power (uV2 per Hz) at each band 
frequency during the eyes closed period.______________________________________________ 127
List of abbreviations
ACSB n-(4-antipyryl)-3-chloro-5-sulphonate-p-benzoquinoneimine
ADA American Diabetes Association
ADP Adenosine diphosphate
ATP Adenosine triphosphate
ALT Alanine transferase
ANOVA Analysis o f variance
BMI Body mass index
CEDAR Centre for Diabetes Endocrinology and Research
CNS Central nervous system
CV Coefficient o f variation (ratio o f the standard deviation to the mean)
DAP Dihydroxyacetone-phosphate
DCHBS3, 5-dichloro-2-hydroxybenzene sulphonic acid
EEG Electroencephalography
EGP Endogenous Glucose Production
EGP Peripheral Glucose Uptake
ELISA Enzyme-linked immunosorbent assay
FFA Free fatty acid
GCMS Gas chromatography mass spectrometry
GH Growth hormone
HLA Human leucocyte antigen
HPLC High performance liquid chromatography
IDF International Diabetes Federation
ISF Interstitual fluid
K D T Karolinska Drowsiness Test
NICE National Institute o f Clinical Excellence
NEFA Non-esterifiedfatty acids
MDI Multiple daily injections
MHC Major Histocompatibility complex
OGTT Oral glucose tolerance test
PI (3) K  Phosphoinositide (3) kinase
RIA Radioimmunoassay
SD Standard deviation
SH2 SRc homology 2
10
TOOS N-ethyl-N-(2hydroxy~3-sulphopropyl) m-tolmdine
WHO World Health Organisation
4AAP 4-aminoantipyrine
11
Acknowledgements
I would like to thank a number of people, without whom this MD would not have been possible.
I would like to thank Professor David Russell-Jones for his support and enthusiasm throughout the 
study and specifically to acknowledge his role in designing the metabolic study protocol and 
securing funding. I would also like to thank my second educational supervisor. Professor Margot 
Umpleby for her invaluable support in understanding stable isotope technology and providing 
guidance on understanding available literature and insightful comments on the thesis.
I am also extremely grateful to Fariba Shojaee-Moradie for providing technical assistance with the 
metabolic studies and Dr Nicola Jackson and Joanne Batt for their invaluable guidance and 
assistance with the laboratory analysis.
I am indebted to Richard Knight and Professor Derk Jan Dijk for sharing their clinical expertise in 
the field of brain recording and assistance with recording and interpreting the 
electroencephalography data.
I would also like to thank the Sarah Close, clinical research nurse at Royal Surrey County Hospital 
for her support during the metabolic studies. Finally but most importantly, I would like to thank all 
the subjects who volunteered to take part in the study.
This research was funded by Novo Nordisk A/S
12
Chapter 1. Introduction
1.1. Diabetes Mellitus
1.1.1 Definition of diabetes mellitus
Diabetes mellitus is a chronic condition characterised by elevated blood glucose levels and results 
from the insufficiency of or diminished effectiveness of endogenous insulin. It is of diverse 
aetiology and pathogenesis and should not be regarded as a single disease. Predominant types are 
type 1 diabetes, type 2 diabetes, diabetes secondary to other pancreatic disease and endocrine 
disease and diabetes of onset in pregnancy (NICE 2007). The classification of diabetes mellitus is 
summarised in Table 1.
Table 1. Classification of Diabetes Mellitus
Adapted from the American Diabetes Association Diagnosis and Classification of Diabetes Mellitus. (American 
Diabetes Association 2009.
I. Type 1 diabetes
A. Immune mediated
B. Idiopathic
II. Type 2 diabetes
III. Other specific types
A. Genetic defects of beta-cell function
B. Genetic defects in insulin action
C. Diseases of the exocrine pancreas
D. Endocrinopathies
E. Drug - or chemical induced
F. Infections
G. Uncommon forms of immune-mediated diabetes
H. Other genetic syndromes sometimes associated with diabetes
IV. Gestational diabetes mellitus
Immune mediated type 1 diabetes accounts for 5-10% of those with diabetes. The World Health 
Organisation has defined type 1 diabetes as a condition of deficiency of insulin secretion from the 
pancreas, usually due to autoimmune damage to the insulin producing cells. The destruction of beta 
cells leads to absolute insulin deficiency and people require life long exogenous insulin therapy. 
The clinical condition is generally recognised by elevated blood glucose levels occurring in mainly 
younger and thinner people in the absence of other precipitating causes. The acute presentation may
13
include polyuria, polydipsia and weight loss, but type 1 diabetes can also be life threatening due to 
the development of hyperglycaemia with ketoacidosis.
Type 2 diabetes accounts for at least 90% of all cases of diabetes. It is characterised by insulin 
resistance and relative insulin deficiency, either of which may be present when diabetes is clinically 
diagnosed. The diagnosis of type 2 diabetes usually occurs after the age of 40 but can occur earlier, 
especially in populations with high diabetes prevalence. Type 2 diabetes can remain undetected for 
many years and the diagnosis is often made following the development of associated complications 
or incidentally through an abnormal blood or urine glucose test. It is often, but not always, 
associated with obesity, which itself can cause insulin resistance and lead to elevated blood glucose 
levels.
Chronic hyperglycaemia leads to significant morbidity and mortality. It is associated with the 
development of micro vascular complications; retinopathy, neuropathy and nephropathy and the 
development of macro vascular complications; myocardial infarction, stroke and peripheral vascular 
disease (Selvin et al. 2004). The benefits of early treatment of hyperglycaemia have long lasting 
beneficial effects both in terms of microvascular and macrovascular disease. The benefits have been 
shown in two landmark trials; the Diabetes Control and Complications Trial (DCCT) and United 
Kingdom Prospective Diabetes Study (UKPDS). The DCCT was a medical study conducted by the 
United States National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The 
study population included a total of 1,441 volunteers with type 1 diabetes between 1983 and 1993. 
It showed a reduction in the risk of progressive retinopathy and nephropathy resulting from 
intensive therapy in patients with type 1 diabetes and this reduction persists for at least four years, 
despite increasing hyperglycaemia (The DCCT research group. 2000). The UKPDS, released in 
1999, found similar results for patients with type 2 diabetes. In addition, the 10 years of post-trial 
follow-up results showed early loss of the glycaemic differences but a continued reduction in 
microvascular risk and emergent risk reductions for myocardial infarction and death fi-om any cause 
(Holman et al. 2008).
Early treatment of hyperglycaemia has long lasting beneficial effects in preventing long term 
complications but it is still unclear how aggressively the blood glucose concentration should be 
lowered, especially in people at high risk of developing diabetes complications. The Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) study was designed to investigate whether 
intensive therapy to target normal glycated hemoglobin levels, would reduce cardiovascular events 
in people with type 2 diabetes who had established cardiovascular disease or additional
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cardiovascular risk factors. The intensive group aimed for a HbAlc less than 6% and the standard 
group 7.0-7.9%. This could be achieved with any glucose lowering medication and suggested 
algorithms were provided. The lower glycated hemoglobin levels in the intensive-therapy group 
were associated with a greater exposure to drugs from eveiy class. There were also more frequent 
changes in the dose or the number of drugs used. The glucose- lowering regimen was modified by 
adding or removing a drug or by increasing or decreasing the dose of an oral agent or insulin (by 
>10% of the previous dose) a mean number of 4.4 times per year in the intensive-therapy group and 
2.0 times per year in the standard-therapy group. In the intensive group 73% received insulin and 
55% received insulin in the standard group. However, three and half years into the trial the 
intensive treatment arm was discontinued due to higher all cause mortality. 1.42% of people died 
each year compared with 1.14% a year in the standard intervention arm (hazard ratio (HR) 1.22,
95% confidence interval (Cl) 1.01 to 1.46; P=0.04) (Nilsson 2010). These findings identify a 
previously unrecognised harm of intensive glucose lowering in high-risk people with type 2 
diabetes. Interestingly, the Action in Diabetes and Vascular Disease (ADVANCE) study which had 
similar study aims but with an intensive group HbAlc target less than 6.5% and standard group 7.0- 
7.9%, achieved a positive trend towards reduction in the risk of cardiovascular death (12%), 
although this was not statistically significant (Gerstein et al. 2008). People who were randomly 
assigned to undergo intensive glucose control were given gliclazide (modified release, 30 to 120 mg 
daily) and were required to discontinue any other sulphonylurea. The standard group did not receive 
sulphonylurea treatment. Additional glucose lowering medication could then be introduced, and 
insulin if needed, to both groups. In the intensive group 40.5% received insulin and 24%received 
insulin in the standard group.
In the ACCORD study, the intensive group experienced a higher number of hypoglycaemic 
episodes than the standard therapy group; therefore one suggestion for the higher mortality rate was 
a link between hypoglycaemia and a QT-mediated effect on coronary vascular disease. A 
retrospective epidemiological analysis of the ACCORD study was initiated to determine this 
possible association. It concluded that symptomatic severe hypoglycaemia did not appear to account 
for the difference in mortality between the two study arms up to the time when the ACCORD 
intensive glycaemia arm was discontinued (Bonds et al. 2010). In summary, early treatment of 
hyperglycaemia has long lasting beneficial effects both in terms of microvascular and 
macrovascular. However, aggressive glucose lowering treatment should be undertaken with caution 
in high-risk people.
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1.1.2. Diagnosis of diabetes mellitus
The current diagnostic criteria for diabetes reflects the concentration of plasma glucose at which 
there is a substantial increased risk of diabetes related microvascular complications, in particular the 
development of retinopathy (American Diabetes Association 2008).
The World Health Organisation (WHO) and International Diabetes Federation (IDF) produced the 
following criteria for the diagnosis of diabetes mellitus:
Symptoms o f diabetes plus plasma glucose concentration >200mg/dl (ll.lmmol/l) at any time o f  
day without regard to the time since last meal. The classic symptoms o f diabetes include polyuria,
polydipsia and unexplained weight loss.
Or
Fasting plasma glucose > 126mg/dl (7.0mmol/l). Fasting is defined as no calorie intake fo r  at least
8 hours.
Or
2-hour plasma glucose >200mg/dl (11. Immol/l) during an OGTT. The test should be performed as 
described by WHO, using a glucose load containing the equivalent o f 75mg anhydrous glucose
dissolved in water.
In the absence of unequivocal hyperglycaemia with acute metabolic decompensation, these criteria 
should be confirmed by repeat testing on a different day.
Once a diagnosis of diabetes has been established. It is important to distinguish the underlying 
aetiology so that the patient is offered successful treatment. The diagnosis is not always 
straightforward and the correct diagnosis may only become apparent with time. The National 
Institute of Clinical Excellence has produced guidance to assist the physicians determine the 
underlying aetiology (NICE 2007).
“Where diabetes is diagnosed, but type 2 diabetes suspected, the diagnosis of type 1 diabetes should 
be considered if: ketonuria is detected, weight loss is marked or the person does not have features of 
the metabolic syndrome or other contributing illness. When diabetes is diagnosed in a younger 
person, the possibility that the diabetes is not type 1 diabetes should be considered if they are obese 
or have a family history of diabetes, particularly if they are of non-white ethnicity. Tests to detect 
specific auto-antibodies or to measure C-peptide deficiency should not be regularly used to confirm
16
the diagnosis of type 1 diabetes. They should be considered if predicting the rate of decline of islet 
B-cell function would be useful in discriminating type 1 from type 2 diabetes” (NICE 2007).
Monogenic diabetes
Diabetes may result from mutations of a single gene, and monogenic forms of diabetes account for 
1-2% of cases in young people. Monogenic diabetes should be suspected in those who develop 
diabetes under the age of 6 months, in familial diabetes, when there is mild to moderate fasting 
hyperglycaemia (5.5-8 mmol/1), or where there are extrapancreatic features. The gene is usually 
inherited but may arise spontaneously. Most forms of monogenic diabetes are caused by a reduced 
ability to process or secrete insulin, but rare variants result in insulin resistance.
Maturity onset diabetes of the young (MODY) is the commonest form of monogenic diabetes. 
Mutations in at least ten genes have been shown to lead to a MODY phenotype, but 3 genes account 
for more than 90% of the reported cases in the United Kingdom (Thanabalasingham and Owen. 
2011). These are due to mutations in the genes encoding the enzyme glucokinase (GCK) and the 
nuclear transcription factors hepatocyte nuclear factors HNFl A and HNF4A. MODY differs from 
type 1 diabetes as people with MODY lack islet cell autoantibodies, they are not prone to ketosis 
and there is no increased frequency of high-risk alleles such as DR3 and DR4 (Owen. 2013).
GCK mutations result in modest elevations of fasting glucose that are present from birth and usually 
asymptomatic. GCK is a key regulatory enzyme in the beta cell, and has been called the pancreatic 
glucose sensor. Heterozygous inactivating mutations cause mild fasting hyperglycaemia, rare 
homozygous inactivating mutations result in more severe hyperglycaemia presenting as permanent 
neonatal diabetes mellitus. Other GCK mutations result in oversecretion of insulin and present with 
hyperinsulinémie hypoglycaemia.
The other common forms of MODY are due to mutations in the genes encoding nuclear 
transcription factors of the hepatocyte nuclear factor (HNF) family, the common variants being 
HNFl a and HNF4a, which account for 50% and 10%, respectively, of cases in the United 
Kingdom. Defects lead to progressive beta-cell dysfunction, with normoglycaemia in childhood and 
diabetes presenting in the 2nd-4th decade. Treatment requirements increase with time and insulin is 
often required for its management. Poor control is associated with the characteristic long-term 
complications of diabetes.
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1.1.3. Epidemiology of type 1 diabetes
The number of people with diabetes is increasing due to population growth, ageing, urbanisation 
and reduced physical activity. In the 5th edition IDF Diabetes Atlas, the prevalence of diabetes 
mellitus was estimated at 366 million people and projected figures forecast that by 2030 this will 
have risen to 552 million (International Diabetes Federation 2011). The global prevalence of 
diabetes in 2011 was reported as 8.3% and projected to be 9.9% in 2030. Figure 1 shows the 
worldwide comparative prevalence of diabetes in 20-70 year age group. A comparative prevalence 
is adjusted to the world population. It has been calculated assuming every country and region has 
the same age profile, which allows comparison between countries. It does not give the prevalence of 
each country’s population that has diabetes. Most of this increasing prevalence reflects the global 
obesity “epidemic” and the spectrum of impaired glucose tolerance and type 2 diabetes but there is 
also an increase in the prevalence of type 1 diabetes (Onkamo et al. 1999).
'N
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Figure 1. Worldwide comparative prevalence (%) of diabetes in 20 - 70 year age group
(International Diabetes Federation. Comparative prevalence is provided as a percentage and is adjusted to the 
world population (International Diabetes Federation. 2011).
There is a striking variation in the incidence of type 1 diabetes between populations and it is still
unclear to what extent this is due to differences in genes or environment. Worldwide the incidenee
of type 1 diabetes ranges from 1.9 to 7.0/100,000/yr in Africa, 0.13 to 10/100,000/yr in Asia,
4.4/100,000/yr in Australasia, 3.4 to 36/100,000/yr in Europe, 2.62 to 20.18/100,000/yr in the
Middle East, 7.61 to 25.7/100,000/yr in North America, and 1.27 to 18/100,000/yr in South
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America. (Adeghate et al. 2006) The largest intercontinental variation is seen in Europe, with the 
highest in Finland and Sardinia and the lowest in Greece (Karvonen et al. 1993).
Worldwide, type 1 diabetes accounts for greater than 85% of all diabetes cases in individuals less 
than 20 years of age. Prospective national and large international registries including DiaMond, 
EURODIAB and SEARCH have demonstrated an increasing trend in incidence in most regions of 
the world over the last few decades but the overall annual increase is estimated to be around 
3%(Intemational Diabetes Federation 2011). The DiaMond project was initiated by the World 
Health Organisation in 1990 to monitor trends in childhood diabetes (The DiaMond Project Group. 
2006). An initial report in 2000 described the incidence of type 1 in children under 14 years of age 
in 50 countries. The lowest incidence was reported (<1/100,000 per year) in the populations from 
China and South America and the highest (>20/100,000 per year) was reported in Sardinia, Finland, 
Sweden, Norway, Portugal, UK, Canada and New Zealand (The DiaMond Project Group 2006). 
The EURODIAB Study group have also monitored the geography and changing incidence of type 1 
diabetes in children across Europe for the past 25 years (EURODIAB. 2000). The rapid rate of 
increase in children aged less than 5 years is of particular concern (Patterson et al. 2009).
The incidence of type 1 diabetes varies by ethnicity, age and sex. The incidence rate of type 1 
diabetes in 2002-2003 peaked in age groups 5-9 years and 10-14 years (Dabelea et al. 2011). In the 
United States, the SEARCH for Diabetes in Youth (<20 years) study showed rates were highest in 
non-Hispanic white youth as compared to other ethnicities. Interestingly SEARCH has shown 
slightly higher rates in females as compared to males (RR, 1.028; 95% Cl, 1.025 - 1.030) 
(EURODIAB. 2000). In adults there seems to be male excess in incidence, especially in the age 
group 25 to 29 years (Kyvik et al. 2004). Seasonal variation in incidence has also been reported 
with the highest incidence in autumn and winter and lowest in summer (Kalliora et al. 2011).
1.1.4 Pathophysiology of type 1 diabetes
The majority of type 1 diabetes cases are attributable to an autoimmune mediated destruction of 
beta cells (Type 1 A), while only a minority of cases results from an idiopathic destruction or failure 
of beta cells (type IB) of which most are of African or Asian ancestry. Markers of the immune 
destruction of p cells in the pancreas include islet cell antibodies, autoantibodies to insulin, 
antibodies to glutamic acid decarboxylase and autoantibodies to the tyrosine phosphatase LA-2 and 
1A2-P (American Diabetes Association. 2009).
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Type 1 diabetes is one of the most widely studied complex genetic disorders, and the genes in the 
human leukocyte antigen (HLA) system are reported to account for approximately 40-50% of the 
familial aggregation of type 1 diabetes. The histocompatibility complex is divided into three 
regions, class I, class II, class III. This group of genes are found on chromosome 6. The major 
genetic determinants of type 1 diabetes are polymorphisms of class II HLA genes encoding DQ and 
DR alleles (Noble & Valdes 2011). These molecules on the surface of antigen presenting cells (e.g. 
macrophages) bind and present short peptides that are recognised by T cell receptors of T 
lymphocytes. For Caucasians with type 1 diabetes the most common diabetes associated haplotypes 
are DR3 and DR4. There are specific haplotypes that also provide protection from diabetes e.g. the 
HLA DR2 (Kulmala et al. 2000).
The concordance for type 1 diabetes is approximately 50% for monozygotic twins and the risk to a 
first degree relative is around 5%. The higher concordance rate in monozygotic twins than in 
dizygotic twins suggests the importance of genetic factors in the aetiology of type 1 diabetes. The 
fact that the concordance rate in monozygotic twins is not 100% implies that environmental factors 
also play a part (Redondo et al. 1999). A complex interaction of genetic and environmental factors 
is therefore thought to trigger immune mediated diabetes.
Seasonal variation in the incidence of type 1 diabetes suggests that certain viruses play a role 
although causalities between viruses and the diabetogenic process are still elusive and difficult to 
prove. Viruses commonly implicated include rubella, cytomegalovirus, mumps and Coxsackie’s 
virus B4. Children of mothers who expressed Coxsackie B virus IgM at delivery have been shown 
to be at increased risk for developing childhood type 1 diabetes (Dahlquist et al. 1995) and the 
association of type 1 diabetes with mumps and rubella has recently been supported by an 
epidemiological study using the Italian insulin dependent diabetes registry (Ramondetti et al. 2012). 
There may be two possible roles for viruses in the pathogenesis of type 1 diabetes mellitus. The first 
possible role is acute cytolytic infection of beta cells (e.g. Coxsackie B viruses), which may 
sometimes induce diabetes in genetically predisposed individuals, and the other possible role is 
slow and persistent infection (e.g. congenital cytomegalovirus and rubella), which may induce 
autoimmunity.
The hygiene hypothesis stems from observations that atopic disorders such as asthma are more 
common in affluent than in traditional societies, their prevalence rising with increasing 
modernisation, and that such disorders are less frequent in children in large families or those 
families receiving day care than in children in small families or those not in day care. These
20
findings suggest that children in these circumstances are less exposed to infections or other immune 
challenges early in life that act as protective environmental influences (Daneman, 2006)
Several studies have also suggested an inverse relationship between vitamin D intake in pregnancy 
or early life and type 1 diabetes (Luong et al. 2005). Recently, a researeher group conducted a 
prospective, nested case-control study among US active-duty military personnel with serum in the 
US Department of Defense Serum Repository and found that low 25-hydroxyvitamin D levels may 
predispose healthy, young, non-Hispanic white adults to the development of TID. (Mungar et al. 
2013). The observation that vitamin D supplementation does not affect development of diabetes in 
the non-obese diabetic mouse, whereas mice rendered deficient in vitamin D more readily develop 
diabetes, suggests that the presumed benefit of vitamin supplementation in humans is mainly due to 
avoidance of vitamin D deficiency (Gale et al. 2013)
The early introduction of cow’s milk formula may also be assoeiated with the development of type 
1 diabetes. Cow’s milk contains bovine insulin that may induce insulin-binding antibodies in 
children. This immune response to insulin may later be diverted into immunity against beta-cells in 
some individuals (Vaarala et al. 1999).
Figure 2 suimnarises the pathogenesis of type 1 diabetes. The disease is divided into a series of 
stages beginning with genetic susceptibility and ending with complete islet beta cell destruction.
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Figure 2. Pathogenesis of type 1 diabetes.
Human leukocyte antigen (HLA), islet cell antibodies (ICA), insulin antibodies (lAA), anti-glutamic acid 
decarboxylase (Anti-GAD). (Eisenbarth et al. 1986)
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1.2. Insulin
1.2.1 The insulin molecule
The first experimental proof that diabetes is of pancreatic origin was by Von Mehring and 
Minkowski in 1889, who acknowledged the importance of the pancreas in carbohydrate metabolism 
Following the successful removal of the pancreas from a dog. Von Mehring and Minkowski 
observed all the symptoms of severe diabetes such as high blood glucose levels, glycosuria, and 
finally ketosis and coma.
In 1905, Ernest Henry Starling (1866-1927) coined the term "hormone" to designate the chemical 
messengers of the body’s endocrine glands. Sir Edward Schafer, who was Professor of Physiology 
in Edinburgh, first named insuline and described its actions. He did so in a book titled ‘The 
Endocrine Organs’, based on a lecture series he gave in California in 1913 (Green. 1916). Schafer 
avoided using the word ‘hormone opting to use ‘autocoid’ being a substance of excitatory action 
and ‘chalone’ one with inhibitory action (Sonksen & Sonksen. 2000). He suggested “insuline” was 
mainly inhibitory and therefore its action was to suppress glucose production.
The successful extraction and introduction of the active principle, insulin was in 1921 by Banting, 
Best, Collip, and Macleod. These developments revolutionised the management of type 1 diabetes 
and was one of the great medical discoveries of the 20th century. Within months of the discovery, 
the manufacturing of insulin began. By 1923 insulin was readily available through Connaught 
Laboratories in Canada, Eli Lilly and Co in the USA and the Nordisk Insulin Laboratory in 
Denmark (De Meyts. 2004).
Insulin was one of the first proteins to be isolated, sequenced and to have its three dimensional 
structure identified. Fred Sanger sequenced the insulin molecule amino acids in 1955, earning him 
his first Nobel Prize in 1958. The amino acid sequence for bovine insulin is shown in figure 3 
Bovine insulin contains 51 amino acids arranged in two chains, an A chain of 21 residues (A1-A21) 
and a B chain of 30 residues (B1-B30), which by themselves are inactive. Sanger later discovered 
the three-disulphide bonds in the unoxidised molecule. There are two inter-chain disulphide bonds 
between A7-B7 and A20-and B19, and an additional disulphide that connects A6-and A11 within 
the A chain (Sanger. 2002).
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Figure 3. The amino acid sequence of bovine insulin 
(Sanger 2002).
The first attempt at insulin crystallisation was by John Abel (Abel. 1926). Over the subsequent 
years the crystallisation method was standardised and eventually led to the discovery by Scot in 
1934 of the need for zinc to secure crystallisation (Scott and Fisher. 1935). It wasn’t until the 
sequencing of the primary structure of insulin by Sanger in 1955 that Schlichtkrull was finally able 
to establish the conditions for reliable crystallisation and define that two crystal forms existed with 
either two or four zinc atoms per six insulin molecules (Marcher. 1960).
Early X ray crystallography identified the rhombohedral structure of insulin (Crowfoot. 1935) and 
later work continued by Dorothy Hodgkins nee Crowfoot confirmed the 3-dimensional hexamer of 
insulin with a molecular weight of 36000 Daltons earning her a Nobel Prize. At neutral pH in the 
presence of zinc, it consisted of three slightly asymmetric dimers each with a molecular weight of 
12000 Daltons and is shown in figure 4.
Figure 4. The insulin hexamer.
One monomer of each dimer is coloured in dark blue and the second in light blue. Zinc is yellow 
(De Meyts 2004).
23
Three helical regions are included in the secondary structure of the molecule, two of which are in 
the A chain (A1-A7, A14-A20) and one in the B chain at the N-terminal end (Blundell et al. 1971). 
The folding of the B chain around the A chain core is formed with disulphide bridges between 
cysteine residues. Insulin has a hydrophobic core with polar residues on the surface. The non polar 
residues, mainly on the B chain, are buried during the formation of the dimers. In the presence of 
zinc ions or other divalent metal ions three dimers assemble to form a hexamer of insulin monomers 
(Blundell etal. 1971).
In 1978, the first successful production of human insulin was produced by recombinant DNA 
technology in Escherichia coli by Robert Crea and David Goeddell (Goeddell et al. 1979). Human 
insulin differs from bovine insulin at positions A8, AlO and B30, where it has threonine, isoleucine 
and threonine, respectively (Clark et al. 1982). Human insulin was first clinically used in 1981 
where it appeared to be a safe alternative to porcine or bovine insulin (Clark et al. 1982).
1.2.2. Biosynthesis of insulin
The (3 cells of the pancreas manufacture the precursor of insulin in the rough endoplasmic 
reticulum. Preproinsulin is a single chain polypeptide, which consists of proinsulin extended at the 
amino terminus by a 24 amino acid signal peptide region of hydrophobic residues (Steiner et al. 
1980). Proinsulin is composed of the A and B subunits joined by the C peptide region (Steiner et al. 
1971).
Secretory vesicles
Proinsulin is packed in clathrin coated secretory vesicles in the Golgi apparatus of the beta cell 
along with proinsulin conversion enzymes. The immature clathrin coated granule is mildly acidic, 
and rich in proinsulin. As granules mature, they become more acidic which allows for activation of 
the proinsulin conversion endoproteases. Proinsulin is then converted to insulin and C-peptide 
(Molinete et al. 2001). Bndopeptidases prohormone convertase PCl/3 cleaves proinsulin first at the 
B chain/C-peptide (Arg-Arg) cleavage site, followed by carboxypeptidase E (CPE) to generate the 
des-31,32-proinsulin intermediate, a preferred substrate for cleavage by PC2 at the C-peptide/A 
chain site (Lys-Arg). The cleavage process is shown in Figure 5. Insulin is then stored in secretory 
granules in |3 cells as hexamers, which form in the presence of zinc (Evans et al. 2011).
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Figure 5. Cleavage of proinsulin and C-peptide in the beta cell.
Carboxypeptidase (CPE), protease candidate 1 (PCI), protease candidate 2 (PC2), protease candidate 3 (PC3). 
(Steiner 2011).
Insulin secretion is initiated by the interaction of several factors. The intracellular metabolism of 
glucose activates GLUT 2 receptors in the (3 cell, which leads to the metabolism of ATP. An 
increase in ATP closes the ATP sensitive potassium channel of the pancreatic (3 cell and leads to 
membrane depolarisation. This causes voltage gated calcium channels to open and the resulting 
influx of calcium leads to insulin release (O'Rahilly. 1997).
The release of insulin from the (3 cells occurs in a rapid and pulsatile fashion with secretory bursts 
occurring every 4-15 minutes superimposed on basal release (Simon & Brandenberger. 2002). The 
normal physiological profile of insulin secretion is shown in figure 6. This "first phase" of insulin 
secretion promotes peripheral utilisation of the prandial nutrient load, suppresses hepatic glucose 
production, and limits postprandial glucose elevation. First-phase insulin secretion begins within 2 
minutes of nutrient ingestion and continues for 10 to 15 minutes. The second phase of prandial 
insulin secretion follows, and is sustained until normoglycemia is restored. Insulin has a short half- 
life of 4-6 minutes and its effects are mediated by binding to the insulin receptor present in all 
insulin sensitive tissues. Small amounts of proinsulin and the C-peptide are secreted along with 
insulin. C-peptide is thought to have a beneficial influence on blood flow and tissue health. 
Moreover, C-peptide and insulin are secreted in equivalent amounts, suggesting that the C-peptide
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is retained within the mature secretory granules along with insulin after the proteolytic cleavage of 
proinsulin within the maturing granules (Steiner. 2011),
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Figure 6. The normal physiological insulin profile of insulin secretion.
The black arrows represent food intake. (Kruszynska et al. 1987).
1.2.3. The insulin receptor (IR)
The insulin receptor belongs to the family of receptor tyrosine kinases (RTKs) that comprise 59 
members in the human genome. Other members include receptors for IGF-1, IGF-2, epidermal 
growth factor, platelet derived growth factor and vascular derived growth factor (De Meyts. 2004). 
Insulin and IGF-1 differ from other members as their receptors are synthesized as proreceptors that 
undergo proteolytic cleavage into two subunits. They have a disulphide-linked dimeric structure 
made of two extracellular a subunits that contain the ligand binding domains, and two 
transmembrane p subunits that contain the tyrosine kinase domain. A schematic view of the insulin 
receptor can be seen in figure 7. The structure of the insulin receptor has been highly conserved 
throughout evolution even more than that of insulin itself (Muggeo et al. 1979).
The insulin receptor has a modular structure encoded by a gene with 22 exons and 21 introns. The 
short exon 11 is alternatively spliced, resulting in two isofomis (A and B) that differ slightly in 
affinity for insulin. The B isofonns binds the IGFs with a lower affinity than insulin and the A
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isofonn has significantly higher affinity for IGF-I and especially IGF-II than insulin (De Meyts & 
Whittaker. 2002).
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Figure 7. The insulin receptor
a. shows a cartoon of the a2p2 structure of the insulin receptor. The left half of the diagram shows the 
boundaries of the 22 exons of the insulin-receptor gene. The right half of the diagram outlines the predicted 
boundaries of the protein modules. Panel b shows the supra-domain organization of the insulin receptor. LI and 
L2, large domains 1 and 2 (leucine-rich repeatsl34); CR, Cys-rich domain; FnO, F n l, Fn2, fibronectin type III 
domains; Ins, insert in Fnl; TM, transmembrane domain; JM, juxtamembrane domain; TK, tyrosine-kinase 
domain; CT, carboxy-terminal tail. Orange arrowheads indicate N-glycosylation sites. Green arrowheads 
indicate ligand-binding ‘hot spots’. (De Meyts & Whittaker 2002)
Ligand binding and activation of the insulin receptor are key events leading to the metabolic 
response of insulin. Mice lacking the insulin receptor gene via targeted disruption die within the 
first week of birth due to severe diabetic ketoacidosis (Joshi et al. 1996). In liver-specific insulin 
receptor knockout (LIRKO) mice, which lack hepatic insulin receptors from birth, insulin fails to 
suppress glucose production, indicating that the effects of insulin require an intact hepatic insulin 
signalling pathway (Fisher. 2003).
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The binding of insulin to the a-chains of the insulin receptor induces structural changes within the 
receptor leading to autophosphorylation of various tyrosine residues within the intracellular tyrosine 
kinase (TK) domain of the p-chain. Insulin receptors trans phosphorylate several immediate 
substrates including insulin receptor substrate family (1RS) I/2/3/4, SHC, and Gab 1, Cbl, APS, and 
P60dok. Each of these provides specific docking sites for other signaling proteins containing Src 
homology 2 (SH2) domains. This results in the activation of downstream signaling molecules 
including phosphoinositide 3 kinase (PI3 kinase) and mitogen activated protein kinase. These 
pathways coordinate glucose regulation via glycogen synthesis and inhibition of gluconeogenesis 
and glycogenolysis as well as promoting glucose utilisation. Protein synthesis is stimulated by 
amino acid uptake into cells and inhibition of protein degradation. Lipid synthesis is promoted by 
the uptake of NEFA and inhibition of lipolysis (Saltiel & Kahn. 2001).
Insulin circulates in relatively low concentrations in the plasma. The binding interaction of the 
insulin and the insulin receptor is characterised by its binding affinity. Scatchard plots have been 
used to estimate the affinity with which a receptor binds its hormone. Insulin plots show a 
curvilinear response (De Meyts et al. 1976). This may be due to heterogeneity of insulin binding 
sites, or the existence of site to site interactions termed negative cooperativity in the binding 
function, or a combination of the two.
It has been proposed that each a-subunit of the receptor dimer contains two distinct, non-identical 
insulin binding sites. Thus, at low insulin concentrations, one molecule of insulin could 
simultaneously bind to both receptor monomers in an asymmetrical manner (using non-identical 
binding sites). The two-site binding would account for the binding being of high affinity. As it is 
further posited that only one two-site binding event can occur, binding of a second molecule of 
insulin, in the presence of higher levels of insulin, would result in a conformational change leading 
to disruption of two-site binding of the first molecule of insulin, thereby reducing binding affinity 
and potentially accounting for negative cooperativity (De Meyts et al. 1976).
1.2.4. Ligand/receptor-binding affinity
A number of factors determine the optimal binding affinities of chemical messengers with control 
functions for their receptors. On-rates need to reflect the required time course of onset of the effect 
and o ff  rates the need for the signal to be terminated. Degradation of the ligand is also an essential 
component of the system that defines the appropriate time courses.
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Insulin binding to either isoform of the receptor initiates at least 2 separate events. Activation of 
tyrosine kinases in the intracellular receptor domain initiates the metabolic effects of the hormone, 
which vary depending on the target tissue. In addition, insulin-receptor complexes cluster in clathrin 
coated pits, which internalise to form endosomes. Internalised receptors are recycled to the cell 
surface but the insulin is degraded within the cell (Gorden et al. 1985).
This relationship between the insulin signal and the degradation of insulin explains an apparent 
discrepancy between the in-vitro and in-vivo potencies of insulin analogues. Insulin analogues have 
been used to understand insulin physiology further and their development is explained in section
1.4.3. Infusion of low-affinity analogues leads to higher plasma concentrations than equimolar 
doses of native insulin because of the reduced rate of receptor-mediated degradation. Thus the 
overall metabolic effect is the same but with a theoretically delayed time course (Ribel et al. 1990). 
Clinically the rate of onset and duration of action of subcutaneous insulin is determined by factors 
relating to absorption from the depot rather than receptor binding kinetics such that most insulin 
analogues with a wide range of receptor binding affinities produce similar degrees of 
hypoglycaemia when injected in equimolar doses (Jones et al. 1976).
Insulin given intravenously and subcutaneously is equally distributed to the liver and peripheral 
tissues. In normal insulin physiology, endogenous insulin is released into the hepatic portal vein 
therefore the liver is exposed to more insulin than the peripheral circulation. With intra-portal 
delivery of insulin analogues the concentrations reaching the liver and peripheral tissues are 
different. First pass hepatic extraction of insulin is reduced when low affinity insulin’s are infused 
intraportally. High affinity insulin analogues have not been administered intraportally in mammals 
but by extension of data from low affinity infusions it can be surmised that first pass hepatic 
extraction would exceed that observed for native pancreatic insulin.
Insulin clearance
Fifty percent of portal insulin is removed by first pass metabolism and is degraded by hepatic 
receptor mediated processes (Duckworth et al. 1998). The kidney also plays an important role in 
removing insulin, proinsulin and C-peptide from the peripheral circulation by glomerular filtration 
and proximal tubular reabsorption. In the presence of insulin-treated patients with diabetes the 
kidney plays an even greater role in insulin clearance since insulin administered by subcutaneous 
injection escapes first-pass removal by the liver (Rabkin et al. 1984)
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1.2.5. The evolution of insulin
In evolutionary tenus the gene family that includes insulin is ancient and highly conserved. Figure I 
shows a modem version of the typical phylogenetic tree of the animal kingdom. The light boxes 
indicate animal classes/phyla in which insulin and insulin-like peptides have been identified. In 
primitive jawless vertebrates and protochordates lacking a pancreas insulin originates from the bile 
duct-associated islet parenchyma (Chan & Steiner 2000).
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Figure 8. A  typical phylogenetic tree of the animal kingdom.
The light boxes indicate animal classes/phyla in which insulin/insulin-like peptides have been identified. Original 
diagram.
As early as 1923, Collip reported finding activity in the bivalve mollusc, Mya arenaria (Collip. 
1923) and by 1975 insulin molecules had been sequenced and isolated from representative species 
in all classes of vertebrates (Nagamatsu et al. 1991). In contrast, it was proving difficult to isolate 
insulin from invertebrates. It wasn’t until 1986 that Nagasawa and coworkers purified an insulin 
like molecule from the silkwonu Bombyx mori (Nagamatsu et al. 1991). Bombyxin A2 was 
isolated from silkworm brain and exhibited 30% sequence homology with human insulin. More 
recently, recombinant DNA has been used to clone insulin like peptide genes from a variety of 
vertebrates and invertebrate species; including molluscs, insects and the nematode Camorhabditis 
elegans (Pierce 2001). The amino acid residues necessary to form the hydrophobic core have been 
conserved but otherwise the sequences are highly divergent (Chan & Steiner. 2000).
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Strong evolutionary pressure has acted to conserve amino acids postulated to be important in the 
biologically active conformation (Conlon. 2000). The evolutionary divergence time between 
humans and hagfish is about 400 million years, however their insulin sequences still share 61% 
amino acid identity and the key residues which are thought to be important for receptor binding 
have been maintained (Chan & Steiner. 2000). The key surface residues thought to be important in 
receptor binding include: Gly A l, Gin A5, Tyr A19, Asp 21 on the A chains and Val B12, Tyr B16, 
Gly B23, Phe B24, Phe B25, Tyr B26 on the B chains (Pullen et al. 1976).
Hagfishes (Myxiniformes) are the only surviving groups of the agnathan (jawless) phase of early 
vertebrate evolution (Peterson & Steiner. 1975). Hagfish insulin is of particular interest as it 
represents an early link between the vertebrates and other phyla. Hagfish insulin has reduced 
affinity for mammalian insulin receptors and exploration of the reasons for this has led to a clearer 
understanding of the residues responsible for receptor binding (Sajid et al. 2009). It is proposed that 
the reduced biological activity of hagfish insulin results from unfavourable substitutions, namely, 
AlO (He to Arg), B4 (Glu to Gly), B13 (Glu to Asn), and B21 (Glu to Val). In this primitive insulin, 
two residues have substitutions, compared to mammalian insulins, which increase binding affinity 
even to mammalian receptors. The substitution of Asp at residue BIO in hagfish insulin and of His 
at residue A8 in both hagfish and lamprey insulins may help compensate for unfavourable changes 
in other regions of the molecules.
The insulin of the primitive amphibian, Amphiuma is remarkably similar to that of human insulin. 
Like turkey and chicken insulin it contains a His A8 residue that is presumed to be responsible for 
its approximately 5-fold higher affinity than pig insulin for binding to the soluble human insulin 
reeeptor (Simon et al. 1977). It is possible that histidine forms further stabilising interactions with 
receptor residues or that the presence of histidine induces a small rearrangement in the structure of 
the receptor-binding residues which increase the affinity (Pullen et al. 1976). The higher binding 
affinity may also be due to a slower dissociation rate from the receptor (Simon et al. 1977).
Among higher vertebrates insulin sequences are highly conserved and retain their properties when 
injected between species. Among mammals (except hystricomorphs) functional species differences 
are minimal such that bovine and porcine insulin can both provide effective replacement therapy in 
human patients with diabetes. However in no case does mammalian insulin have a histidine residue 
at the A8 position. In contrast most bird insulins do retain the A8 His residue. The molecular 
evolution of insulin is shown in Figure 9. Human insulin is at the top and then the related amino 
acid changes are shown for a selection of vertebrates.
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B IA A N Q H L c G s H L V E A L Y L V C G E R G F F Y T P K T
Chicken A IG 1 V E Q C c H N T C s L Y Q L E N Y C N
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B li T N Q Y L c G S H L V E A L Y L V C G D R G F F Y S P K
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Figure 9. The molecular evolution of insulin.
A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, 
isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; 
T, threonine; V, valine; W, tryptophan; Y, tyrosine. Original diagram.
Mammals are different from ancient vertebrate phyla and in particular from birds with respect to 
anastomoses of the hepatic portal vein. Birds need to escape fast, for example if a predator appears 
and rapid metabolic changes are important under those circumstances. Shifts in energy substrate 
availability are an important part of that response and insulin may have a significant role. The avian 
anatomy is shown in figure 10. In birds, the coccygeomesenteric vein links the hepatic portal and 
the systemic circulations via valves in the kidneys, which are under neural control. Insulin is 
delivered anatomically via vascular shunts to the periphery diverting insulin away from the liver, 
meaning the degree of first pass hepatic extraction was not an issue. Instead optimisation of insulin 
action was by maximisation of the binding affinity and explains the presence of the A8 histidine 
residue.
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Figure 10. The avian circulation.
Original diagram.
During the evolution of mammals, vascular shunts between the hepatic portal and peripheral 
circulations were lost and the level of first pass hepatic insulin extraction became important. To 
ensure an appropriate distribution of insulin action between the liver and the rest of the body, 
insulin receptor binding affinity was reduced and the A8 histidine was lost. This is an important 
observation and has therapeutic implications for the use of insulin in the treatment of diabetes. If 
insulin is injected peripherally that has been designed through evolution to be delivered 
intraportally, it will be inappropriate.
1.3. Normal insulin physiology
Plasma glucose levels are tightly controlled by insulin. Insulin suppresses endogenous glucose 
production from the liver both directly and indirectly and stimulates peripheral glucose uptake in 
muscle and adipose tissue.
1.3.1. Endogenous glucose production
Endogenous glucose production is predominately from the liver with the kidney only contributing 
approximately 15 - 20% (Ekberg et al. 1999). The kidney is involved in glucose homeostasis by 3 
insulin independent mechanisms, the release of glucose into the circulation via gluconeogenesis
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(Gerich et al. 2001), the uptake of glucose from the circulation and the reabsorption of glucose at 
the proximal tubules (Wright et al. 2007).
The acute regulation of hepatic glucose production is predominately by direct insulin action 
(Edgerton et al. 2006). Insulin suppresses up to 85% of glucose production by inhibiting 
glycogenolysis, especially at lower insulin concentrations (Marks & Botelho.1986) and by 
suppressing gluconeogenesis (Girard. 2006). Glycogenolysis involves the breakdown of glycogen 
to glucose-6-phosphate and then hydrolysis by glucose-6-phosphatase to glucose. Gluconeogenesis 
is the biosynthesis of new glucose from pyruvate, lactate, glycerol and amino acids alanine and 
glutamine. The liver and kidney contain glucose-6-phosphatase so the breakdown of hepatic 
glycogen releases glucose whereas glucose that is from the breakdown of muscle glycogen is 
metabolised to lactate. Lactate can be absorbed by the liver and kidneys, which can then generate 
glucose by gluconeogenesis.
The importance of direct insulin action in the liver has been shown in liver-specific insulin receptor 
knockout (LIRKO) mice. Mice that lack hepatic insulin receptors from birth, demonstrate severe 
hepatic insulin resistance. Since the livers of LIRKO mice cannot respond directly to insulin, any 
effect of insulin administered in vivo must be mediated by indirect actions of insulin on 
extrahepatic tissues (Barrett. 2003; Fisher. 2003). Indirect effects of insulin include reduction of 
glucagon secretion, inhibition of lipolysis in adipose tissue and decreased protein catabolism in 
muscle thereby reducing gluconeogenic substrate delivery to the liver (Girard. 2006). Recent 
studies have also suggested an indirect action via the hypothalamus. Insulin is thought to have an 
influence on glucose regulation via central nervous system connections that regulate hepatic 
glucose production, glycogen synthesis in skeletal muscle and fat metabolism in adipocytes 
(Fagotto. 2009).
In mammals, pancreatic insulin is delivered directly and entirely to the sinusoids of the liver such 
that physiologically the predominance of the direct rather than indirect effects of insulin on hepatic 
glucose metabolism is reinforced by anatomy. The separation of the hepatic portal system from the 
systemic circulation determines a further issue that relates the receptor binding affinity to metabolic 
balance. First pass insulin extraction by the liver removes about 50% of the insulin secreted by the 
pancreas and that elimination reflects receptor binding followed by internalisation and degradation 
(Duckworth. 1998). The affinity of endogenous insulin for the hepatic receptors directly defines the 
level of first pass extraction of insulin and hence the degree to which insulin is delivered to the 
systemic circulation to supply peripheral tissues. It can be calculated that, when recycling of insulin
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to the liver from the arterial supply and via mesenteric drainage is considered the total contribution 
of the liver to insulin clearance and activity approximates 80% (Duckworth. 1998). It has been 
suggested that an important function of liver insulin receptors is to control the degree to which the 
periphery is insulinised and that regulation of receptor number in the liver may be a mechanism to 
optimise this (Bergman. 2000). Removal of insulin from the circulation by the liver depends upon 
receptor binding as the initial and rate-limiting step. This was demonstrated by studies in which low 
affinity analogues were delivered into the portal circulation, which predictably resulted in reduced 
levels of first-pass hepatic extraction (Chap et al. 1987). It follows that the distribution of insulin 
action between the liver and the periphery is dependent on the receptor binding affinity.
In mammals, the constants defining the interaction of insulin with its receptors have been optimised 
by evolution to ensure that the liver is exposed to approximately four times the concentration of 
insulin than tissues supplied by the systemic circulation. This concept is shown in Figure 11. In the 
fasting state and after an oral glucose load, insulin levels reaching the liver via the hepatic portal 
vein are clearly greater than those reaching peripheral tissues supplied by systemic arteries.
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Figure 11. Insulin concentration before and after glucose load in the hepatic vein, portal vein and hepatic 
arterv in normal doss.
Oral glucose load was given at time zero. Adapted from Chap et al. 1986.
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The biological effects of insulin are therefore not only a function of the affinity of the receptor for 
the insulin but also the plasma insulin concentration, insulin-receptor concentration and receptor 
concentration.
1.3.2. Glucose transport and glucose uptake into muscle and adipose tissue
The ability of insulin to stimulate glucose uptake into muscle and adipose tissue is also important to 
the maintenance of whole body glucose homeostasis. Glucose is taken up into peripheral tissues via 
transport systems. The intracellular glucose concentration is lower than the extracellular glucose 
concentrations. This produces a concentration gradient where by glucose can enter cells by 
facilitative diffusion across a cell membrane. Glucose transport is mediated through solute carriers 
called the GLUT family of facilitative glucose transporters. Currently 14 members of this family 
have been identified (Karim et al. 2012). The best understood members of the GLUT family are 
GLUT 1,2,3 and 4.
The GLUTl transporter is responsible for basal glucose uptake, the GLUT2 isoform which is 
primarily expressed in the liver and beta cells, has a relatively low affinity for glucose, GLUTS has 
the highest affinity and is expressed during fetal development and in adult neurons and finally 
GLUT4 protein is predominantly restricted to fat and muscle and is responsible for insulin 
stimulated peripheral uptake. The primary effect of insulin on peripheral glucose uptake is to 
stimulate translocation of the glucose transporter GLUT4 from an intracellular pool to the cell 
surface primarily in skeletal muscle, adipose tissue and heart (Kanzaki. 2006).
Activation of the insulin receptor by insulin elicits a wide range of cellular responses that together 
coordinate a shift in the steady-state distribution of GLUT4 to the cell surface. In addition, insulin 
has substantial effects on the docking and fusion of GLUT4 vesicles with the plasma membrane 
(Leney & Tavare. 2009). The P13 kinase/Akt pathway has been demonstrated to be upstream of 
GLUT4 translocation and therefore implicated in the translocation process. Recent studies have 
shown that an additional pathway may also be involved. Insulin stimulates tyrosine phosphorylation 
of c-Cbl in metabolically responsive cells. C-Cbl is recruited to complex with the insulin receptor 
via the adaptor protein CAP (Ribon & Saltiel. 1997). Figure 12 shows how these parallel pathways 
may lead to GLUT4 translocation.
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Figure 12. Action of insulin to stimulate glucose uptake.
Phosphatidyl inositol kinase-3 (PI3K), insulin receptor substrate (1RS), adaptor protein (She). Adapted from 
Ribon and Saltiel. 1997).
Glucose taken up by the cells is stored as glycogen in muscle or lipid within fat cells, alternatively it 
can be metabolised through glycolysis to pyruvate. The pyruvate can be reduced to lactate, 
transaminated to alanine or converted to acetyl coenzyme A. If converted to acetyl coenzyme A, it 
is then oxidised to CO2 and H2 O through the tricarboxylie acid cycle or converted to NEFA. In the 
liver NEFA can be used for ketone body synthesis (acetoacetate and P-hydroxybutyrate) and 
acetyly Co A for cholesterol synthesis. Brain and muscle are the major tissues for glucose oxidation 
whereas adipose tissue, splanchnic tissues and to some extent muscle are geared towards storage 
(Zorzano et al. 1998).
1.3.4. Fat and lipid metabolism
The major lipids present in the plasma are free cholesterol, cholesterol ester, triglycerides (glycerol 
and fatty acids) and phospholipids. Cholesterol and triglycerides are insoluble and circulate in the 
plasma bound to lipoproteins. The lipid protein complexes are classified according to their density 
after separation by ultracentrifugation: high density lipoprotein (HDL), intemiediate density 
lipoprotein (IDE), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) and 
chylomierons.
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Insulin increases the clearance of triglyceride rich chylomicrons and VLDL jfrom the circulation by 
stimulating lipoprotein lipase in adipocytes and suppressing activity in skeletal muscle, resulting in 
the transfer of triglycerides to adipose tissue for storage (Farese et al. 1991).
1.3.5. Lipolysis in adipose tissue
Release of NEFA and glycerol from adipose triglyceride stores occurs during periods of insulin 
deficiency. This is termed lipolysis. Lack of insulin causes increased hormone sensitive lipase 
(HSL) activity, which increases triglyceride hydrolysis and NEFA delivery to the liver. NEFA are 
then oxidised in mitochondria in the liver, giving rise to the products of ketogenesis, acetoacetate, 
P-hydroxybutyrate and acetone (Kitabchi et al. 2001).
The rate of appearance of NEFA is not an accurate reflection of the rate of lipolysis as some NEFA 
can be re esterified within adipocytes. On the other hand, glycerol is not recycled into TAG within 
the adipocytes as glycerol kinase is absent. Glycerol kinase is an enzyme required for the 
conversion of glycerol to a-glycerol phosphate, which is essential for the formation of the TAG 
molecule. Thus the measurement of the rate of appearance of glycerol in plasma can be used as a 
direct index of lipolysis (Wolfe 1984).
Lipolysis is under tight regulation by catecholamines and insulin. The regulation of lipolysis by 
insulin involves both cAMP dependent and cAMP independent mechanisms. In the cAMP 
dependent mechanism, insulin induces phosphorylation and activation of phosphodiesterase 3B 
(PDE3B) by the phosphatidyl inositol kinase-3 (PI3K) pathway. PDE3B dephosphorylates cAMP 
resulting in deactivation of protein kinase A (PKA) in adipocytes. Activation of PKA increases 
lipolysis through phosphorylation and activation of HSL. The hydrolytic action of HSL is also 
regulated by perilipin A, a lipid droplet protein. Phosphorylation activation of HSL enhances the 
breakdown diacylglycerol (DAG) into 2-monoacylglycerol (MAG). Finally the hydrolysis of MAG 
is catalysed by monoacylglycerol lipase to glycerol and fatty acids. This process is shown in figure
13. The cAMP independent regulation of lipolysis by insulin involves the stimulation of protein 
phosphatase-1, which rapidly dephosphorylates and deactivates HSL, causing a fall in the rate of 
lipolysis (Jaworski et al. 1997).
Further understanding of the role of HSL in overall adipose tissue lipolysis came from the 
identification of an additional TAG lipase that was originally termed desnutrin. Subsequent to the 
identification of desnutrin another lipase was characterised and called adipose triglyceride lipase 
(ATGL). Desnutrin and ATGL are the same protein so it is often designated desnutrin/ATGL. 
Desnutrin/ATGL has also recently been identified to play a significant role in the process of
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lipolysis (Lafontan and Langin. 2009). Over expression of desnutrin / ATGL results in TAG 
breakdown and the release of NEFA.
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Figure 13. Regulation of lipolysis in adipocytes.
Insulin receptor substrate family (1RS), insulin receptor (IR), Phosphodiesterase 3B (PDE3B), phosphatidyl 
inositol kinase-3 (PI3K), lipoprotein lipase (LPL), protein kinase A (PKA), hormone sensitive lipase (HSL), 
diacylglycerol (DAG), triacylglycerol (TAG), monoacylglycerol lipase (MGL), 2-monoacylglycerol (MAG), fatty 
acid (FA), adipose triglyceride lipase (ATGL). Adapted from Jaworski et al. 1997.
1.4. Insulin in diabetes
Under normal physiological post-absorptive conditions euglycaemia is primarily maintained by 
insulin acting to modulate hepatic glucose production. Healthy individuals maintain a continuous 
degree of insulinisation of hepatocytes. At levels of insulin below normal the liver is capable of 
generating and releasing glucose by both unrestrained glycogenolysis and increased 
gluconeogenesis, thus in type I diabetes, severe insulin deficiency reveals more of the hepatic 
insulin dose-response curve than is ever seen in healthy individuals (Gerich. 1993).
1.4.1. Hyperglycaemia
In type 1 diabetes with severe hyperglycaemia, glucose flux and uptake is increased above nomial 
(Hall et al. 1979; Luzi et al. 1988). Without adequate direct insulin action in the liver the excess 
glucose production is so great that even an increase in glucose dependent peripheral glucose uptake 
and the associated glycosuria fail to limit progressive hyperglycaemia.
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The introduction of isotopically labelled glucose in the 1970s’ enabled further insights into 
mechanisms of insulin action and glucose flux. A study by Sonksen and his team is shown in figure
14. It shows the response to incremental doses of intravenous insulin of a patient admitted in 
diabetic ketoacidosis. Radioactive glucose tracer was infused and a stepped insulin infusion was 
given to the patient who had presented with diabetic ketoacidosis. The plasma glucose 
concentration falls but the concentration (dpm.ml) of the tracer remains constant showing that the 
fall in glucose concentration is due to inhibition of endogenous glucose production from the liver 
rather than increased peripheral glucose clearance. The tracer concentration only changes if there is 
increased peripheral glucose uptake. The level of tracer is seen to decline when insulin is infused at 
10 units/hour. It is only at this high level of insulin that peripheral glucose uptake becomes 
stimulated. This work was fundamental in guiding the current clinical treatment of diabetic 
ketoacidosis and lead to the introduction of the intravenous sliding scale regimen.
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Figure 14. The response to incremental doses of intravenous insulin of a patient admitted in 
diabetis ketoacidosis.
Plasma glucose concentration (closed circles, top panel), and tracer (open circles, middle panel). 
Personal communication Sonksen.
Another important study is the work published by Brown et al, in 1978. The study demonstrated 
that hyperglycaemia of diabetes was due to excess hepatic glucose production rather that reduced 
uptake in the periphery, an entirely new concept at the time. Six patients with type 1 diabetes were 
studied following a twenty four hour insulin withdrawal period. On three separate occasions each 
patient received a two-hour infusion of low dose actrapid insulin (2.6 units hour), high dose actrapid 
(10.6 units hour) or nomial saline. The rate of production and utilisation of glucose was measured
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isotopically. As glucose concentration fell, the effects on glucose utilisation and glucose production 
are shown in figure 15. During the normal saline infusion there was a non-significant fall in the 
rates of glucose uptake and production rate. At low insulin infusion, glucose concentration fell 
mainly by reduction in hepatic glucose production and at high dose insulin infusion there was a 
combined effect of reduction in hepatic glucose production and increased peripheral glucose uptake 
(Brown et al. 1978).
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Figure 15. Mean rates of appearance and disappearance of glucose for 6 patients during saline infusion 
and low-dose and high-dose prandial insulin infusion.
(Brown et al. 1978)
With the introduction of the euglycaemic hyperinsulinaemic clamp the fundamental importance of 
insulin action on hepatic glucose production is easily forgotten. The euglycaemic hyperinsulinaemic 
clamp has become the gold standard method for investigating the action of insulin preparations on 
glucose metabolism (DeFronzo et al. 1979). The clamp measures glucose metabolism in response to 
a fixed infusion of exogenous insulin. Endogenous insulin production is prevented by the method of
42
clamping the glucose concentration. To maintain the required glucose concentration, the glucose 
infusion is continually adjusted. The recorded glucose infusion rate (GIR) then constitutes a 
measure of the net effect of the insulin (i.e., it describes the resulting sum of the suppression of 
hepatic glucose production and the stimulation in glucose utilization), making it possible to 
establish the onset, peak activity, and duration of insulin action (Porcellati et al. 2011).
The problem with this methodology is that euglycaemia is the starting condition, which inevitably 
falls near the top of the dose-response curve for insulin action in the liver and near the bottom of 
that relationship for peripheral tissues. The prevention of hypoglycaemia by clamping during 
experimentally induced increased insulin concentrations serves further to focus attention on 
peripheral insulin action particularly as any fall in glucose dependent glucose uptake due to 
developing hypoglycaemia is eliminated by the glucose infusion of the clamp protocol. Glucose 
clamp experiments therefore serve to underestimate the vital physiological significance of hepatic 
insulin action and overestimate the importance of peripheral glucose uptake (Finegood et al. 1988).
1.4.2. Importance of portal insulin
Loss of the normal portal / peripheral insulin gradient results in relative peripheral 
hyperinsulinaemia and underinsulinisation of the liver (Shojaee Moradie et al. 1995). This can lead 
to a variety of metabolic abnormalities including glycaemic fluctuations, dyslipidaemia and 
reduction in hepatic IGF-1 with consequent elevation in GH (Sonksen et al. 1993). The metabolic 
changes are more pronounced in patients with poor diabetes control and may be implicated in the 
long-term micro and macro vascular complications of diabetes (Shojaee-Moradie et al. 2000).
The portal vein is relatively inaccessible for therapeutic insulin delivery but data from portal insulin 
delivery methods are available and have shown beneficial effects on glycaemic control,
(Logtenberg et al. 2009) and insulin sensitivity (Radziuk et al. 1993). Implantable insulin pumps 
can deliver insulin into the peritoneal cavity where the majority of insulin drains into the portal 
venous system. This restores the portal systemic insulin gradient and reduces peripheral 
hyperinsulinaemia (Giacca et al. 1993). In addition, insulin delivered into the hepatic portal system 
is rapidly absorbed resulting in less glycaemic excursions and beneficial effects on lipoprotein and 
lipid metabolism (Selem et al. 1989). However, practical difficulties and cost have limited their 
clinical use (Duckworth et al. 1992). Pancreatic transplantation can also deliver insulin into the 
portal circulation but the current practice of draining exocrine secretions into the bladder has meant 
that endocrine drainage into the iliac vessels is favored (OsamaGaber et al. 1995). Finally, islet cell
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transplantation involves islets cells being slowly infused into the liver by the portal circulation. The 
procedure may successfully restore long-term endogenous insulin production and glycaemic 
stability in subjects who have type 1 diabetes mellitus. However, normal endocrine reserve is rarely 
achieved, and insulin independence is gradually lost in most cases over time (Shapiro. 2006).
Insulin by oral administration has also excited attention not just for avoidance of injections but also 
because of perceived advantages of intra-portal delivery. In a recent review attention is drawn to the 
benefits of rapid insulinisation of liver and adequate insulin delivery avoiding peripheral 
hyperinsulinaemia (Iyer et al. 2010).
1.4.3. Challenges of peripheral insulin delivery
The challenges to peripheral insulin delivery are numerous. The ideal insulin needs to maintain the 
physiological portal / peripheral insulin gradient and mimic physiological insulin action. The 
progression from animal to human insulin preparations had obvious advantages linked to sequence 
homology with the native human protein, reducing the incidence of antibody formation that led to 
injection site reactions and blocking of therapeutic effect (Evans et al. 2011). However, the 
difficulty is still how to ensure a physiological mode of action.
NPH insulin
The principal method of delaying absorption of insulin was by adding protamine and/or zinc to 
stabilize insulin hexamers. The first successful insulin preparation with a prolonged action was 
neutral protamine hagedom (NPH) insulin. Protamine insulin is a complex of the fish protein 
protamine and insulin. The principle of protracting the insulin action was to make the insulin less 
soluble at the neutral pH of tissue fluid. When injected subcutaneously, proteolytic enzymes 
degrade the protamine, and the insulin is absorbed.
NPH insulin action has a peak of action of around 3-8 hours after injection with duration of action 
14 ± 3 hours and a variable absorption on a daily basis (Lepore et al. 2000). Factors that can 
contribute to the daily variation include the size of the dose, injected volume, insulin concentration 
and changes in blood flow to the tissue that it is injected (Hordern & Russell-Jones. 2005). NPH 
insulin is usually injected twice a day to achieve twenty four hour insulin cover. An injection before 
bed can mean that there is over insulinisation in the middle of the night with risk of hypoglycaemia 
and not enough residual insulin action in the morning resulting in fasting hyperglycaemia (Lepore
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et al. 2000). Subject variability is further exacerbated by inconsistencies in resuspension before 
injection (Havelund et al. 2004).
More recently, insulin analogues have been engineered to enhance the desired molecular properties 
without altering immunogenicity (Heller et al. 2007). The first insulin analogue, insulin lispro was 
given approval by the European Medicines Agency (EMEA) in April 1996 and by the Food and 
Drug Administration (FDA) in June 1996. Insulin lispro is an analogue protein of human insulin 
obtained by recombinant DNA technology that has a reverse position of the aminoacids at positions 
28 (lysine) and 29 (proline) on insulin’s B chain when compared to the natural sequence of the 
human insulin. It has an increased dissociation rate-constant and is relatively quickly absorbed from 
subcutaneous tissue. When administered immediately before meals, the prandial peaks of insulin 
secretion seen in normal physiology can be mimicked. To date, there are two different categories of 
insulin analogues: rapid acting insulin analogues (insulin lispro, insulin aspart and insulin 
glulisine); and long-acting insulin analogues (insulin glargine and insulin detemir). Strategies for 
reducing insulin self association for rapid acting insulins include changing the charge repulsion by 
substituting with Asp®^ ,^ Asp® ,^ Glu®" ,^ Asp^^  ^and Asp®^ ,^ decreasing interface hydrophobicity by 
substituting with Glu®^ ’^ Glu®" ’^ Glu®^ ,^ removing the metal-ion binding site, interfering with 
hydrophobic contacts and beta sheet formation by substituting with lysB28 and Pro®^ .^ Figure 16 
shows the amino acid structure of human insulin and summarises the amino acid changes with 
different insulin analogues.
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Figure 16. Insulin analogues using single letter coding for amino acids.
Adapted from (Kaarsholm & Ludvigsen 1995). A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, 
phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, 
proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine. Original 
diagram.
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Two strategies to protract absorption by altering the insulin molecule have been tested clinically. 
The first principle was to shift the isoelectric point of the molecule toward neutrality to provide 
reduced solubility at physiological pH values. The first acid-soluble extended action insulin 
analogue made by this method was Novosol Basal GlyA21, ArgB27, ThrB30-NH2-insulin, but 
escalating dose requirements possibly associated with local inflammatory reactions at the injection 
site meant that this insulin was abandoned (Hordern et al. 2005). This principle was also used for 
insulin glargine, in which two arginine residues added to the C-terminus of the B-chain shift the 
isoelectric point fi*om pH 5.4 to pH 6.7. Glargine was more successftil and is injected as an acid 
solution (pH 4.0) and forms a slowly absorbed precipitate in the neutral environment of the 
subcutis. This property means that it cannot be mixed with neutral formulations of other insulins.
A more recent strategy has been to acylate fatty acid species to the insulin molecule to allow 
insulin-albumin binding in an attempt to protract the time-action profile while retaining the practical 
advantages of a neutral liquid preparation. The first clinically available acylated analogue was 
insulin detemir, in which the amino acid threonine at B30 is removed, and a 14-carbon myristoyl 
fatty acid is acylated to lysine at B29. Insulin degludec is a new basal insulin that forms soluble 
multihexamer assemblies after subcutaneous injection, resulting in an ultra-long insulin action 
profile. The insulin degludec molecule retains the human insulin amino acid sequence except for the 
deletion of ThrB30 and the addition of a 16-carbon fatty di-acid chain attached to LysB29 via a 
glutamic acid spacer. The primary structure is designed to allow the formation of soluble multi­
hexamer assemblies upon subcutaneous injection, to give an ultra-long peak-less pharmokinetic 
profile. In the clinical exploratory phase 2 trial in people with type 1 diabetes degludec has been 
shown to provide comparable weight and glycaemic control to insulin glargine (Birkeland et al.
2011). Phase 3 trials have shown that it provides effective glycaemic control while lowering the risk 
of nocturnal hypoglycaemia, which is a major limitation of insulin therapy (Heller et al, 2012).
1.4.4. The endothelial barrier
An insulin analogue exerting greater effects on the liver than the periphery has the potential to 
restore the physiological normal portal / peripheral insulin gradient and therefore reduce 
hypoglycaemic episodes (Hordern et al. 2005) and reduce weight gain (Zachariah et al. 2011). A 
potential mechanism to develop a novel hepatoselective insulin analogue is by reducing the passage 
through the endothelial barrier.
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To reach peripheral target cells insulin must pass through the capillary wall lined by a continuous 
epithelium. The rate of insulin diffusion is inversely related to its molecular size (Vora et al. 1988). 
In contrast, highly fenestrated epithelial cells line the vascular sinusoids within the liver, with large 
pores between them and no basal lamina. Therefore no barrier exists between protein molecules 
within the plasma, in the sinusoid and surface of the hepatocyte.
If an insulin analogue can be developed that can easily enter the hepatocytes, but with reduced 
capability to reach peripheral tissues, it should be possible to restore the portal / peripheral insulin 
gradient. Increasing the size of the insulin molecule is a potential mechanism.
1.4.5. Therapeutic hepatoselective insulins: size matters
Proinsulin
Proinsulin the single-chain precursor of insulin is relatively more effective in the liver than the 
periphery than insulin itself. The reasons for this selectivity are not fully understood but molecular 
size is a potential mechanism. The proinsulin molecule is 50% larger than that of insulin and would 
be expected to diffuse more slowly than insulin from the circulation into peripheral tissues 
(Sonksen et al. 1973). A dose response analysis showed that proinsulin mediated glucose disposal 
was approximately 8% that of insulin. In contrast, proinsulin mediated suppression of hepatic 
glucose output was approximately 12% of that seen with insulin (Revers et al. 1984). One of the 
biggest problems was that the dose requirements for proinsulin were higher than for human insulin 
and there was a possible association with myocardial infarction (Hanley et al. 2001). Consequently 
proinsulin is regarded as unsuitable for clinical use but recognition of its relatively greater hepatic 
effects stimulated further research (Galloway et al. 1992).
Covalent insulin dimers
As with proinsulin the molecular size of the synthetic insulin analogue may control its rate of 
transfer through capillary endothelial barriers. Insulin-like moieties of high molecular weight have 
been tested in vivo. Covalent insulin dimers N_B1, N_B’ 1-suberoylinsulin and N_B29, N_S’29- 
suberoyl insulin were prepared to increase molecular size and their potencies were compared with 
human insulin. With N_Bl,N_B'l,-suberoyl-insulin dimer molar potencies relative to insulin were 
68% (34-133 - mean and 95% fiducial limits) for inhibition of hepatic glucose production and 14.7 
% (10.3-20.9) for glucose disposal. WithN_B29,N_S'29,-suberoyl-insulin dimer potencies were 
75% (31-184) and 2.5% (1.5-4.3), for inhibition of hepatic glucose production and for glucose
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disposal, respectively. In summary, they exhibited a greater effect on hepatic glucose output than 
peripheral uptake showing relative hepatoselectivity but the lower hypoglycemic potency than 
predicted by in vivo receptor binding affinities which limits their use in clinical practice (Shojaee 
Moradie et al. 1995).
Covalently linked thyroxyl insulin
Another alternative method is that an analogue could be monomeric on injection but acquire an 
increased molecular weight by protein binding on reaching the circulation. The transport of protein 
bound hormones into tissues is regulated by the capillary transit time, the dissociation rate and 
membrane permeability. Membrane permeability does not apply to liver sinusoids. Liver 
endothelium has large pores permitting albumin-ligand complexes directly to contact the microvilli 
of the sinusoidal surface of the hepatocyte (Berk et al. 1987).
Thyroxyl insulin analogues include T4-lns, T4-(CH2)6-lns, rT3-lns, DT4-lns and T4-(CH2)12- 
lns(Shojaee-Moradie et al. 2004). They were designed to bind to thyroid hormone binding proteins 
(THBPs), thyroxine binding globulin (TBG), transthyretin (TTR) and human serum albumin (HSA) 
to form high molecular weight complexes. Two insulin analogues covalently linked to T4 (Napi 
thyroxyl insulin and Napi thyroxyl-aminohexanoyl) insulin showed greater hepatoselectivity than 
insulin in anaesthetised dogs (Shojaee Moradie et al. 1998). When injected subcutaneously into 
normal human subjects, Napl-thyroxyl-insulin (Bl-T4-lns) was well tolerated, quickly absorbed, 
and highly protein bound (86%), resulting in a long plasma half-life. The analogue demonstrated 
less effect on peripheral glucose uptake than NPH insulin, had no effect on metabolic clearance rate 
of glucose, and exhibited a reduced capacity to inhibit lipolysis (Shojaee-Moradie et al. 2000).
Further work showed that complexes of thyronine-insulin analogues with thyroid hormone binding 
proteins exhibit impaired insulin receptor binding affinities compared with those of the analogues in 
their free form. In conclusion the hepatoselectivity in vivo may not depend on binding of the intact 
complexes to hepatocytes (Shojaee-Moradie et al. 2004). This further supports the hypothesis that 
insulin like moieties bound to plasma proteins may be prevented by the endothelial barrier from 
reaching receptors sites on cells of peripheral tissue, producing a reduced peripheral insulin effect.
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Insulin detemir
Insulin detemir is a soluble analogue of human insulin with a 14-carbon fatty acyl group linked to 
the lysine at position B29 and with the B30 tyrosine deleted (Havelund. 2004). It is produced by 
recombinant DNA technology using a genetically modified strain of yeast (Saccharomyces 
cerevisiae) as the host organism. The purpose of the molecular change is so that detemir has a high 
affinity for albumin as a way of protracting its biological effects and has been reported to be 98% 
bound to albumin in circulation (Plank et al. 2005). The fatty acid residue associates with fi*ee fatty 
acid binding sites on albumin in interstitial fluid and plasma (Kurtzhals et al.l995). The duration of 
action is up to 24 hours. For doses in the interval of 0.2-0.4U/kg, detemir exerts more than 50% of 
its maximum effect from 3-4 hours and up to approximately 14 hours after dose administration. 
Maximum insulin concentration is reached between 6 - 8  hours after administration. Determining 
the pharmakinetics (PK) and pharmadynamics (PD) properties of detemir has been difficult owing 
to its relatively lower affinity for the insulin receptor compared with human insulin (Kurtzhals et al. 
2000). Therefore, initial studies focused on finding the dose equivalence with human insulin as well 
as proportionality of dose-response effects with a detemiriNPH molar ratio of 1:1 (Brunner et al. 
2000). Moreover, because the PK of detemir is difficult to determine as measurement of its 
concentration in plasma does not distinguish among the bioavailable (free) and albumin bound 
fractions in the circulation, the majority of the studies report only on the PD profile of detemir.
Detemir has been reported to be less effective than human insulin when given in equimolar doses to 
healthy individuals (Heinemann et al. 1999). Insulin detemir is less potent than human insulin in 
binding to the insulin receptor. The binding affinity of detemir is thought to be approximately 46% 
(Kurtzhals et al. 2000) and detemir dissociates 2 fold faster from the insulin receptor than human 
insulin (200%), suggesting an increased off rate reducing the insulin receptor affinity of this insulin. 
It is therefore possible that the low receptor binding affinity and altered pharmacokinetic properties 
could contribute to the reduced biological activity by allowing a greater fraction of insulin detemir 
than human insulin to undergo non-receptor mediated clearance (Kurtzhals et al. 2000). In clinical 
studies, the molar potency of insulin detemir was approximately a quarter of that of human insulin. 
Preparations are marketed so that when given subcutaneously, 1 unit of human insulin equals 6 
nmol/ml and 1 unit of insulin detemir equals 24 nmol/ml to produce a comparable blood glucose 
lowering effect.
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1.4.6. Insulin and hypoglycaemia
Despite the advantages offered by basal insulin analogues, hypoglycaemia remains a treatment 
limitation. It can cause a decreased level of consciousness, inconvenience, embarrassment, and 
anxiety, as a result people with diabetes may reduce their insulin doses or increase food intake to 
reduce the frequency (Birkeland et al). Clinical studies have suggested that people with diabetes 
have an average of two episodes of symptomatic hypoglycaemia a week (Macleod et al. 1993). In 
the DCCT and UKPDS studies those on intensive treatment regimes were more likely to have more 
frequent hypoglycaemia. Hypoglycaemia seems to be an important consequence for improving rates 
of progression to complication.
Clinical studies have shown detemir to be associated with a lower or similar incidence of 
hypoglycaemia in patients with type 1 diabetes receiving insulin detemir when compared with NPH 
insulin (Frier et al. 2013). There is also a reduced relative risk of nocturnal hypoglycaemia when 
compared with NPH insulin (Kolendorf et al. 2006; Hermansen et al. 2004; Vague et al. 2003).
1.4.7. Insulin and weight gain.
Studies have shown that exogenous insulin is often associated with weight gain. Both the DCCT 
and UKPDS showed increased weight gain in their intensively treated group (Holman et al. 2008, 
The DCCT researcg group. 2000). Clinical trials have also shown significant differences in the 
magnitude of weight change when detemir is compared with glargine and NPH. The differences 
range from -0.5 to -1.7kg less gain in weight with insulin detemir compared with NPH insulin (Frier 
et al. 2013).
In two experimental conditions, during a euglycaemie hyperinsulinaemic elamp and during free fall 
of glucose concentration to hypoglycaemia (Hordern et al. 2005; Smeeton et al. 2009) insulin 
detemir appears to be hepatoselective when compared with NPH insulin. This hepatoseleetivity may 
be an important contributor to the weight sparing effect by restoring the portal / peripheral insulin 
gradient. Interestingly, detemir has also been shown to be associated with a lower intake of energy 
in comparison with NPH which may also contribute to the weight sparing effect either directly, or 
indirectly by affecting a signal from the periphery to the brain (Zachariah et al. 2011).
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1.4.8. Insulin and cancer
The insulin molecule can bind to two receptors, the insulin receptor and IGF-1 receptor. The 
duration of action at the insulin receptor has metabolic implications and may also increase 
mitogenic effects. Sustained signalling from the insulin receptor after stimulation with insulin 
analogues have been shown to exhibit increased mitogenic potency.
The metabolic and mitogenic potencies of six different insulin analogues were determined by 
measuring glucose transport in primary adipocytes and DNA synthesis in CHO cells respectively. 
Glargine and detemir were not one of the six analogues. Three analogues showed a 
disproportionately high mitogenic potency compared with their metabolic potency, and were up to 7 
times more mitogenically than metabolically potent when compared with human insulin. The 
mitogenie/metabolic potency ratio of the analogues were found to be inversely correlated with the 
insulin receptor dissociation rate constant (Kd) in an exponential fashion (r=0.99), with a 
disproportionately greater increase in mitogenic potential compared with metabolic potential for 
analogues with Kd values of less than 40% of that of human insulin (Hansen et al. 1996). The 
insulin receptor off-rates for aspart, lispro, glargine and detemir are below the level of eoneem so 
one can be relatively confident that these insulin analogues are safe (Kurtzhal et al. 2000).
Peripheral hyperinsulinaemia causes a secondary increase in IGF-1. Changes in the insulin-IGF-1 
axis may support growth signals, which may promote resistance to apoptosis and programmed cell 
death. This offers an adaptive advantage to malignant foci (Smith et al. 2009). The ratio of binding 
between IGF-1 and IR tells us how strong this affinity to IGF-1 is, and enables us to predict whether 
we might have concerns for mitogenicity based on receptor binding profile (Kurtzhal et al.2000).
Insulin glargine was noted to promote the growth of some cell types in the laboratory. This raised 
the theoretical possibility that it might have the same effect on cancer cells. The risk of all cancers, 
and of specific cancers commonly seen in type 2 diabetes was examined in the course of four 
separate studies based on large patient databases in Germany, Sweden, Scotland and England. The 
rate of tumour diagnosis was compared in patients with mainly type 2 diabetes taking insulin 
glargine as against other types of insulin. These studies included details of about 300,000 patients, 
more than 10% of who were on glargine.
The German study compared the rate of all solid tumours in patients on glargine alone versus other 
insulins. Diagnosis of cancer was ascertained from the same database, as was the dose of insulin
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prescribed for each patient. Individual cancer types were not examined. The authors concluded that 
considering the relationship between insulin dose and cancer, and the lower dose with glargine, the 
cancer incidence with glargine was higher than expected compared with human insulin. However, 
patients were found to have a short median exposure to glargine with a median of 1.31 years 
(Hemkens et al. 2009).
The Swedish study focused on the rate of cancer development in patients treated with glargine 
insulin alone, as against any insulin other than glargine, or glargine taken in combination with 
another insulin. Overall cancer risk was examined, and also the risk for cancer of the breast, 
prostate or gastrointestinal tract. Women using insulin glargine monotherapy had an increased risk 
of breast cancer compared with women using types of insulin other than glargine. The authors 
stated that no firm conclusions regarding a causal relationship between glargine use and occurrence 
of malignancies can be drawn and that random fluctuation remains a possibility (Jonasson et al. 
2009).
The Scottish study was designed in the same way as the Swedish study. Patients were divided into 
the same three categories of insulin treatment. Overall cancer risk was examined, and also the risk 
for cancer of the breast, colon or pancreas. The group concluded that overall, use of insulin glargine 
was not associated with an increased risk of all cancers or site-specific cancers in Scotland over a 4- 
year time frame (Colhoun et al. 2009).
Finally, the UK Study, based on a general practitioners registry used a pre existing database. 
Patients on glargine alone were compared with patients on NPH insulin alone and patients treated 
with premix insulin or other insulin analogues. The study compared the rate of cancer for all 
cancers and for cancers of the breast, colon, pancreas and prostate. Patients on insulin were more 
likely to develop solid cancers than those on metformin; combination with metformin abolished 
most of the excess risk. Use of insulin analogues was not associated with increased cancer risk 
compared with human insulin (Currie et al. 2009).
In summary, evidence produced by the four studies does not support the orginal theory that glargine 
may exhibit an increased mitogenic potency in people with type 2 diabetes. There were also no 
indication of an increased risk of cancer or cardiovascular outcomes in a cardiovascular outcome 
trial, which used insulin glargine to target normal fasting plasma glucose levels for more than 6  
years (Gerstein et al. 2012).
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1.5. Using isotopes to measure metabolic flux
Radionuclides have previously been the most commonly used tracers for metabolie studies. A 
radioactive nuclide spontaneously disintegrates to form an atom of another element, with radiation 
being emitted in the process. Advances in tracer technology have increased the use of stable isotope 
technology and the technique has become a fundamental part of understanding carbohydrate 
metabolism in humans. Stable isotopes have the advantage over radioactive isotopically labelled 
tracers as they are not associated with a radiation dose and therefore can be used to study subjects 
such as children and women who may be pregnant or breast feeding.
Stable isotopes are chemical isotopes that differ in the number of neutrons but do not decay 
spontaneously and therefore do not emit radiation. This alters the mass of the atom but not its 
chemical nature. To be of use in metabolic research, the natural abundance of a given isotope (and 
the presence of multiple other isotopes) needs to be low. Commonly analysed stable isotopes are 
and '*0 .
In addition to the safety of stable isotopes for human use, there are other practical advantages. Mass 
spectrometry is necessary to distinguish such isotopes, which only requires small samples of blood 
to determine the enrichment. In addition, simultaneous and repeated use of several tracers is 
possible in the same participant, and the enrichment of each tracer measured independently of the 
other labelled compounds.
1.5.1. Isotope dilution technique
An isotopic tracer can be used to measure the flux of a naturally occurring substrate (tracee). An 
important requirement is that the tracer should have an identical metabolic fate as the tracee and the 
ideal tracer should not alter the metabolism of the tracee. Isotopic tracers used for metabolic 
research in humans are usually very similar to the tracee, except that one or more atoms differ from 
the more abundant naturally occurring form of that atom (Vella & Rizza 2009).
Calculation of substrate kinetics means the determination of the rate of appearance (Ra) of a 
substrate and rate of disappearance (Rd). It is assumed that the Ra of a substrate (tracee) and the 
infusion of tracer occur into, and sampling is from, a single, homogenous, instantly mixing pool. A 
schematic diagram illustrating the single pool concept in tracer dilution studies with a constant 
tracer infusion is shown in figure 17.
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Ra
>  Rd
The rate of appearance = Infusion rate of tracer
Tracer/tracee
Figure 17. The single pool concept in tracer dilution studies.
Adapted from (Wolfe 1984). Closed circles indicate tracer. Isotopic infusion (F), rate of appearance (Ra), rate of 
disappearance (Rd)
Tracers used to measure metabolic fluxes are usually infused at a (constant) rate. Assuming that the 
tracer and tracee are cleared at the same rate, the concentration of tracer and tracee in the body pool 
will reflect their respective rates of infusion/appearance. The dilution of infused glucose and 
glycerol tracers with unlabelled glucose from the liver or unlabelled glycerol from adipose tissue 
respectively is a measure of the rate of appearance (Ra) of glucose and glycerol in a participant 
studied in a fasting state. In an isotopic steady state, Ra equals the Rd of the substrate if the infusion 
rate remains constant. The effect of exogenous insulin on glucose and glycerol metabolism can then 
be calculated.
1.6. Brain function
Insulin signalling in the brain seems to occur earlier than in the periphery (Hennige et al. 2006) and 
has effects on brain development, cognition and control of appetite (Moore et al. 2011). The central 
nervous system produces little or no insulin. Therefore, insulin is derived from the circulation and 
has to cross the blood brain barrier. Insulin crosses the blood brain barrier through the process of 
saturable receptor-mediated transcytosis to reach insulin receptors. Insulin receptors have been 
demonstrated throughout the human brain, with particularly high concentrations in the 
hypothalamus, cerebellum, and cortex (Hopkins & Williams 1997). Figure 18 shows a schematic 
diagram of the endothelial cells that form the blood-brain barrier.
Endogenous insulin has been shown to inhibit food intake and reduce body fat in humans and
animals suggesting that insulin has negative, anorexigenic feedback on the brain (Moore et al
2011). There have also been a number of studies suggesting that dysregulation of insulin action at
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the level of the insulin receptor in the central nervous system is associated with obesity (Tschritter 
et al 2006). Insulin therefore seems to play an important role in the control of appetite and 
inversely weight.
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Figure 18. A schematic diagram of the endothelial cells that form the blood-brain barrier.
(Abbott et al. 2006).
Exogenous insulin also seems to have an ability to influence weight but interestingly it is associated 
with weight gain. There also seems to be marked differences in the extent of weight gain between 
insulin’s. Insulin detemir has been shown to cause no weight gain in patients with type 1 diabetes 
(Zachariah et al. 2011), compared with NPH insulin, and lower weight gain in patients with type 2 
diabetes (Frier et al. 2013) Insulin detemir appears to have a beneficial effect by significantly 
reducing energy intake when compared with NPH in patients with type 1 diabetes (Zachariah et al. 
2011). The mechanism behind this is not fully understood but a possible hypothesis is that insulin 
detemir results in a reduction in defensive snacking. However, the assumption that insulin detemir 
limits weight gain because it has favourable safety profile that decreases defensive snacking to 
prevent hypoglycaemia has not been supported by a number of studies (Wing et al. 1990; Davies et 
al. 2008). An alternative hypothesis is that insulin detemir may lead to a reduction in peripheral
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lipogenesis and reduction in lipolysis resulting in less weight gain or insulin detemir may in fact 
have a greater direct effect on the brain to influence appetite and therefore reduce energy intake.
In 2010, Hallschmid investigated the relevance of enhanced central nervous detemir action in the 
regulation of food intake by assessing the effects of intravenous insulin detemir in comparison with 
human insulin on electroencephalography (EEC) direct current potentials during a euglycaemie 
clamp protocol. EEG direct current (DC) potentials are sensitive to changes in insulin concentration 
(Hallschmid et al. 2004). Differential effects on DC potential EEG were seen between insulin 
detemir and human insulin with an associated relative decrease in food consumption, supporting an 
enhanced anorexigenic effect from detemir (Hallschmid et al. 2010). In this study detemir was 
given intravenously to 15 healthy weight normal men. Intravenous insulin may act differently to 
subcutaneous insulin, which is the preferred method of insulin administration in people with type 1 
diabetes. There may be a difference between subcutaneous and intravenous insulin in the portion of 
insulin that is bound and unbound to albumin and the volunteers were given a higher dose of insulin 
detemir than human insulin to compensate for the delayed onset of action that equimolar detemir
1.7. Hypothesis
The ideal insulin needs to maintain the physiological portal / peripheral insulin gradient and mimic 
physiological insulin action. However, the frequency of hypoglycaemia and associated weight gain 
are major concerns to the patient and the persistence of micro vascular and macro vascular 
complications are a significant cause of morbidity and mortality.
Insulin detemir appears to result in less weight gain and be associated with reduced hypoglycaemia 
frequency when compared with human insulin and insulin glargine. It is hypothesised that this 
favourable profile is because insulin detemir partially restores the normal portal / peripheral insulin 
gradient. Loss of the normal portal / peripheral insulin gradient results in relative peripheral 
hyperinsulinaemia and underinsulinisation of the liver (Shojaee Moradie et al. 1995). This can lead 
to a variety of metabolic abnormalities including glycaemic fluctuations, dyslipidaemia and 
reduction in hepatic IGF-1 with consequent elevation in GH (Sonksen et al. 1993). The metabolic 
changes are more pronounced in patients with poor diabetes control and may be implicated in the 
long-term micro and macro vascular complications of diabetes (Shojaee-Moradie et al. 2000).
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If insulin detemir demonstrates partial hepatoseleetivity, it would have a greater effect on 
endogenous hepatic glucose production during hyperglycaemia than the comparative NPH insulin 
and a lesser effect on peripheral glucose uptake. This should be more apparent at the lower end of 
the dose response curve for hepatic glucose production. It is also hypothesised that insulin detemir 
may affect brain function differently than NPH insulin. Any differences in central nervous effect 
may be responsible for the beneficial effects on weight gain.
To correlate the study findings to clinical practice it is important to establish the effects of insulin 
detemir using clinically relevant insulin doses and clinically relevant delivery methods. Insulin 
detemir has historically been compared with NPH insulin due to the similar action profiles. 
However, currently insulin glargine or insulin detemir are the preferred choice for basal insulin in 
people with type 1 diabetes. It would seem reasonable to consider a three-arm study including 
insulin glargine. However, this would have required additional metabolic studies and an extension 
to the metabolic study duration, which was technically difficult.
1.7.1. Aims
To delineate the importance of the physiological action of insulin on the liver versus the periphery 
and to compare the effects of insulin detemir and conventional insulin on glucose flux, lipolysis and 
brain function in type 1 diabetes. Specifically
A) To study the effect of subcutaneous insulin detemir and NPH insulin on glucose flux and 
lipolysis measured using stable isotope techniques at the lower end of the dose response curve for 
hepatic glucose production.
B) To study the effect of subcutaneous insulin detemir and NPH on glucose flux, measured using 
stable isotope techniques and brain function measured by EEG during a period of euglycaemia with 
blood glucose clamped at 5mmol/l and hyperglycaemia with blood glucose clamped at lOmmol/1.
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Chapter 2. Clinical Methodology
2.1. Participants and informed ethical consent
This was a single centre, investigator led, metabolic study with two protocols studying 12 patients 
with type 1 diabetes. The two protocols were identified as:
1. Insulin withdrawal protocol
2. Euglycaemie / hyperglycaemic clamp protocol
Participants for each protocol were recruited fi*om 6  September 2011 until 6  June 2012 from the 
diabetes register at Royal Surrey County Hospital. Suitable participants were identified from clinic 
lists with the assistance of the diabetes specialist team. All subjects gave written informed consent. 
Withdrawals were replaced on a case by case basis. Subjects could volunteer for both protocols.
Ethics was granted from NRES Committee London - Hampstead. REC reference: 11/LO.0687. The 
trial was registered on the European Clinical Trials Database (EudraCT) number: 2011-001642-14 
and funding was provided by Novo Nordisk A/S.
Inclusion Criteria:
1. Informed consent obtained before any trial related activities.
2. Type 1 diabetes according to clinical judgement.
3. Duration of Type 1 diabetes greater than 12 months.
4. Current treatment basal bolus, biphasic insulin regimes or continuous subcutaneous insulin 
infusion.
5. Age greater than 18 years.
6 . BMI of less than 35.
7. HbAlc of greater or equal to 37mmol/mol (5.5%) and less than 75mmol/mol (9%).
8. Able and willing to complete the trial.
Exclusion Criteria:
1. Proliferative retinopathy that has required acute treatment within last three months.
2. Impaired hepatic or renal function as judged by the investigator.
3. Cardiac problems as judged by the investigator.
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4. Uncontrolled hypertension. (BP greater than 160/90)
5. Mental incapacity.
6 . Pregnancy.
7. Known or suspected allergy to trial products.
8 . Any other condition that the investigator feels would interfere with trial participation. 
Withdrawal Criteria
A subject was withdrawn due to the following
1. Withdrawal of informed ethical consent
2. If protocol violation or current illness occurred which was judged to invalidate the study
3. An adverse event: if participants reported symptoms, which were considered unacceptable by 
the subject or clinically unacceptable to the study coordinators.
2.2. Study protocol
Participants could consent for either or both of the study protocols. For each protocol, participants 
were required to attend the research unit at Royal Surrey County Hospital for three visits.
Visit 1 : Screening and informed ethical consent
Visit 2 and Visit 3: The randomised metabolic study visits.
Visit 2: First metabolic study for insulin detemir or NPH insulin 
Visit 3: Second metabolic study for insulin detemir or NPH insulin
2.2.1. Metabolic study preparation for both protocols
Randomisation and informed ethical consent
45 participants were screened for inclusion and participation in the study. The screening, 
randomisation and study participants details are shown in figure 19. For the insulin withdrawal 
protocol, 15 participants gave written informed ethical consent and were randomised. One 
participant withdrew informed consent before the first metabolic study (NN12), one was withdrawn
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following difficulty with venous access (NN8 ) and one was withdrawn due to failure to reach a 
hyperglycaemic state after 6  hours of intravenous insulin withdrawal (NN2). 12 participants 
completed the insulin withdrawal protocol but one participant was withdrawn during the analytical 
process, as the metabolic tracer could not be detected for the last 4 hours of one metabolic study 
(NN9).
For the euglycaemie / hyperglycaemic hyperinsulinaemic clamp protocol, 13 participants gave 
written infonned consent and were randomised. 1 2  participants completed the study with 1 
participant withdrawing consent before the first metabolic study (NN18)
45 Screened for participation
26 Withdraw before screening or 
did not meet inclusion criteria
Euglycaemie / hyperglycaemic 
clamp protocol
13 Consented and randomised
Insulin withdrawal protocol
15 Consented and randomised
[
1 Dropped out __ 3 Dropped out
1
. i .
12 Participants completed the 12 Participants completed the
euglycaemie / hyperglycaemic insulin withdrawal metabolic
clamp metabolic protocol protocol
I
12 Participants data analysed.
1 Dropped out
Analytical
problem
11 Participants data analysed.
Figure 19. Screening, randomisation, and metabolic studies of study participants.
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For each protocol, participants were randomly allocated at the trial site to receive either insulin 
detemir or human insulin in random order. Randomisation was undertaken by the chief investigator 
using the website randomization.com. A copy of the randomisation list was kept in Pharmacy.
This trial was single blind. It was difficult to achieve double blind as the participants were given 
commercially available insulin pen devices and could tell if the insulin was clear or cloudy. The 
trial investigator remained blinded throughout. Trial products were insulin detemir 100 units/ml 3 
ml fiexpen solution for injection (Novo Nordisk A/S) and isophane human insulin (NPH) Insulatard 
100 units/ml, solution for injection (Novo Nordisk A/S). Accurate records of all trial products 
received and the products used for each participant were kept. Insulin detemir and NPH insulin 
were stored refidgerated (2 to 8  C) in Pharmacy and all used insulin was returned to Pharmacy.
Metabolic study preparation
Participants were asked not to consume food and to drink only water after 22:00 the day before a 
metabolic study. They were also discouraged from exercising and drinking alcohol the evening 
before a metabolic study due to the effects on insulin sensitivity. To minimise any carry-over effect 
from the participants’ regular insulin, participants using a multiple daily injection insulin regime 
were asked to omit their long acting insulin (basal insulin) the night before the metabolic study. 
Participants using a subcutaneous insulin infusion pump were asked to continue with their normal 
insulin pump settings until they attended the research unit on the morning of the metabolic study.
Participants were admitted to the research unit at 7:30 the morning of the metabolic study. Baseline 
participant information was collected. Weight (without shoes) was measured using body 
composition analyser (MC780 Multi frequency segmental body composition analyser, Tanita. 
Tokyo, Japan). Height (without shoes) was recorded using a stand-alone stadiometer for height 
measurement, manufacturer unknown. Body Mass Index (BMI) was calculated. The calculated BMI 
was rounded up/down to nearest whole figure.
All participants were studied in a semi-recumbent position and allowed to drink clear water only. 
Cannulation was made with an 18-gauge venfion cannula inserted into a vein in each arm. One 
cannula was used for blood sampling, the other for administration of intravenous infusâtes (human 
insulin, [6 ,6 -^H2 ]glucose and [1,1,2 ,3 ,3 -^H2 ]glycerol).
Following cannulation, baseline blood samples were taken to measure glucose and glycerol 
concentration and isotopic enrichment (sample time -120 mins). Blood samples were taken with
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sterile syringes and blood collected in vacutainer blood collecting tubes. Blood taken for glucose 
concentration and enrichment was collected in a floride oxalate vacutainer, blood for glycerol 
concentration and enrichment was collected in a lithium heparin vacutainer, blood for insulin 
concentration were collected in serum vacutainers and blood taken for NEFA concentration was 
collected in an EDTA vacutainer. Blood samples were separated immediately using a centrifuge 
(Heraeus Labofuge 400 centrifuge. Thermo Fisher Scientific. UK) and plasma stored at -20°C, with 
the exclusion of the glycerol samples which were stored at -80°C.
Blood glucose concentration was measured throughout the metabolic study using a glucose 
oxidase technique on a glucose analyser (YSI2300 Clandon Scientific, Yellow Springs 
Instruments, Yellow Springs, Ohio, USA). This method is based on glucose oxidation.
2.2.2. Insulin withdrawal protocol
Participants were transferred to a soluble variable insulin infusion to maintain a blood glucose 
concentration of 5mmol/1. The insulin infusion consisted of 50 units of human insulin actrapid 
(manufactured as 1 0  ml solution in vial (type 1 glass) closed with a disc (bromobutyl/polyisoprene 
rubber) and a protective tamper proof plastic cap for injection ((Novo Nordisk A/S) in 48ml sodium 
chloride 0.9% and 2ml of autologous blood.
Stable isotopes of glucose and glycerol were infused from -120 mins to the end of each study 
protocol to measure the rate of hepatic glucose production, peripheral glucose uptake and peripheral 
lipolysis. Stable labelled isotope [6 ,6 -^H2 ]glucose and [ 1,1,2,3,3-^H2 ]glycerol tracers (Cambridge 
isotopes, CK Gas Products Ltd, UK) were prepared in sterile solutions suitable for intravenous use 
by the Pharmacy Production Unit at Guys and St Thomas’ NHS Trust. Glucose and glycerol tracers 
were dissolved in sterile pyrogen free saline (NaCl 0.9%) to give lOOmg/ml and 30mg/ml, 
respectively. The glycerol and glucose tracers were stored at room temperature in sealed ampoules. 
On the day of the metabolic study 1.7mg per minute of [6 ,6 -^H2 ]glucose and 0.4mg/kg/h of 
[ 1,1,2,3,3-^H2 ]glycerol was required for a continuous infusion with 1.7mg priming dose of 
[6 , 6 -^H2 ]glucose at commencement of the infusion. The calculated amount of glycerol and glucose 
tracer was transferred to a sterile 50ml syringe and volume made up to 50ml with sterile normal 
saline. The infusion rate was set at 5ml/h. The priming dose of [6 ,6 -^H2 ]glucose reduced the time 
to isotopic stabilisation. It took approximately 120 mins to achieve isotopic steady state, which is 
defined as the point where the isotopes entering and leaving remain constant with time.
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At isotopic steady state (0 mins) the intravenous insulin infusion was stopped and the blood glucose 
concentration was allowed to rise to 7mmol/l. At 7miuol/l participants were given in random order 
0.5 Units/kg of either insulin detemir (Novo Nordisk) or NPH insulin (Novo Nordisk). Insulin was 
administered by subcutaneous injection to the abdomen using a Novopen 4 insulin pen by a clinical 
research nurse not involved in the study. The research doctor leading the metabolic studies was 
blinded to the insulin received. The clinical protocol for the insulin withdrawal study is shown in 
Figure 20.
15-
1 0
Glucose concentration 
(mmoi/l)
in s u l in  D e te m ir  /  N P H  O .SU /kg
Insulin infusion Insulin withdrawn
6,6 glucose infusion 1.7mg/min and 1.1,2,3,3 glycerol (0.4mg/kg/hr)
-120 O 240 320 410 min
Figure 20. Insulin withdrawal protocol.
Blood samples for the measurement of glucose and glycerol concentration and enrichment and 
NEFA concentration were taken at pre determined time intervals and continued until 420 mins or 
until the blood glucose levels fell to 5mmol/1. The schedule for blood sampling is shown in
Table 2.
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Table 2. Blood Sampling Scheme for insulin withdrawal protocol
Time (min) Action Blood sampling (volume)
Glucose 
Cone and 
Enrichment 
(Fluoride)
(1 ml)
Glycerol 
Cone and 
Enrichment 
(Lith hep)
(4 ml)
Lipids
(EDTA)
(2 ml)
Arrival 
Cedar Centre
Sliding scale insulin infusion 1 U/ml (3-0.5 ml/h)
Arrival to 
8  am
15 minute interval blood glucose monitoring; maintenance of 
glucose at 5 mmol/1
- 1 2 0 X X
- 1 2 0  to the 
end of study
Start [ 6 , glucose and [l,l,2,3,3-^H2]glycerol infusion
-30 X X
- 2 0 X X
- 1 0 X X
0 X X X
0 - Cessation of insulin infusion and glucose concentration and letting glucose 
to rise to 7 mmol/1. Monitoring at 20 minute intervals
Time scale 
from 0 ?
SC Bolus injection of NPH insulin or detemir when glucose concentration 
is 7 mmol/1
+ 0 10 minute interval blood glucose monitoring to avoid hypoglycaemia
+ 0 X X
2 0 X X
40 X X
60 X X
80 X X
1 0 0 X X
1 2 0 X X X
140 X X
160 X X
180 X X
2 0 0 X X
2 2 0 X X
240 X X X
270 X X
300 X X
330 X X
360 X X
420 X X X
64
Participants were provided with food at completion of the metabolic study. To reduce the risk of 
nocturnal hypoglycaemia following the metabolic study, participants were asked to resume their 
normal bolus insulin requirements but not to administer their long acting insulin the evening of the 
metabolic study. For participants with a subcutaneous insulin infusion pump they suspended their 
basal rate until they went to bed then set their basal rate at half their normal rate for 6  hours.
2.2.3. Euglycaemie / hyperglycaemic clamp protocol
EEG electrodes were attached from -240 to 300 mins to measure AC (alternating current) and DC 
(direct current) activity. Participants were then transferred to a soluble variable insulin infusion to 
maintain a blood glucose concentration of 5mmol/l. The insulin infusion consisted of 50 units of 
human insulin actrapid (manufactured as 1 0  ml solution in vial (type 1 glass) closed with a disc 
(bromobutyl/polyisoprene rubber) and a protective tamper proof plastic cap for injection ((Novo 
Nordisk A/S) in 48ml sodium chloride 0.9% and 2ml of autologous blood.
Stable isotopes of glucose were infused from -120 mins to the end of each study protocol to 
measure the rate of hepatic glucose production, peripheral glucose uptake. On the day of the 
metabolic study 1.7mg per minute of [6 ,6 -^H2 ]glucose was required for a continuous infusion with 
1.7mg priming dose of [6 , glucose at commencement of the infusion. The calculated amount 
of glucose tracer was transferred to a sterile 50ml syringe and volume made up to 50ml with sterile 
normal saline. The infusion rate was set at 5ml/h. It took approximately 120 mins to achieve 
isotopic steady state.
At isotopic steady state (0 mins), participants were given in random order 0.5 Units/kg of either 
insulin detemir (Novo Nordisk A/S) or NPH insulin (Novo Nordisk A/S). The insulin was 
administered by subcutaneous injection to the abdomen using a Novopen 4 insulin device by a 
clinical research nurse not otherwise involved in the study. The intravenous variable rate insulin 
was tailed off over a period of 90 mins following the subcutaneous insulin injection. This enabled 
the effects of subcutaneous NPH or detemir to be studied after 90 mins but also maintaining a 
relatively constant euglycaemie period. A variable rate infusion of dextrose spiked with 
[6 ,6 -^H2]glucose was given to maintain the blood glucose at 5 mmol/1. Blood glucose concentration 
was measured at 7 min intervals and the rate of glucose infusion altered. At 210 mins the GINF 
was increased with the aim of raising the blood glucose concentrations to 10 mmol/1 until 300 
minutes using 7 min glucose determinations and a variable rate of glucose infusion, which consisted
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on a 15 min ‘priming dose’ and then adjustable infusion rate. The euglycaemie / hyperglycaemic 
clamp protocol is shown in Figure 21.
EEG - AC and DC potential recording
10 mmol/l
Blood concentration 5mmol/l
s c  Bolus NPH/ 
Detemir 0.5U kg BW
Glucose infusion spiked 
with 6,6 glucose
Insulin infusion
6,6  g lu c o s e  1 .7m g/m in
-120min 0 300 Time
Figure 21. Euglycaemie / hyperglycaemic hyperinsulinaemic clamp protocol.
Blood samples for measurement of glucose concentration and enrichment and enrichment and 
NEFA concentration were taken at pre determined time intervals and continued until 300 mins or 
until the blood glucose levels fell to 5mmol/l. The schedule for blood sampling during the 
euglycaemie hyperglycaemic clamp protocol is shown in table 3.
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Table 3. Blood Sampling Scheme for euglycaemie / hyperinsulinaemic clamp protocol
Time (min) Action Blood sampling (volume)
Glucose 
Cone and 
Enrichment 
(Fluoride)
( 1ml)
Lipids
(EDTA)
(2 ml)
-240 Sliding scale insulin infusion 1 U/ml (2-0.5 ml/h)
-240 to 300 15 minute interval blood glucose monitoring; maintenance of 
glucose at 5 mmol/l;
AC and DC EEG monitoring to the end of study at 300 min.
- 1 2 0 X
-120 to 400 Start [6 ,6 -^H2]glucose infusion
- 2 0 X
-15 X
- 1 0 X
-5 X
0 X X
0 SC Bolus injection of NPH/Detemir
0-90 Cessation of sliding scale insulin infusion as glucose 
concentration falls below 5 mmoEl
0-90 Initiation of variable infusion of 20% glucose spiked with 2H2 
glucose; maintenance of clamp glucose at 5 mmoE 1
15 X
30 X
45 X
60 X
90 X
1 2 0 X X
150 X
180 X
2 1 0 X X
2 1 0 Variable 20% glucose infusion is increasec 
clamp concentration to 1 0  mmol/l
to adjust glucose
240 X
270 X
300 X X
Food will be given to the patient with appropriate insulin dose
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To prevent rapid changes in the tracer to tracee ratio of glucose during the euglycaemie and 
hyperglycaemic clamp protocol, the 2 0 % dextrose was spiked with tracer at the start of the 
euglycaemie and the start of the hyperglycaemic clamp. Four mg/g of [6 , glucose tracer was 
injected into the 500ml bag of 20% dextrose at the start of the euglycaemie clamp and a further four 
mg/g of [6 ,6 -^H2 ]glucose tracer was injected into the same 500ml bag of 20% dextrose at the start 
of the hyperglycaemic clamp period.
EEG is the recording of electrical activity from the scalp. It measures voltage fluctuations from 
ionic current flows within the brain and is easy to perform in a clinical or research environment. 
EEG has advantages over other methods for measuring brain function such as positron emission 
tomography (PET) scanning or functional magnetic resonance imaging (FMRI) because it is non- 
invasive, is not labour intensive and recordings can be obtained over a prolonged period of time. 
However, the limitations of EEG are that the recorded electrical activity is not related to activity in 
specific brain locations and there is also no direct correlation with human or behavioural activity.
EEG recordings can be obtained using direct current (DC potentials) and alternating current (AC 
potentials). EEG activity is measured in mVolts at different frequencies. The DC-potential is the 
actual “standing” or “zero hertz” component of the EEG. It allows the measurement of slow graded 
changes in brain potential. The predominant source is the glial cells, which support and regulate 
neurons. Glial cells are related to cortical arousal and have insulin receptors. AC-potentials 
represent synchronised activity over a network of neurons and are grouped according to a variety of 
signal frequencies, which are associated with different states of brain functioning (e.g. waking and 
various sleep stages). The delta band has a frequency of 0.5 - 5Hz, the theta band has a frequency of 
5-8Hz, the alpha band has a frequency of 8-12Hz, the beta band has a frequency of 12-25Hz and the 
gamma band has a frequency of 25-35Hz.
EEG recordings were taken using a portable SKU: M97130 Vitaport recorder, (Temec Instruments 
B.V. Netherlands) The EEG electrode positions are shown in figure 22. Continuous DC-potential 
EEG recordings were obtained from left and right frontal (F3, F4), left and right frontocentral (FC3, 
FC4) and left and right central (C3, C4) electrodes. The DC-potential during baseline was set at 0 
V, and potential shifts during treatment were expressed as difference from baseline. AC-potential 
was recorded continuously from left and right frontal (F3, F4), left and right frontocentral (FC3, 
FC4) and left and right occipital (01,01) electrodes.
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To interpret EEG AC-potential data, a reliable method is needed to assess subjective and 
behavioural alertness. The degree of alertness may affect the EEG AC-potential recordings. The 
Karolinska Drowsiness Test (KDT) is a recognised objective method to measure EEG activity 
during periods of alertness and sleepiness (Akerstedt & Gillberg 1990) and is technique familiar to 
the research team. Alertness was assessed during a 3 min period of eyes open and sleepiness during 
a 3 min period of eyes closed. Each KDT session lasted 6 mins and was undertaken at time points - 
120, -30, subcutaneous insulin dose (0) +30, +45, +90, +135, + 180, +225 and +270 minutes. The 
KDT sessions were labelled on the continuous EEG AC-potential recordings as 3 minutes eyes 
open and 3 minutes eyes closed.
F3 F4
FC3 FC4
C3 C4
F3 F4
C3 04
01 02
Figure 22. EEG electrode positions for AC and DC potential recordings
The biggest challenge with monitoring EEG is artifact recognition and elimination. There are 
patient related artifacts (e.g. movement, sweating, eye movements) and technical artifacts (50/60 Hz 
artifact, cable movements, electrode paste-related). To limit interference and any shift in electrode 
position, a manual operated bed was used, the syringe pump was placed at the end of the bed and 
run on battery supply rather than mains supply and participants were encouraged to undertake low 
movement activities such as reading, watching a film and not to use mobile phones.
At the end of the metabolic study participants were provided with food. To reduce the risk of 
nocturnal hypoglycaemia following the metabolic study, participants were asked to resume their 
normal bolus insulin requirements but not to administer their long acting insulin the evening of the 
metabolie study. For participants with a subcutaneous insulin infusion pump they suspended their 
basal rate until they went to bed then set their basal rate at half their normal rate for 6 hours.
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Chapter 3. Analytical methods
3.1. Gas-chromatography mass spectrometry (GC-MS)
The analysis of stable isotope enrichment for the metabolic tracer studies was performed by gas- 
chromatography mass spectrometry (GC-MS) (model HP 5971A and a mass selective 
detector (Agilent Technologies, Berkshire, U.K.).
The advantage of GC-MS is that plasma enrichment and concentration can be measured at the same 
time, multiple samples can be analysed in one assay and molecular separation occurs by time and 
mass. However, before samples can be analysed by GC-MS they must be derivatised.
The aim of derivatisation was to convert the samples to molecules (derivatives) that were thermally 
stable, chemically inert and volatile at temperatures below 300°C. Compounds that have poor 
volatility, poor thermal stability, or that can be adsorbed in the injector will exhibit non 
reproducible peak areas, heights, and shapes.
The GC utilises a capillary column to separate the molecule of interest from other molecules in a 
complex mixture. The separation depends on the column's dimensions (length, diameter, film 
thickness) as well as the stationary phase properties (e.g. crossbonded dimethyl polysiloxane) and 
column temperature. Derivatised samples are injected into the gas chromatograph and then 
vaporised in the injection chamber (250°C) of the GC-MS. They are swept through the GC column 
by an inert mobile phase (helium) gas. The difference in the chemical properties between different 
molecules in a mixture will separate the molecules as the sample travels the length of the column. 
The molecules enter the ionisation chamber, which results in the formation of charged ions. 
Electrons bombard the molecules, causing the molecules to fi*agment in a characteristic way. The 
ions can then be separated in the quadruple mass analyser according to their mass to charge ratio 
(m/z).
3.2. Experimental protocols 
Plasma glucose concentration
Analysis of [6 ,6 -^H2 ]glucose (enriched glucose) was performed at the Wolfson Centre for 
Translational Research, Leggett building. University of Surrey.
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Total plasma glucose concentrations and infusate glucose concentrations were measured on a Roche 
Cobas MIRA, using the ABX Pentra glucose kit (Horiba ABX, Northampton, UK). This kit is a 
diagnostic assay for the quantitative determination of glucose in human serum, plasma and urine 
based on an enzymatic method using hexokinase coupled with glucose-6 -phosphate dehydrogenase.
The inter assay coefficient of variation (CV) was determined for the glucose concentration using 
quality control samples fi'om 26 assays specific to this study. The inter assay is the variation 
between standards for different assays. The inter assay CV was 4.45% for the normal control 
(5.34mmol) and 5.22% for the high control (13.6mmol).
Plasma glucose enrichment
The isotopic enrichment of plasma glucose was determined as the trimethylsilyl 0-methyloxime 
derivative (MOX-TMS), a method previously employed by Laine and Sweeley in 1971, using 
GC-MS (model 597SCMSD inert XL EI/CIMSD, Agilent Technologies, Berkshire, U.K.).
Plasma samples to provide quality controls (QC) for batch analysis were prepared from aliquots of 
pooled plasma. Three levels of [6 ,6 -^H2 ]glucose enriched QCs (baseline, medium and high) were 
prepared using the pooled plasma. Quality controls were analysed with each batch of study samples.
Deproteinisation
Samples and quality controls were fully thawed and thoroughly mixed by vortexing. After 
centrifugation at 4°C, 2500 rpm for 10 mins, plasma (50pl) samples were deproteinised by the 
addition of 500pl of ethanol and repeat centrifugation for 10 mins at the same settings as before. 
The supernatant was then transferred and dried under a continuous stream of oxygen fi*ee nitrogen 
(OFN) at 50°C.
Derivatisation
The sample was then treated with lOOpl of methylhydroxamine hydrochloride freshly made in 
pyridine 2% % . Following this, the solution was heated at 90°C in a heating block for 2 hours.
Once cooled, 50pl BSTFA (V, 0-Bis (trimethylsilyl) trifluoroacetamide with 
trimethylchlorosilane) was added, followed by additional heating at 120°C for 15 mins. Excess 
reagents were removed under oxygen free nitrogen (OFN) at room temperature and then the sample 
was reconstituted in 500pl of decane. Fifty pi of the above sample was further diluted in 500pl of
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decane ready for GC-MS analysis. The MOX-TMS derivative of glucose and [6 ,6 -^H2 ]glucose are 
shown in figure 23 and 24. The dotted line represents the point of ion fragmentation.
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Figure 23. MOX-TMS derivative of glucose.
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Spiked 20% dextrose samples were diluted in 1:300 in duplicate for each bag (10 pg dextrose in 
3mis of double distilled H2 O before processing through the same assay as the plasma glucose 
samples.
Samples were then injected (Ipl) into the GC eolumn by the auto sampler, in the splitless mode.
The injection port temperature was 250°C. The GC column (30m, 0.25mm internal diameter, 
0.25pm film thickness, 100% dimethyl polysiloxane) temperature was held at 120°C for 1 minute 
and then increased at 20°C/minute to 300°C and held at the final temperature for 1 minute. The total 
run time was 12 minutes. The mass spectrometer was operated in the positive ion electron 
ionisation mode (70eV). Selected ions at 319 and 321 were monitored for glucose and [6 , 6 ^H2 ] 
glucose respectively. Figure 25 shows the selected ion chromatograms for the MOX-TMS glucose 
derivative ion 319.
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Figure 25. Selected ion chromatograms for m/z 319 and m/z 321 in a plasma sample.
Peak areas were used to calculate the stable isotopic enrichment. The area ratio of peaks at m/z 
321.2 and 319.2 were calculated at each time point and corrected for the area ratio at time -120 
minutes (i.e. before administration of metabolic isotopes).
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The inter assay CV was determined for the baseline and enriched quality control samples for 25 
assays specific to this study. The inter-assay CV’, were 0.54% for QCl (baseline), 0.40% for QC2 
(medium) and 0.55% for QC3 (high).
To ensure a linear response for the glucose enrichment measurements, standards were prepared and 
analysed on the GC-MS. The observed enrichments were calculated from the 321 and 319 ion area 
ratios and plotted against theoretical enrichments to obtain an enrichment calibration curve. A 
glucose calibration curve is shown in figure 26. A linear relation (r2=0.9989) was observed with a 
slope close to unity (0.98)
D2 Enrichment
y = 0.9816x4-0.1432
= 0.99899
N 0.18
0.14
0.04 0.06 0.08
T heoretical ratio m o l/m o l D 2 /D 0
0.12
Figure 26. Glucose enrichment calibration curve.
Plasma glycerol concentration
Total plasma glycerol concentrations were measured on a Cobas MIRA. Plasma glycerol 
concentrations were measured using Randox glycerol kit (Randox Laboratories, Co. Antrim, UK).
It is a direct colorimetric assay that utilises a quinoneimine chromogen system in the presence of 
glycerol kinase, peroxidase and glycerol phosphate oxidase.
The inter assay CV was determined for enriched quality control samples from 10 assays specific to 
this study. The inter assay CV was 10%.
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Plasma glycerol enrichment
The plasma glycerol enrichment was determined as the tert-butyltrimethylsilyl (tBDMS) glycerol 
derivative using a GC-MS model 5973 network MSD, Agilent Technologies, Berkshire, U.K.).
Plasma samples to provide QC’s for batch analysis were prepared from aliquots of pooled plasma. 
A baseline and 2 levels of [l,l,2,3,3-^H5]glycerol enriched QCs (approximately 1.0 pg/mL and 3.0 
pg/mL respectively) were prepared using the pooled plasma and stock standards of natural glycerol 
and [ 1,1,2,3,3-^Hs]glycerol in deionised water. QCs were analysed with each batch of study 
samples.
Deproteinisation
Samples and quality controls were fully thawed and thoroughly mixed by vortexing. Plasma 
samples (500 pL) were then centrifuged at 2500 rpm for 10 mina at 4°C to precipitate any proteins. 
While ensuring the pellet was not disturbed, 500 pL of each plasma sample and quality control was 
pipetted into a labelled tube. One millilitre of 3.5% sulphosalicylic acid (SSA) was added to each 
test tube to precipitate proteins dissolved in the samples and QCs and thoroughly mixed by 
vortexing. The samples were left to stand in a refrigerator for 30 minutes before centrifuging at 
2000 rpm for 20 mins at 4°C.
Ion exchange chromatography
The ion exchange columns were first washed with 500 pL of deionised water. Slurries of cation 
resin AGX-X8 100-200 mesh, hydrogen form and anion resin AG1-X8, 200-400 mesh, formate 
form were prepared in separate beakers in deionised water. Approximately ImL of cation resin was 
pipetted into each column and the water allowed to drain. The resin was washed with ImL of 
deionised water and allowed to drain. Once the resin had settled, ImL of anion resins was added to 
create a second layer. The resin was washed with 2mL of deionised water and capped to prevent the 
resin from drying up before the next step.
Caps were removed and the water was allowed to drain from the column. A labelled 10.5mL glass 
vial was placed under the column once the meniscus of the water reached the top of the resin. The 
supernatant in the test tubes after centrifugation was transferred to the top of the resin and the eluate 
was collected in the 10.5mL glass vial. The column was then rinsed with 3mL of deionised water 
and the eluate collected in the same 10.5mL glass vial. The vials were covered with parafilm with 
small holes pierced into them and frozen at -20°C. Once completely frozen, the contents of the vials
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were lyophilised overnight on the freeze dryer (MODULYOD Thermo Electron, UK). Lyophilised 
samples were removed from the freeze dryer and capped for storage in the refrigerator (4°C) or 
freezer (-20°C) until ready for analysis on the GC-MS.
Derivatisation
The glycerol samples were converted into highly volatile tri-acetate derivative to be analysed by 
chemical ionisation mode by GC-MS. Chemical ionisation is more gentle than electron ionisation 
and is associated with less fragmentation. The samples were frozen, so 200 pL of dichloromethane 
(DCM) was added to the vial and thoroughly mixed by vortex. The contents of the vial were then 
put under OFN to blow dry, with care being taken not to over dry the contents to prevent it from 
being blown away.
Fifty pL of pyridine and 50 pL of acetic anhydride were added to each vial and allowed to stand for 
30 mins at room temperature to allow complete derivitisation. The contents of the vial were then put 
under OFN to blow dry for approximately 25 mins at room temperature. Fifty pL of ethyl acetate 
was added to the dried residue and thoroughly mixed by vortex. The contents of each vial were 
transferred into labelled small GC-MS autosampler vials for measurement on the instrument.
After a 2pL splitless injection of the derivatised sample into the GC column (30m, 0.25mm internal 
diameter, 0.25pm film thickness, 5% diphenyl / 95% dimethyl polysiloxane), the oven was held at 
70°C for 2 min then increased to 250°C at 25°C/min. The total run time was 12 mins with glycerol 
and [l,l,2,3,3-^Hs] glycerol eluting at approximately 7.5 mins.
Peak areas were used to calculate the stable isotopic enrichment. The area ratio of peaks at m/z 164 
[1,1,2,3,3-^H5] glycerol and 159 for unlabelled glycerol were calculated at each time point and were 
corrected for the area ratio at time -120 minutes (i.e. prior to administration of the isotopes).
The inter assay CV was detennined for the enriched quality control samples from 41 assays. The 
inter assay CVs were, 2.1% for QC 1 (1.0 pg/mL) and 0.4 % for QC2 (3.0 pg/mL).
Dilutions of the stock standards were used to determine elution times, reproducibility and 
calibrations. A linear relation (r2=0.99946) was observed with a slope close to unity (1.0326) and 
is shown in figure 27.
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Figure 27. Glycerol enrichment calibration curve.
Non-esterified fatty acids
Plasma NEFA was measured using a Randox Calorimetric kit (Randox Laboratories, Co. Antrim, 
UK) on a Roche Cobas MIRA. The nonnal range for plasma NEFA concentration is between 0.1- 
0.9 mmol.
The inter assay CV was determined for quality control samples for 30 assays of which 2 assays 
were specific to this study. The inter assay CV was 10.4% .
3.3. Data analysis
Endogenous glucose production, peripheral glucose uptake and glycerol production were calculated 
using Steele’s non-steady state equations modified for stable isotopes (Steele et al. 1956). Before 
calculation of glucose turnover and glycerol production rates, time courses were smoothed and 
interpolated to 5 min intervals using optical segments technique analysis (OPSEG) (Finegood & 
Bergman 1983). Glucose Ra and Rd were plotted against glucose concentration. The boundaries for 
each glucose concentration were ±0.05 mmol/1, so for example, any plasma glucose concentration 
between 5.95 and 6.05 mmol/1 was considered to be a concentration of 6 mmol/1.
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3.3.1. The Steele Equation
Insulin withdrawal protocol
The Steele equation is a standard equation and can be used to calculate the rate of appearance and 
rate of disappearance. For the last 50 years, there has not been any other approach published that is 
better. Consequently, the Steele equation is widely used and generally accepted in the literature as a 
reliable way to measure glucose metabolism. The Steele equation is shown below (Wolfe 1984).
Rate of appearance (Ra) = F-pV r(C2 +CQ/21 ([TTR^-TTRO/ (t?-t01
TTR2 -TTR1
Rate of disappearance (Rd) = EGP -pV  (C2 -Ci)/(t2 -ti)
Where F= infusion rate (mg/min) corrected for % enrichment, P= fraction of plasma pool (0.65)
V= total extracellular pool (calculated as 0.221/kg body weight for glucose), TTR= tracer/tracee 
ratio
t=time (mins).
The numbers 1 and 2 refer to adjacent sampling times (minutes)
C=glucose concentration (mg/1)
Glucose Ra, Rd and glycerol Ra were calculated using a specially designed spreadsheet incorporating 
the Steele equation. Data required for the spreadsheet included; the subjects weight, plasma glucose 
concentration in mmoEl for each time point, tracer / tracee ratio for each time point, glucose and 
glycerol infusate concentrations and for the clamp protocol the glucose infiision rates in mg/min.
Before calculation of glucose turnover and glycerol production rate, time courses were smoothed 
and interpolated to 5 min intervals using optical segments technique analysis (Finegood at al.l987).
Euglycaemic /  hyperglycaemic clamp protocol
The Steele equation was adapted to account for the addition of stable labelled tracer to the variable 
rate glucose infusion (Finegood et al. 1987). A volume of distribution of 221 ml/kg and an effective 
glucose: actual space of 0.65 was used. By adding sufficient tracer to the exogenous glucose 
infusion, it enabled the glucose enrichment to remain similar to the baseline plasma enrichment, 
thereby minimising large changes in glucose enrichment and thus the need to accurately describe 
the glucose distribution space.
Spectral analysis of EEG
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The raw EEG data was uploaded from a SKU: M97130 Vitaport 3 28 channels full PSG set 
recorder, onto the Profusion Sleep System software from Compumedics (Josef-Schuttler-Strasse 2 
D-78224 Singen Germany) for analysis.
DC-potential EEG
European Digital Format (EDF) records were inspected for manual identification and removal of 
artifacts. Artifacts were defined as non-physiological events distorting the EEG, for example eye 
blinks, unmasked movement. DC channels were then exported as an ASCII file at 128Hz. The excel 
program averaged each channel into 10 second epochs. An epoch can be defined as a period of 
time. Data was excluded if the channel went out of range.
The results for participants are reported for each electrode as mean ± SEM at each time point. The 
median was taken from a 5 min recording at each time point and normalised to 0 using the average 
readings from time -30 to 0 mins. DC-potential during baseline was set at OmVolts and potential 
shifts following subcutaneous injection were expressed as difference values. A typical DC- 
potential recording for one participant is shown in figure 28.
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Figure 28. EEG DC potential recordings.
From left and right electrodes over frontal (F3,F4), frontocentral (FC3, FC4) and central (C3,C4) cortical areas 
at isotopic state for subject NN05 during visit 1 and visit 2 of the euglycaemic / hyperglycaemic clamp protocol.
AC- potential EEG
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AC potentials were obtained by continuous recording but with KDT sessions at specific time points. 
A KDT session lasted for 6 mins and was conducted at time points -120, -30, 0, +30, +45, +90, 
+135, +180, +225, +270 minutes. A KDT session was identified and labelled as 3 mins eyes open 
(awake) followed by 3 mins eyes closed (sleep) on the EEG recordings.
Each KDT was then exported as a separate EDF recording and then imported into the Vitascore 
analysis system. Using the Vitascore analysis system, each KDT was scored as awake for the first 
three mins using the marker channel as a guide. The second three mins was scored as Stage 1 as a 
guide to start and end of eyes open/closed segments. Where the marker did not coincide with the 
epoch boundary, the unwanted EEG was excluded fi*om the analysis by marking it as a meta-artifact 
and it was then removed fi*om the individual EEG channels.
Each electrode and each time point produced a spectral power at a resolution of 0.5Hz from OHz to 
31.5Hz. The frequency was divided into 8 averaged bands (0-0.5, 0.5-4.5Hz, 5-7.5Hz, 8-11.5 Hz, 
12-14.5Hz, 15-19.5Hz, 20-24.5Hz and 25-31.5.Hz). Each KDT could then be analysed for each 
EEG electrode channel (F3,F4,C3,C4,01,02) for each segment (eyes open / eyes closed) for each 
time point and each visit.
3.4. Statistical analysis
Differences for glucose Rd, glucose Ra and glycerol Ra for each time point were calculated. All 
values were expressed as means and standard errors of means (SEM). The statistical data did not 
require transformation. Glucose Rd, glycerol Rd and glucose Rd at each glucose concentration were 
compared using a two way ANOVA (analysis of variance) with repeated measures. ANOVA is a 
recognised statistical model to analyse differences between group means and associated factors. 
Repeated measures were included because the same participants were used in the insulin detemir 
group and the NPH insulin group. Bonferroni correction was used to allow for multiple analyses.
Differences in insulin action for AC-potentials and DC-potentials were compared using two way 
ANOVA, including repeated measured factors of treatment and electrode location. Bonferroni 
correction was used to allow for multiple analyses.
All other comparisons were made with paired Students t-test with P values less than 0.05 being 
considered statistically significant. Prism statistical GraphPad software was used.
3.4.1. Power calculation
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The sample size calculation for both protocols was based on a previous study by (Hordern et al. 
2005) which compared the effect of insulin detemir with NPH insulin on endogenous glucose 
production rate during a euglycaemic hyperinsulinaemic clamp protocol, in this study there was a 
difference in production rate of 0.24mg/kg/min between the insulins. The intra subject coefficient 
was assumed to be a maximum of 25%. Intra subject coefficient can be biological e.g. influences 
such as sleep, exercise, food intake and stress or analytical e.g. related to manual techniques such as 
time, analysis technique and temperature. The power was calculated using a two-sided paired t-test 
and a significance level of 5%. Power is the probability of not committing a type 2 error i.e. 
confirming an alternative hypothesis when it is true. The primary endpoint was the minimum 
endogenous glucose Ra. If 8 patients completed each study, the study had a power of 81% at a P 
level of <0.05. If any participants were withdrawn replacements were to be enrolled.
The sample size calculation was based on the criterion variable of glucose rate of production using 
information from a clamp study by Hordern et al. 2005. The insulin withdrawal study was a novel 
study protocol design with no other studies available to give an indication of effect size. The major 
difference between this novel protocol and a clamp protocol is the variability in metabolic study end 
points between studies and participants. It was therefore felt, that the sample size should be 
increased to 12 participants to ensure significant power and to increase the chance of finding a 
significant difference in EEG potentials.
The effect size for EEG DC-potentials and AC-potentials were not included in the power 
calculation. Previous studies have not looked at the differences between the insulin and AC- 
potential and only one previous study compared intravenous insulin and changes in DC-potential 
(Hallschmid et al. 2010). This study used 15 healthy volunteers and showed a significant difference.
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Chapter 4. Results for the insulin withdrawal protocol.
4.1. Participant characteristics
Twelve participants completed both metabolic studies. The infusion of metabolic tracer for 
participant NN9 was interrupted for one of the metabolic studies due to cannulation dislodgement 
that only became apparent during plasma sample analysis. The results for the subject could not be 
paired and therefore the subject was excluded.
The participant characteristics are shown in table 4. All values are expressed as mean±SEM. There 
were 6 females and 5 males: mean age 40.6 ± 4.6 years, mean weight 76.5 ±4.1 kg, mean BMl 25.4 
± 0.9 kg/m^, mean HbAle 56 ± 1.5mmo 1/mol, mean duration of diabetes 14.0 ± 2.6 years. Five 
participants used a continuous subcutaneous insulin infusion (CSll) and 6 followed a multiple daily 
injection (MDl) regime. Mean total daily insulin was 36.1 ± 4.3international units.
Table 4. Insulin withdrawal participant characteristics.
Participant Gender Age (years) Weight (kg) BMI (kg/m") HbAlc
mmol/mol
(%)
Duration of 
Diabetes 
(years)
Regular basal 
insulin
Total daily 
dose of 
insulin (lU)
N Nl F 47 79.5 27.2 72 (8.7) 29 CSII 30
NN3 F 40 67.4 29.6 44 (6.2) 11 CSII 28
NN4 F 48 71.3 27.2 60 (7.6) 20 CSII 25
NN5 F 37 55.3 21.3 60 (7.6) 19 MDI 32
NN6 F 76 73.9 25.9 45 (8.3) 3 MDI 25
NN7 M 44 82.5 24.1 49 (6.6) 26 MDI 46
NNIO M 44 110.2 29.3 58 (7.5) 2 MDI 69
NN13 F 19 73.6 26.1 57 (7.4) 9 CSII 21
NN14 M 35 81.0 23.7 48 (6.5) 11 MDI 30
NN15 M 37 79.1 23.9 57 (7.4) 15 MDI 42
NN19 M 20 68 21 52 (6.9) 9 CSII 49
Mean ±  SEM - 40.6 ± 4.6 76.5 ±4.1 25.4 ±0 .9 56± 2 .1 14.0 ± 2 .6 - 36.1 ± 4 .3
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4.2. Plasma glucose concentration
At commencement of the metabolic study (-120 minutes) the fasting plasma glucose concentration 
was 13.1 ± 1.2 mmol/1 for the insulin detemir group and 12.0 ±1.3 mmol/1 for the NPH group. The 
fasting plasma glucose concentration for participants using MDI regimen were 14.2 ±1.2 mmol/1 
and for participants using a subcutaneous continuous insulin infusion 9.3 ± 0.7 mmol/1 in the 
detemir group and 15.4 ± 0.95 mmol/1 for participants using MDI regimen and 11.5 ± 1.67 mmol/1 
for participants using subcutaneous continuous insulin infusion in the NPH group. The plasma 
glucose at isotopic equilibrium was 6.4 ± 0.4 and 6.4 ± 0.3, respectively.
Following withdrawal of the intravenous insulin infusion, blood glucose of > 7mmol/l was achieved 
in 80 ± 18.5 mins for the detemir group and 78.2 ± 13.5 minutes for the NPH insulin group. The 
duration in time for each participant is summarised in Table 5 and was significantly shorter for 
subjects who normally used CSII (P = 0.006), 36.0 ± 8.9 mins for the detemir group and 58.0 ± 12.9 
in the NPH group compared with participants who used a MDI regimen, 115.0 ± 22.3 mins and 95.0 
± 20.8 mins, respectively.
Table 5. Time in mins to reach blood glucose concentration of 7>mmol/l following insulin withdrawal.
Regular insulin 
administration
NPH insulin (minutes) Insulin Detemir (minutes)
Continuous subcutaneous insulin infusion (CSII)
NNI 95 20
NN3 40 25
NN4 80 60
NNI3 25 20
NN19 50 55
Mean ±  SEM 58 ±12.9 36 ± 8 .9
Multiple daily injections (MDI)
NN6 140 135
NN5 75 140
NN7 20 90
NNIO 135 215
NN14 60 75
NN15 140 40
Mean ± SEM 95 ± 20.8 115 ±22.3
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Once the blood glucose level reached >7minol/l, a subcutaneous injection of either 0.5units/kg 
insulin detemir or NPH insulin was given. The total mean subcutaneous insulin dose was 38.3 ± 2.1 
units. The mean plasma glucose coneentration, at the time of subcutaneous injection was 8.3 ± 0.3 
for the detemir group and 8.7 ± 0.4 mmol/1 for the NPH insulin group.
Following administration of insulin, the plasma glucose concentration continued to rise and 
achieved peak values of 9.4 ± 0.6 at 51.0 mmol/1 ± 7.0 mins for the detemir group and 10.3 ± 0.6 
mmol/ at 62.3 ± 7.8 mins for the NPH group. The metabolic study end-point was either, 420 mins 
after the subcutaneous insulin injection or when the blood glucose level fell below 5mmol/1. No 
participant reached the study end-point before 180 mins. The mean plasma glucose profiles are 
shown for both insulins in Figure 29. A is the period of isotopic steady state, B is the period 
following withdrawal of the soluble variable insulin infusion and until subcutaneous insulin 
injection and C the period following subcutaneous insulin injection. As shown in table 3, the length 
of period B varied from partieipant to participant. There was no significant difference in plasma 
glucose profiles between insulin detemir and NPH insulin up to 180 minutes (ANOVA P=0.39).
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Figure 29. Plasma glucose concentration plotted against time in the insulin withdrawal protocol.
A=isotopic steady state, B = soluble variable insulin infusion withdrawn, C = period following subcutaneous 
insulin injection. Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are 
m eaniSEM , n = ll  for all time points up to 180 mins.
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The time taken to reach the defined metabolic study end-point for each participant is shown in table 
6. The mean end-point time was 270.9 ± 29.7 mins for the detemir group and 284.6 ± 29.5 mins for 
the NPH group.
Table 6. Time in mins to reach the defined end-point for each metabolic study.
Group NNl NN3 NN4 NN5 NN6 NN7 NNIO NN13 NN14 NNl 5 NN19 Mean ±  
SEM
NPH 180 420 200 200 270 420 280 420 180 240 330 284.6 ±29.5
Detemir 200 420 220 180 200 330 200 420 240 180 390 270.9 ± 29.7
4.3. Glucose metabolism
For each time-point up to 180 minutes the glucose rate of appearance (Ra) and glucose rate of 
disappearance (Rd) was calculated. All values are expressed as means ± SEM. 180 mins was chosen 
because up to this time point as there were data for all participants at all time points.
Glucose rate o f appearance (Glucose Ra)
At isotopic steady state glucose Ra was 14.51+ 1.24 pmol/kg/min in the detemir group and 15.52 ± 
0.88 pmol/kg/min in the NPH group. The difference was not statistically significant.
(mean difference -1.00 pmol/kg/min Cl -2.57 to 0.58 t-test P=0.19).
Following 0.5units/kg of subcutaneous insulin, glucose Ra fell rapidly resulting in a nadir at 180 
mins. The glucose Ra profiles for the two insulins up to 180 mins were not statistical different 
(ANOVA P=0.47) and are shown in figure 30.
Glucose Ra at subcutaneous injection minus the glucose Ra at 180 mins for detemir was 8.2±1.0 
and 9.7 ±1.0 for the NPH group. This difference was not statistically significant (mean difference
1.56 pmol/kg/min Cl -0.47 to 3.59 t-test P=0.12).
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Figure 30. Glucose rate of appearance (Ra) plotted against time from subcutaneous injection in the insulin 
withdrawal protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n = ll  
for all time points up to 200 mins.
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Glucose rate of disappearance (Glucose Rd)
At isotopic steady state glucose Rd was 14.6 ± 1.25 pmol/kg/min in the detemir group and 15.2 ±
I.04 mg/kg/min in the NPH group. The difference was not statistically significant (mean difference 
-0.51 pmol/kg/min Cl -1.75 to 0.73 t-test P=0.38).
At the time of insulin injection, glucose Rd was 10.9 ± 0.8 pmol/kg/min in the detemir group and
II.5 ±1.3 pmol/kg/min in the NPH insulin group. This difference was not statistically significant, 
(mean difference -0.52 pmol/kg/min Cl -2.22 to 1.19 t-test. P=0.52).
Glucose Rd plotted against time from subcuatenous insulin injection is shown in figure 31. At the 
doses of 0.5 unit/kg, neither, insulin detemir or NPH insulin had any significant effect on glucose 
disappearance up to 180 mins following insulin injection.
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Figure 31. Glucose rate of disappearance (Rd) plotted against time from subcutaneous injection in the insulin 
withdrawal protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n = ll  
for all time points up to 200 mins
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The effects on glucose Ra and glucose Rd are plotted aceording to insulin group in figure 32 and 
33. Figure 32 shows glucose Ra and glueose Rd plotted against time for participants in the detemir 
group and figure 33 shows glucose Ra and glueose Rd plotted against time for partieipants in the 
NPH group.
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Figure 32. Plasma glucose Ra and Rd in the detemir group plotted against time in the insulin withdrawal 
protocol.
A=isotopic steady state, B = soluble variable insulin infusion withdrawn, C = period following subcutaneous 
insulin injection. Values are mean±SEM, n = ll for all time points up to 180 mins. n=9 at 200mins, n= 6 at 220 
mins, n=5 at 240 mins, n- 4 at 300 mins, n- 3 at 360 mins, n- 2 at 420 mins
88
IV Insulin Subcutaneous insulin 
I 1
c
1
I
o
E
3
S '
0U)oo
3
U>
"Oc0
£
0
(/>oo
3
O
2 0 i
10-
5-
I 
0
NPH Insulin Rd 
-*■ NPH insulin Ra
I
I— r
-30-15 0
H I- —I-------------- 1-------------- 1------------- 1---------------1-------------- 1-------------- 1
60 120 180 240 300 360 420
B
Sam ple Time (mins)
Figure 33. Plasma glucose Ra and Rd in the NPH group plotted against time in the insulin withdrawal protocol 
A=isotopic steady state, B = soluble variable insulin infusion withdrawn, C = period following subcutaneous 
insulin injection. Values are mean±SEM, n = ll for all time points up to 180 mins, n -9  at 200mins, n= 7 at 220 
mins, n=7 at 240 mins, n- 4 at 300 mins, n- 3 at 360 mins, n- 3 at 420 mins
In conclusion, the glucose lowering effect of subcutaneous detemir and NPH occurs primarily by 
reduction in hepatic glucose production rather than an increase in peripheral glucose uptake. A 
summary of the effect of insulin detemir and NPH on glucose metabolism plotted against time is 
also shown in table 7.
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Table 7. A summary of the glucose measurements plotted against time before and after subcutaneous injection of 
insulin detemir and NPH insulin.
Insulin
Detemir
NPH
Insulin
Mean difference 
(Cl)
P-value
Fasting plasma glucose (mmol/1) 13.06±1.19 11.96±1.34 1.10 (-0.90 to 3.09) 0.25
Plasma glucose at isotopic equilibrium 
(mmol/1)
6.42±0.39 6.41±0.36 0.01 (-1.19 to 1.22) 0.98
Plasma glucose at subcutaneous 
insulin injection (mmol/1)
8.30±0.30 8.70±0.38 0.38 (-0.38 to 1.15) 0.29
Peak plasma glucose (mmol/1) 9.4Ü0.63 10.25±0.58 0.86 (0.05 to 1.67) *0.03
Glucose Ra at subcutaneous insulin 
injection (pmol/kg/min)
15.01±0.60 16.58±0.69 -1.57 (-3.25 to 0.10) 0.06
Glucose Ra at peak glucose 
(pmol/kg/min)
13.2±1.42 15.10±1.35 -1.57 (-5.35 to 1.60) 0.26
Glucose Ra at 180 mins after 
subcutaneous injection (pmol/kg/min)
6.8Ü 0.78 7.59±0.71 -0.75 (-1.59 to 0.08) 0.07
Glucose Rd at subcutaneous insulin 
injection (pmol/kg/min)
10.94±0.88 11.46±1.34 -0.52 (-2.22 to 1.19) 0.52
Glucose Rd at peak glucose 
concentration (pmol/kg/min)
11.13±0.915 12.01±1.05 -0.88 (2.90 to 1.13) 0.35
Glucose Rd at ISOmins after 
subcutaneous injection (pmol/kg/min)
10.04±0.63 11.86±0.61 -1.35 (-2.81 to 0.10) 0.06
Values are mean ±  SEM, * P value <0.05.
Comparison o f insulin action
The number of participant observations was lower at higher plasma glucose levels and higher at the 
lower plasma glucose levels. The number of participant observations for glucose Ra and Rd at each 
glucose concentration is shown in Table 8.
Due to the variability in metabolic end-point time between the participants, glucose Ra and Rd were 
plotted against glucose concentration so a direct comparison of insulin could be interpolated at a 
given plasma glucose level. The boundaries for each glucose concentration were ±0.05 mmol/1, so 
for example, any plasma glucose concentration between 5.95 and 6.05 mmol/1 was considered to be 
a concentration of 6 mmol/1.
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Table 8. The number of participant observation for glucose Ra and Rd at each glucose concentration.
Glucose
cone
(mmol/1)
14 13. 
5 :
13 12.
5
12 11.
5
11 10.
5
10 9.5 9 8.5 8 7.5 7 6.5 6
No. of obs 
in detemir 
group
1 2 2 2 2 2 3 3 3 3 4 6 10 10 10 9 6
No. of obs 
in NPH 
group
1 1 2 2 2 2 4 6 6 8 10 10 10 9 8 7 5
Matched 1 0 2 2 2 2 4 3 3 3 4 6 10 9 8 7 5
Matched = participant observations matched to insulin group . Shaded area indicates greater than 5 paired subject 
observations.
At each glucose concentration the number of participants and arc not directly matched i.e. the same 
participants arc not necessarily in the detemir group and NPH group at each glucose concentration. 
To address this, the glucose concentrations were matched so that participants were included in the 
analysis if they reached the specific glucose concentration in both the detemir and NPH metabolic 
study.
Blood glucose concentrations from 8.5 to 6 mmol/1 had a minimum of 5 matched observations and 
were plotted against glucose Ra and glucose Rd. If there were greater than 5 matched observations 
the probability of a statistically significant difference between the two insulins was more likely.
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Glucose rate o f appearance plotted against glucose concentration
Figure 34 shows the glucose Ra at each glucose concentration as the plasma glucose concentration 
decreased. There was no statistical difference in glucose Ra between the detemir group and NPH 
group at each glucose concentration.
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Figure 34. Glucose rate of appearance (Ra) at each glucose concentration as the plasma glucose concentration 
decreased in the insulin withdrawal protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM.
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Glucose rate o f disappearance plotted against glucose concentration
In contrast, glucose Rd was greater with NPH insulin when compared with detemir at the same 
glucose concentration (e.g. at 6 mmol/l, detemir v NPH glucose Rd was 9.5±0.7 v 11.4±0.4 
pmol/kg/min (ANOVA 0.04). In figure 31, glucose Rd tended to be lower at all time points for 
those treated with insulin detemir. However, glucose concentration was not clamped resulting in a 
variety of glucose concentrations at each time point. Plotting glucose Rd against glucose 
concentration removes this variability to allow direct comparison of insulin action. Glucose Rd at 
each glucose concentration is shown in figure 35.
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Figure 35. Glucose rate of disappearance (Rd) at each glucose concentration as the plasma glucose concentration 
decreased in the insulin withdrawal protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM. * 
=ANOVA p<0.05
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Metabolic clearance rate (MCR) of glucose
The probable dominant effeet of the ‘mass action’ of the glueose coneentration on the absolute 
value of glucose Rd can make interpretation of the differing action of subcutaneous insulin difficult. 
Calculation of metabolic clearance rate of glucose can be used as an in vivo measure of insulin 
action, because it is independent of the glucose concentration when below the renal blood glucose 
threshold (Proietto et al. 1983).
The metabolic clearance rate (MCR) of glucose did not change as the glucose concentration 
increased and then increased as the glucose concentration decreased. Following the insulin 
injection, the difference in MCR of glueose remained similar in both insulin groups as the glueose 
concentration continued to increase but was lower in the detemir group than the NPH group when 
the plasma glucose coneentration fell below Smmol/l. (e.g. at 8mmol/l detemir v NPH, MCR was 
1.3 ± 0.07 V  1.5. ± 0.04 ml/kg/min) (P = 0.01) and 6 mmol/l, detemir v NPH, MCR was 1.59 ± 0.09 
V 1.91 ± 0.08 ml/kg/min. (P = 0.03). MCR plotted against time is shown in figure 36.
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Figure 36. Metabolic clearance rate of glucose at each glucose concentration, in the insulin withdrawal protocol. 
Closed circles represent detemir and closed squares represent NPH insulin. Values are mean±SEM. *= ANOVA  
P <0.05.
In summary, insulin detemir has a lesser effect on glucose Rd than NPH insulin at the same glucose 
concentration but comparable effects on glucose Ra.
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4.4. Glycerol metabolism
At commencement of the metabolic study (-120 minutes) the fasting plasma glycerol concentration 
was 95.8 ± 32.1 pmol/1 for the insulin detemir group and 109 ± 39.7 pmol/1 for the NPH group. The 
plasma glucose at isotopic equilibrium was 55.5 ± 12.7 and 48.8 ± 8.9 pmol/1, respectively.
Following subcutaneous insulin injection, the mean plasma glycerol concentration achieved peak 
values of 100.6 ± 19.8 and 148.8 ± 35.1 pmol/1 respectively before the glucose concentration began 
to decrease at 51.0 ± 7.0 minutes and 62.3 ± 7.8 minutes. The glycerol profile is shown in Figure 
37. The plasma glycerol profiles were not significantly different up to 180 minutes. (ANOVA 
F=0.859)
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Figure 37. Plasma glycerol concentration plotted against time in the insulin withdrawal protocol in the 
insulin withdrawal protocol.
A=isotopic steady state, B = soluble variable insulin infusion withdrawn, C = period following subcutaneous 
insulin injection. Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are 
m eaniSEM , n = llfor  all time points up to ISOmins
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Percentage change in glycerol Ra from time 0
To correct for the difference in mean glycerol Ra at time 0, the point of subcutaneous insulin 
injection, glycerol Ra was eompared according to the change from the insulin injection (time 0). 
This is shown in figure 38.
The percentage change of glyeerol Ra was consistently greater in the NPH study group when 
compared with the detemir group (ANOVA P=0.04). The maximum % change in glycerol Ra from 
time 0 was -11.0 ± 9.5 in the detemir group and -43.7 ± 10.0 in the NPH Group (mean difference -
30.5 Cl -44.8 to -16.2 t-test=0.002). The effect of detemir and NPH glycerol metabolism are 
summarised in table 9.
c
o
Ü0)
v>3
OQ)
Ctü4-»
3On
3(/>
E o
Q)
U)c
(0
Insulin detemir 
■ NPH insulin
30 60 90 120 150 180 210 240 270 300
Time in mins
Figure 38. Glycerol Ra % change from subcutaneous insulin injection in the insulin withdrawal protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n = ll  
for all time points up to ISOmins.
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Table 9. The effect of detemir and NPH glycerol Ra.
Detemir NPH Mean difference 
(Cl)
P value
Glycerol Ra at time of subcutaneous 
injection (pmol/kg/min)
2.76 ± 0.44 3.96 ±0.78 -1.2 (-2.45 to 0.01) 0.07
Glycerol Ra at 180 minutes from 
subcutaneous injection 
(pmol/kg/min)
2.23 ±0.26 1.74 ±0.24 0.48 (0.05 to 0.91) *0.03
Maximum % change in glycerol Ra -11.0 ±9.5 -43.7 ± 10.0 -30.5 (-44.8 to -16.2) *0.002
Values - means ± SEM, * p value <0.05
4.5. Non esterified fatty acids (NEFA)
The relationship between NEFA eoncentration and time from insulin injection is shown in figure 
39. Suppression of NEFA concentration was not statistically significant between the insulin detemir 
group and NPH insulin group (ANOVA P=0.21).
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Figure 39. NEFA concentrations plotted against time in the insulin withdrawal protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM
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Insulin detemir has a lesser effect on lipolysis. This is supported by the findings that insulin detemir 
has a lesser suppressive effect on percentage change of glycerol appearance. Detemir also appeared 
to have a lesser suppressive effect on NEFA concentration but this association did not reach 
statistical significance.
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Chapter 5. Discussion of insulin withdrawal protocol
5.1. Summary of main findings
Following a period of insulin withdrawal in subjects with type 1 diabetes, insulin detemir had a 
lesser effect on glucose uptake into peripheral tissues but similar effect on hepatic glucose 
production when compared with NPH insulin at the same glucose concentration. In addition, there 
was lower suppression of glycerol production rate and NEFA concentration with insulin detemir. 
Insulin detemir thereby has the potential to restore the physiological insulin gradient.
5.2. Factors influencing the results
Study group
Participants enrolled in the study used either a multiple daily injection (MDI) regimen or 
continuous subcutaneous insulin infusion (CSII) to control their diabetes on a day to day basis. At 
the time of recruitment glycaemic control as evidenced by HbAlc was very good. However, it 
should be acknowledged that participants using CSII therapy had previously experienced 
difficulties controlling their blood glucose levels using MDI insulin. To qualify for CSII therapy in 
the United Kingdom, the National Institute of Clinical Excellence (NICE) recommends that patients 
should only be considered if attempts to achieve target HbAlc levels with multiple daily injections 
result in the person experiencing disabling hypoglycaemia. Disabling hypoglycaemia is defined as 
the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about 
recurrence and is associated with a significant adverse effect on quality of life or HbAlc levels that 
have remained high (at 8.5% or above) on MDI therapy despite a high level of care. The 
combination of subjects using MDI and CSII therapy could partially explain the greater than 
anticipated participant variation.
Participant variation may also be due to the possibility of on-going metabolic activity of 
subcutaneous basal insulin. On-going metabolic activity after 24 hours, has been shown to be more 
pronounced for insulin detemir than NPH insulin (Heise et al. 2004). The duration of action of 
detemir has also been reported to be longer with higher doses in both single-dose and steady-state 
conditions (Plank et al. 2005). This is important, as participants using a continuous subcutaneous 
insulin infusion would have received no prior exposure to the study insulin whereas 5 of the 6 
participants using a MDI regimen used insulin detemir for their regular management. Inter and intra
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participants variation may also be independent of insulin for example it may be dependent on the 
participant’s glycogen storage and decreased availability of gluconeogenic precursors (Felig et al. 
1970).
Plasma glucose concentration
The fasting blood glucose measurements taken at the beginning of the metabolic studies have been 
reported in the results section. However, the mean values are lower than one might expect. This is 
because participants using CSII therapy only disconnected their subcutaneous insulin infusion an 
hour before the baseline blood samples were taken, whereas participants using the MDI regimen 
would not have received any basal insulin for at minimum of 24 hours and their last prandial insulin 
dose would have been before their evening meal the day before the metabolic study. In addition, 
patients using CSII often increase their basal rates early morning for example from 4.00am to 
7.00am to account for the influence of the dawn phenomenon. This blood glucose rise is caused by 
the release of counter regulatory hormones such as cortisol, glucagon and adrenaline all of which 
increase the release of hepatic glucose (Rybicka et al. 2011).
The plasma glucose profiles plotted against time were similar for NPH and insulin detemir. Inter 
and intra-individual variation was observed when looked at in isolation but this did not achieve 
significance in the final analysis. The problem of both, inter and intra-individual variation following 
exogenous insulin is not new. Studies have reported coefficients of variation for inter and intra­
individual variability in the pharmacodynamic action of long acting zinc insulin preparations to be 
between 35 and 55% (Ziel et al. 1988). This coefficient of variation may be even greater for NPH 
insulin (Galloway et al. 1981). Insulin glargine does not appear to provide any improvement 
compared with NPH insulin. However, detemir has been shown to have lower intra subject 
variability (Heise et al. 2004). Unlike NPH, insulin detemir is not dependent on resuspension before 
injections or dissolution of crystals in the subcutaneous tissue and it is not dependent on formation 
and dissolution of microprecipitates as seen with glargine.
Metabolic study protocol
Subcutaneous insulin was administered when the blood glucose concentration reached 7mmol/l.
The glucose concentration in whole blood has been reported to be 13% lower than the glucose
concentration in plasma (Holtkamp et al. 1975). The blood glucose concentration was measured
using the YSI glucose analyser. To use plasma glucose concentration during the metabolic study,
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the blood sample would require spinning in a centrifuge and separating which takes a minimum of 
10 minutes and then after separating the sample would need a further minute on the YSI analyser.
Finally, due to concerns expressed by the ethics committee the subcutaneous insulin was 
administered at a blood glucose concentration of 7mmol/l. Consequently, the mean plasma glucose 
levels achieved peak values of only 9.4±0.6 mmol/1 in the detemir group and 10.3±0.6 mmol/1 in 
the NPH group. The peak glucose concentrations were below the renal glucose threshold and meant 
participants experienced shorter periods of hyperglycaemia and reached the metabolic end point 
earlier than originally intended.
5.3. Discussion of insulin withdrawal results
Towards the end of the 1970‘s the euglycaemic hyperinsulinaemic clamp was introduced and is 
now the gold standard method to study insulin sensitivity. The problem with this methodology, is 
that euglycaemia is the starting condition which falls near the top of the dose-response curve for 
insulin action in the liver and near the bottom of that relationship for peripheral tissues. The 
prevention of hypoglycaemia by clamping serves further to focus attention on peripheral insulin 
action particularly as any fall in glucose dependent glucose uptake due to developing 
hypoglycaemia is eliminated by the glucose infusion of the clamp protocol. Glucose clamp 
experiments therefore serve to underestimate the vital physiological significance of hepatic insulin 
action and overestimate the importance of peripheral glucose uptake (Finegood et al. 1988).
Using our novel protocol to study the action of subcutaneous basal insulin on hepatic glucose 
production, peripheral glucose uptake and lipid metabolism, we have been able to show the effects 
of insulin at the lower end of the dose response curve and compare the differences between detemir 
and NPH insulin using clinically relevant insulin doses. It is at the low end of the dose response 
curve that insulin acts primarily to suppress hepatic glucose production (Groop et al. 1993). The 
low end of the insulin dose response curve has been neglected in previous studies.
Glucose metabolism using stable isotopes
Following withdrawal of intravenous insulin, the blood glucose concentration increased. The 
increase in blood glucose concentration was associated with an increase in the rate of glucose Ra. In 
this early stage of insulin deficiency, the increased rate of glucose Ra is thought to be primarily by 
unrestrained glycogenolysis with a smaller contribution from increased gluconeogenesis (Boden et
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al 2003). Boden also looked at the action of excess insulin on hepatic glucose production and found 
that in patients with type 1 diabetes, the acute regulation was mainly via changes in glycogenolysis 
and that gluconeogenesis contributed very little or not at all. In conclusion, during the early phases 
of either insulin excess or deficiency glycogenolysis plays a dominant role in regulating hepatic 
glucose production (Boden et al. 2003). It is only after time, when glycogen stores are depleted that 
gluconeogenesis plays a more important role (Sonksen and Sonksen. 2000).
In insulin deficiency, the main factor driving glucose uptake in the periphery appears to be the 
‘mass action’ effect of hyperglycaemia and the concentration gradient between extracellular and 
intracellular glucose concentrations (Sonksen and Sonksen. 2000). This is an insulin independent 
process. In the current study, the mean peak glucose concentration did not exceed the renal 
threshold for glucose uptake. When glucose concentration exceeds the renal glucose threshold, 
glycosuria develops and the blood glucose concentration eventually reaches a dynamic state where 
hepatic glucose production is matched by an increase in glucose utilisation in peripheral tissues and 
glucose excretion in the urine (Miles et al. 1980). The two mechanisms balance to temporarily 
produce a steady state. This steady state effect has been extensively investigated following 
discontinuation of continuous subcutaneous insulin infusions (Pickup et al. 1982). Continuous 
subcutaneous insulin infusions use a continued infusion of short acting insulin and early in their 
clinical use there was increasing concern about metabolic deterioration if the pump malfunctioned. 
Pick up et al, stopped the continuous subcutaneous insulin infusions in 9 participants with type 1 
diabetes. Mean plasma glucose remained unchanged at normal fasting levels for the first hour, then 
rose to plateau at about 10 mmol/1 until the end of the experiment (9 hours). The final plateau level 
of glucose varied from participant to participant. In contrast, blood 3-hydroxybutyrate rose 
progressively, without plateauing. Plasma free insulin concentrations fell during the withdrawal 
period and there was a highly significant negative correlation between free insulin and 3- 
hydroxybutyrate (Pickup et al. 1982). This plateau of blood glucose concentration has also been 
observed in a number of studies following the withdrawal of intravenous insulin in participants with 
type 1 diabetes (Gerich et al. 1975; Miles et al. 1980).
Early studies have consistently reported the importance of insulin action to reduce hepatic glucose 
production (Madison et al. 1959, Craig et al. 1961). However, this has frequently been forgotten 
and the role of insulin on peripheral glucose uptake has been favoured as insulin’s dominant action 
of lowering glucose concentration (Henderson et al. 1955). One reason may be related to the fact, 
that studies frequently used high insulin concentrations that were not physiological (Daniel et al. 
1975). Following the introduction of low dose insulin concentration infusions to treat diabetic
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ketoacidosis (Sonksen et al. 1972). Brown et al developed a protocol using an isotope turnover 
technique to measure the rates of production and utilisation of glucose during different rates of 
insulin infusion in hyperglycaemic patients with diabetes (Brown et al. 1978). With the low dose 
insulin actrapid infusion, glucose concentration fell mainly by reduction in hepatic glucose 
production and with the high dose insulin actrapid infusion there was a combined effect of 
reduction in hepatic glucose production and increased peripheral glucose uptake (Brown et al. 
1978). It was only when insulin was administered at rates producing high physiological insulin 
concentrations that an increase in peripheral uptake of glucose by fat and muscle tissue contributed 
to the lowering of the plasma glucose concentration. In conclusion, the insulin infusion rate and 
conversely insulin concentration is important in determining the contribution of hepatic glucose 
production and peripheral glucose uptake.
In normal physiology insulin is secreted in a pulsatile fashion superimposed on basal release 
(Kruszynska et al. 1987). High insulin concentrations are reached following pulsatile insulin, 
which effects both hepatic glucose production and peripheral glucose uptake. The pulsatile pattern 
consists of rapid pulses that occur every 5-10 minutes and slow, ultradian oscillatory pulses with a 
period over 50-120 minutes (Simon and Brandenberger. 2002). The rapid pulses act on glucose 
production while the ultradian oscillations affect peripheral glucose utilisation. The rapid insulin 
pulses are large in the portal vein, immediately before passing the liver. However, because of their 
short periodicity, they are much smaller in the interstitium, from where insulin acts peripherally. In 
contrast, the ultradian oscillations are quite large in peripheral blood circulation, particularly when 
stimulated by intravenous insulin, enteral nutrition and after meals when glucose utilisation is high 
(Sturis et al. 1995).
The current study looked at the action of clinically relevant, low dose subcutaneous basal 
exogenous insulin. During fasting hyperglycaemia it was shown that basal subcutaneous insulin 
(both NPH and detemir) acts primarily to suppress hepatic glucose production. The effect of insulin 
on peripheral glucose uptake remained unchanged, suggesting that at high glucose concentrations 
the majority of peripheral glucose uptake was insulin independent. This supports previous studies, 
which have shown in the basal state that 60-80% of glucose uptake is non-insulin mediated 
(Gottesman et al. 1983). It is unlikely that the high glucose concentration is responsible for the 
reduction in glucose Ra since suppression of hepatic glucose production by hyperglycaemia has 
been reported to be deficient in diabetes (Miles et al. 1980).
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The mechanism by which hyperglycemia stimulates peripheral glucose uptake to a greater extent in 
subjects with diabetes as compared with normal subjects remains to be elucidated (Sacca et al.
1982). One possibility is that the condition of hyperglycemia to which subjects with untreated 
diabetes are chronically exposed could induce slow adaptive changes by enhancing the efficiency of 
the glucose transport system or activating some enzymatic systems capable of being affected by 
glucose concentration (Capaldo et al. 1986).
Lipid metabolism using stable isotopes
The action of insulin on adipose tissue was measured by the rate of glycerol appearance and the 
extent of NET A suppression. Following insulin administration there was a rapid suppression of 
glycerol production and concomitant reduction in NEFA concentration. Suppression of glycerol Ra 
was seen before complete suppression of glucose Ra, further supporting the evidence that lipolysis 
is extremely sensitive to the action of insulin (Nuijhan et al. 1986). Adipose tissue lipolysis is 
normally exquisitely sensitive to insulin and that sensitivity, but not responsiveness to insulin can 
be is impaired in poorly controlled type 1 diabetes (Jensen et al. 1989).
The fall in NEFA concentration and turnover following insulin treatment was originally reported in 
1972 and later supported by Hall and colleagues (Lewis et al. 1972, Hall et al. 1979). However, the 
relationship between lipolysis and insulin action is still poorly understood. Studies using changes in 
plasma NEFA levels as an index of lipolysis may have resulted in an error in the estimation of the 
insulin sensitivity of lipolysis because NEFA can be re-esterified and the insulin sensitivity of 
NEFA re-esterification might differ from that of lipolysis. In contrast, glycerol formed during 
lipolysis cannot be re-esterified to a significant extent in human adipose tissue (Shapiro et al. 1957). 
Consequently, the rate of appearance of glycerol should be a more precise index of lipolysis. Early 
studies showed that intravenous infusion of insulin into anaesthetised rabbits caused a decrease in 
the concentration of plasma glycerol. The authors suggested that insulin did not alter the release of 
glycerol from adipose tissue but seemed to increase the rate of disappearance (Hagen 1963). Studies 
have since shown that insulin decreases glycerol concentration primarily by a reduction in glycerol 
production (Nuijhan et al. 1986). This is also consistent with the findings of this study.
Insulin potently suppresses plasma NEFA appearance rate. Elevation of plasma insulin level has 
been associated with enhanced plasma NEFA clearance in human studies during the basal 
(Mittendorfer et al. 2003) and the post prandial state (Miles et al. 2003). The linear relationship 
between the plasma concentration and the respective turnover rates of glycerol and NEFA, in 
animals and normal man is well known (Hall et al. 1979, Bergman 1968). An increase in NEFA
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concentration can inhibit skeletal muscle glucose utilisation (Notle et al. 1994). It may act by 
interfering with insulin signaling and glucose transport or phosphorylation or both (Dresner et al. 
1999; Roden et al. 1996). The relationship between elevated NEFA concentration and hepatic 
glucose production is more confusing. When an intralipid infusion was given to subjects during a 
hyperinsulinaemic state, the decline in NEFA concentration was prevented and decline in hepatic 
glucose production was blunted (Sindelar et al. 1997). These results suggested that the ability of 
peripheral insulin to regulate hepatic glucose production is partially linked to its inhibition of 
lipolysis. Numerous studies have examined the relationship between NEFA and hepatic glucose 
suppression, using pharmacological means to lower NEFA levels. The results of these studies are 
conflicting (Mittleman and Bergman. 2000, Fery et al. 1997, Lee et al. 1996, Puhakainen and Yki- 
Jarvinen 1993). Interestingly, detemir resulted in lesser suppression of NEFA concentration when 
compared with NPH insulin but produced similar effects on glucose Ra suggesting that the action of 
detemir and NPH insulin may be independent of NEFA delivery to the liver. Hordern et al, used a 
euglycaemic clamp protocol to compare the effects of detemir and NPH on glucose flux and 
lipolysis in healthy volunteers. They found that detemir had a greater effect on glucose Ra but a 
lesser effect on NEFA concentration than an equipotent dose of NPH insulin again suggesting that 
the action of detemir on glucose Ra may be independent of NEFA delivery to the liver (Hordern et 
al. 2005)
Difference in action o f detemir and NPH on glucose metabolism and lipid metabolism
The study protocol used subcutaneous insulin rather than intravenous insulin. When people with 
diabetes are treated with subcutaneous insulin the portal vein insulin concentrations are equal to or 
lower than those in the peripheral plasma (Smeeton et al. 2009). The higher insulin concentration in 
the periphery would be expected to have a greater effect on peripheral glucose uptake than 
endogenous insulin. We have demonstrated that this distribution is different when comparing 
detemir and NPH insulin. Following a period of insulin withdrawal in subjects with type 1 diabetes. 
Insulin detemir had a lesser effect on glucose uptake into peripheral tissues but similar effect on 
hepatic glucose production when compared with NPH insulin at the same glucose concentration. In 
addition, glycerol production was consistently higher with insulin detemir and there was less 
suppression of NEFA concentration. Insulin detemir thereby has the potential to restore the 
physiological insulin gradient.
It was hypothesised that insulin detemir would have a greater suppressive effect on hepatic glucose 
production when compared with NPH insulin. It appears there is no difference between the two
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insulins at this part of the dose response curve for glucose Ra. However, there is a potential 
difference at the top end of the dose response curve for insulin action in the liver (Hordern et al, 
2005). One difference between the current study and the study by Hordern and colleagues is that the 
glucose concentration was clamped which may impact the results.
At the lower end of the dose response curve, there was a difference in glucose Rd. Levemir had a 
lesser effect in glucose uptake into peripheral tissues than NPH insulin. To reach peripheral target 
cells insulin must pass through the capillary wall lined by continuous epithelium. In contrast, highly 
fenestrated epithelial cells line the vascular sinusoids within the liver, with large pores between 
them and with no basal lamina. No barrier exists between protein molecules in the plasma, in the 
sinusoids and hence to the surface of hepatocytes. Detemir has been shown to have a slowed 
appearance rate into the interstitial fluid compared with insulin, together with elevated total plasma 
concentrations, suggesting that albumin binding retards transendothelial transfer (Dea et al. 2002). 
This unique albumin binding may also be responsible for prolonging its duration of action seen with 
detemir (Kurtzhals et al. 2000). It is difficult to measure the exact concentration of detemir in 
plasma as currently available methods to do not distinguish among the free and albumin fractions in 
the circulation, therefore studies tend to report on the pharmacodynamics of insulin detemir and not 
pharmacokinetics (Porcellati et al. 2011).
In contrast, NPH insulin can easily passes through the endothelium. Two distinct hypotheses have 
emerged regarding the mode of transport of insulin across the capillary endothelium from plasma to 
interstitium: passive diffusion versus receptor-mediated transcytosis. Skeletal muscle capillary 
endothelium has been described as a continuous endothelium across which hydrophilic solutes with 
a radius of less than 30 A can diffuse through small pores or paracellular pathways (Haraldsson B. 
1986). The radius of native insulin is 21 Â and unbound detemir is 22 Â. Vincent and colleagues 
demonstrated no change in insulin action in vascular endothelial insulin receptor knockout mice, 
consistent with non receptor-mediated transcapillary insulin transport (Vincent et al. 2000).
Evidence for a second process via a receptor-mediated transendothelial insulin transport emerged 
from in vitro studies of bovine aortic endothelial cells; King and Johnson reported saturability of the 
transendothelial insulin transport across a cell monolayer consistent with receptor-mediated 
transport (King and Johnson. 1985). Insulin transport across the brain microvascular endothelium in 
vivo is a saturable, receptor-mediated process (Schwartz et al. 1991).
Hamilton-Wessler and colleagues reported that the rate of appearance of insulin detemir in hindlimb 
ISF remained constant in the absence and presence of saturating plasma insulin concentrations
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(Hamilton-Wessler et al. 2002). This upports the hypothesis that transcapillary transport of detemir 
in the periphery occurs primarily via a nonsaturable process, such as transcytosis or passive rather 
than a receptor mediated process. However, it is notable that the appearance of detemir in hindlimb 
ISF is considerably delayed in comparison with native insulin. This is a result of retention of 
detemir by binding to plasma albumin rather than a slowing of the transcapillary transport rate (Dea 
et al. 2002). In addition to the pore and molecular size, temperature, capillary haemodynamics, net 
molecular charge on the molecule, electrical resistance of the capillary endothelium may also 
significantly influence the passage of molecules across the capillary endothelium (Hamilton- 
Wessler et al. 2002).
The biological effects of insulin are a function of the affinity of the receptor for insulin, the plasma 
insulin concentration and insulin-receptor concentration. The other unique property of detemir is the 
partial non-receptor mediated clearance. It is possible that the low receptor binding affinity and 
altered pharmacokinetic properties of detemir could contribute to the reduced biological activity in 
the periphery. Non receptor mediated clearance may also explain the different metabolic potencies 
seen with insulin detemir and human insulin (Kurzhal et al. 2000).
The reduced suppression of glycerol Ra observed with insulin detemir is likely to be due to its 
molecular size and the capillary endothelial barrier. However, an alternative explanation could be 
due to the less potent action of insulin detemir on the insulin receptor on adipocytes, resulting in 
less suppression of lipolysis (Garcia-Escobar at al. 2011). Insulin detemir has been shown to be less 
potent than human insulin in binding to the insulin receptor. The B26-B30 region is not particularly 
crit- ical for insulin receptor binding and has been a preferred site for structural modifications of the 
insulin molecule. This is the part of the insulin structure that has been modified to prolong the 
action of insulin detemir. (Slieker et al. 1997). However, insulin detemir has a reduced insulin 
receptor affinity. It is likely that the 014 fatty acid attached to the B29Lys side chain makes 
hydrophobic contacts to one or more of the aromatic amino acids in positions B24-B25 and thereby 
partly shields these residues from recognition by the insulin receptor (Kurzhal et al, 2000).
5.4. Comparison with similar work
The physiological effect of insulin detemir following a period of insulin withdrawal provides 
further evidence that detemir has the potential to restore the physiological insulin gradient. The 
hepatoselective potential of detemir has also been seen under two other experimental conditions, 
during an euglycaemic hyperinsulinaemic clamp and during free fall of glucose concentration to
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hypoglycaemia (Hordern et al. 2005; Smeeton et al. 2009). Following a 16 hour euglycaemic 
clamp protocol in healthy volunteers, insulin detemir had a greater effect on mean suppression of 
glucose Ra. However, it had a lesser effect on mean suppression of NEFA concentrations than 
NPH. There also appeared to be less suppression of glycerol Ra with detemir than NPH, but these 
differences were not found to be significant statistically (Hordern et al. 2005). During 
hypoglycaemia in subjects with type 1 diabetes insulin detemir had a greater effect than NPH 
insulin on suppression of glucose Ra and a lesser effect than NPH insulin on the stimulation of 
glucose Rd (Smeeton et al. 2009).
The hepatoselective potential of detemir may help explain some of the findings in clinical studies. 
When compared with NPH insulin, subcutaneous detemir is associated with reduced episodes of 
hypoglycaemia, reduced episodes of nocturnal hypoglycaemia and lower weight gain observed 
(Vague et al. 2003; Hermansen et al. 2004; Kolendorf et al. 2006; Bartley et al. 2008). Three 
randomized clinical trials have also reported lower HbAlc with insulin detemir versus NPH insulin 
at the end of the treatment periods ranging from 6-18 months. In one study with patients with type 
1 diabetes, treatment with insulin detemir led to a (0.2-0.3 kg) decrease in weight, whereas NPH 
insulin resulted in weight gain ranging from 0.4 to 1.4 kg over 6-12 months (Russell-Jones et al. 
2003). The long-term efficacy and safety of insulin detemir compared to NPH insulin has also been 
studied. In the 2-year randomised, controlled trial in patients with type 1 diabetes using a treat-to- 
target basal-bolus regimen with insulin aspart, 22% of patients treated with insulin detemir reached 
a HbAlc <1.0%  without confirmed hypoglycemia during the last month of treatment vs 13% on 
NPH insulin (p=0.02). Detemir was associated with a 69% lower risk of major hypoglycemic 
episodes compared to NPH (p<0.001) and the risk of nocturnal hypoglycemia was 46% lower with 
detemir than with NPH (p<0.001). Moreover, patients treated with detemir gained less weight. At 
baseline, the mean and weight range was 71.2 kg (39.5-128.4) in the detemir group and 70.9kg 
(33.6-119.0) in the NPH group. At the end of the trial the mean weight was 72.9 ± 0.26 kg in the 
detemir group and 73.9 ± 0.37 kg in the NPH group (mean difference -0.99 Cl -1.86 to -0.13) p=
0.02) (Bartley et al. 2008).
Insulin glargine has similar pharmacodynamics when compared to insulin detemir and is more 
commonly used in modem day clinical practice. It is therefore of interest to compare the metabolic 
effects. In participants with type 1 diabetes, suppression of lipolysis appears to be less with 
subcutaneous insulin detemir when compared to insulin glargine using euglycaemic
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hyperinsulinaemic clamp methodology (Porcellati et al. 2007). However, during intravenous 
administration of detemir and glargine in healthy dogs, there were no significant differences 
between detemir and glargine on hepatic or whole body glucose metabolism or glycerol metabolism 
using tracer ([3-3H]glucose) techniques during a euglycaemic hyperinsulinaemic clamp protocol 
(Moore et al. 2011). Results from clinical trials have consistently shown detemir to be associated 
with less weight gain and lower hypoglycaemic episodes than with treatment of NPH insulin or 
glargine (Hollander 2012). Hollander reported on a multinational, 52-week, open-label, parallel 
group, noninferiority, treat-to-target trial. Insulin detemir has likewise caused less weight gain 
compared to glargine when added to oral agents at comparable level of glucose control (p=0.012) in 
patients with type 2 diabetes (Rosenstock et al. 2008).
We are entering an exciting period with the development of newer analogues, which show the 
potential of hepatoselectivity combined with a longer duration of action, and might offer a more 
physiological basal insulin supplementation.
Insulin degludec (IDeg) forms soluble multihexamer assemblies after subcutaneous injection, 
resulting in an ultra-long action profile. The structural addition of glutamic acid may change its 
hydrophobic properties. Insulin degludec provides comparable weight and glycaemic control to 
insulin glargine (Birkeland et al. 2011). Due to its molecular size it may be hepatoselective. 
However, there are no clamp data available. Degludec’s in-vitro potency without albumin is 13% 
for the A receptor isoform and 15% for the B isoform and the receptor binding off rate is 100% and 
on rate only 14%. Degludec’s binding affinity for albumin is 2.4 fold higher than detemir. In 
addition, to the molecular size of degludec when bound to albumin, the binding affinity is crucial 
for access to liver receptors as is blood transit time in the space of Disse relative to that in muscle 
and fat capillaries. Considering these values it is likely that hepatic receptor occupancy by degludec 
will be less than that of detemir with consequently a reduced tendency to be hepatoselective.
LY2605541 is insulin lispro covalently bonded to 20,000 Dalton monomethoxy poly(ethylene 
glycerol) (mPEG) moiety at lysine B28 increasing the hydrodynamic diameter to four time sthe size 
of insulin lispro (7.8+0.4nm) which delays insulin absorption and reduces clearance, resulting in 
prolonged duration of action. Clamp data has shown LY2605541 to have a preferential hepatic 
effect similar to endogenously produced insulin, i.e. it suppresses endogenous glucose production to 
a greater extent and stimulates muscle glucose uptake to a lesser extent when administered via 
peripheral vein (Courtney Moore et al. 2012). In the phase 2 studies, LY2605541 demonstrated 
similar or improved glycaemic control, lower glycaemic variability, and less nocturnal
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hypoglycaemia in type 2 diabetes when compared with insulin glargine (Bergenstal et al. 2012) and 
lower meal time insulin doses (Rosenstock et al. 2013). Phase 3 studies are currently ongoing. Not 
unsurprisingly, it is speculated that the large molecular and hydrodynamic size of this insulin 
contributes to this aspect of different action. This large size may reduce insulin transport (and thus 
action) into peripheral target tissues such as adipose tissue further supporting the hypothesis that 
size is important in hepatoselectivity. Mean serum ALT and AST levels were increased from 
baseline and were higher than with glargine, but were within the normal range. This increase in 
ALT and AST may reflect a hepatic adaptation reaction to the pegylated insulin, as it has not been 
found to be clinically relevant with detemir (Rosenstock et al. 2013).
Information is beginning to emerge about another insulin analogue known only as insulin 327. So 
far details of its structure have not been revealed but it is of interest that data implying a valuable 
potential hepatoselectivity have already been published in abstracts. Relative to the basal period, 
intravenous insulin 327 suppressed net hepatic glucose balance and glucose Ra (mg/kg/min: last 3h) 
by 1.9±0.1 and 1.7±0.1, respectively, while human insulin reduced these by only 0.5±0.6 and 
1.1±0.3. On the other hand, insulin 327 only increased non-hepatic glucose uptake and glucose Rd 
(mg/kg/min; last 3 h) by 1.0±0.4 and 1.5±0.3, respectively, while human insulin increased these by 
2.4±1.2 and 2.5±1.1. Suppression of lipolysis was also delayed with insulin 327 compared to human 
insulin (Edgerton et al. 2012).
5.5. Directions for the future
1. The outcomes of the phase III clinical trials of LY2604451 and phase II clinical trials of insulin 
327 are of interest. Both insulins appear to demonstrate hepatoselective potential as evidenced by 
clamp data. Indicating that molecular size is important. Interestingly, early clinical studies have also 
suggested slight derangements on liver function, which may limit the clinical use of LY264451 and 
it will be of interest to see the difference on weight gain and hypoglycaemia.
2. It would also be of clinical interest to study the differential effects on glargine and detemir on 
glucose metabolism and lipid metabolism using isotopic tracers in subjects with type 1 diabetes. It 
was not possible in this study but it should be acknowledged that currently insulin glargine or 
insulin detemir are the preferred choice for basal insulin in type 1 diabetes in the clinical setting.
3. There are no clamp data available for insulin degludec and comparison with detemir may help
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clarify its hepatoselectivity potential and develop further understanding of the mechanisms relating 
to hepatoselectivity. Degludec has a fatty acid side chain but does not seem to have the beneficial 
side effect profile of reduced hypoglycaemia frequency and less weight gain.
4. Due to ethical restraints we did not study the action of insulin in patients presenting with diabetic 
ketoacidosis or after a prolonged period of insulin withdrawal. Emergency treatment of diabetic 
ketoacidosis is changing. Basal insulins are consistently being continued to prevent rebound 
hyperglycaemia when intravenous insulin infusions are discontinued and patient demographics are 
changing. Patients with diabetic ketoacidosis are more likely to be obese or suffering from other 
insulin resistance states. This has resulted in fixed doses per kilogram body weight of insulin 
infusions being encouraged for the emergency treatment of diabetic ketoacidosis. It would be of 
interest to see how glucose metabolism and lipid metabolism and ultimately acidosis resolution 
differs with the fixed dose insulin infusions in comparison with traditional sliding insulin infusions.
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Chapter 6. Results for euglycaemic / hyperglycaemic clamp protocol
6.1. Participant characteristics
12 participants completed both metabolic studies. The participant characteristics are shown in table 
10. All values are expressed at mean ± SEM. There were 8 females and 4 males: mean age 33.5 ± 
4.7 years, mean weight 70.0 ±2.5 1 kg, mean BMI 24.5 ± 0.8 kg/ni2, mean HbAlc 6.9 ± 0.7 %, 
mean duration of diabetes 16.1 ± 2.4 years. Five participants used a continuous subcutaneous 
insulin infusion and 6 followed a multiple daily injection regimen. Mean total daily insulin was 
37.8 ± 5.6 international units.
Table 10. Participant characteristics in the euglycaemic and hyperglycaemic hyperinsulinaemic clamp protocol.
Participants Gender Age (years) Weight
(kg)
BMI (kg/m3 HbAlc
(mmol/mol)
(%)
Duration of 
Diabetes 
(years)
Regular insulin 
administration
Total daily dose 
of insulin (lU)
N N ll F 43 6±2 2Z4 66 (8.2) 34 CSII 17
NNl F 47 8Z3 283 72 (8.7) 29 CSII 30
NN3 F 40 6&9 293 44 (6.2) 11 CSII 28
NN5 F 37 55.0 21.2 60 (7.6) 19 MDI 32
NN4 F 48 6&5 263 60 (7.6) 20 CSII 25
NNl 5 M 37 79.1 2±9 57 (T4) 15 MDI 42
NN16 M 20 75^ 233 65(83) 10 CSII 45
NN14 M 35 8E0 233 48(63) 11 MDI 30
NN9 F 19 66.1 253 73 (8.8) 16 MDI 90
NN13 F 19 7±6 263 57(34) 9 CSII 21
NNl 7 F 38 603 2±6 62 (7.8) 10 MDI 45
NN19 M 20 68 21 52 (6.9) 9 CSII 49
Mean ± SEM - 33.5 ±4.7 70.0 ±2.5 24.5 ±0.8 60 ±2.3 16.1 ±2.4 - 37.8 ±5.6
1 1 2
6.2. Plasma glucose concentration
At commencement of the metabolic study, the fasting plasma glucose concentration was 10.8 ±1.7 
mmol/1 for the detemir group and 11.4 ± 1.8 mmol/1 for the NPH group. Plasma glucose at time 0 
(isotopic equilibrium) was 6.9 ± 0.4 in the detemir group and 6.0 ± 0.3 mmol/1 in the NPH group. 
Due to the lag phase for subcutaneous insulin aetion, plasma glucose eoncentration of 5mmol/1 was 
maintained by eontinuation of the intravenous insulin infusion for a maximum of 90 minutes after 
the subcutaneous injection. This means any difference in action between the two subcutaneous 
insulins can only be compared after 90 minutes. The glucose metabolism data were analysed using 
90 to 210 minutes as the euglycaemic clamp period and 210 to 300 as the hyperglycaemic period.
The plasma glucose concentrations are shown in figure 40.
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Figure 40. Plasma glucose concentration plotted against time in the clamp protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n=12
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At 90 minutes (beginning of euglycaemic clamp period) the plasma glucose concentration was 6.0 ± 
0.3 mmol/1 in the detemir group and 5.8 ± 0.4 in the NPH group. At 210 minutes (the end of the 
euglycaemic clamp period) plasma glucose concentration was 6.6 ± 0.3 mmol/1 in the detemir group 
and 6.2 ± 0.4 in the NPH group and at 300 minutes (the end of the hyperglycaemic period) plasma 
glucose concentration was 10.4 ± 0.4 mmol/1 in the detemir group and 10.6 ± 0.3 in the NPH group. 
There was no difference between the glucose concentration profiles in the euglycaemic clamp 
period (ANOVA P=0.30) and the hyperglycaemic period (ANOVA P=0.61).
Glucose infusion rates
The exogenous glucose infusion rates were similar in both groups confirming the equipotency of 
the doses of insulin (ANOVA P=0.17). There were no statistical differences in the time of starting 
the variable rate glucose infusion, the peak glucose infusion rate or glucose infusion rates during the 
euglycaemic and hyperglycaemic clamp period. Glucose infusion rates are shown in figure 41.
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Figure 41. Glucose infusion rates plotted against time in the clamp protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n=12
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6.3. Glucose metabolism
Figure 42 shows the mean glucose Ra plotted against time. At the time of subcutaneous injection, 
glucose Ra was marginally lower in the detemir group at 12.3 ±1.5 pmol/kg/min and 13.2 ±2.1 
pmol/kg/min in the NPH group. The difference was not statistically significant (mean difference - 
1.0 pmol/kg/min Cl -6.9 to 4.9 t-test P=0.72). A reduction in glucose Ra was seen with both 
insulins. However, there was no statistical difference in glucose Ra between the detemir and NPH 
group in the euglycaemic period (ANOVA P=0.81) or the hyperglycaemic period (ANOVA P= 
0.53).
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Figure 42. Glucose rate of appearance (Ra) plotted against time in the clamp protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n=12
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Figure 43 shows the mean glucose Rd plotted against time. At the time of subcutaneous insulin 
injection, glucose Rd was 12.4 ±1.5 pmol/kg/min in the detemir group and 13.4. ± 2.1 pmoFkg/min 
in the NPH group. The difference was not statistically significant, (mean difference -1.0 
pmol/kg/min Cl -6.9 to 4.9 t-test P=0.72). There was no statistical difference in glucose Rd between 
the detemir and NPH group during the euglycaemic period (ANOVA P=0.31) but there was a 
significant difference during the hyperglycaemic period (ANOVA P= 0.003).
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Figure 43. Plasma glucose rate of disappearance (Rd) against time, in the clamp protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n=12
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Metabolic clearance rate (MCR) of glucose
The MCR of glucose was lower in the detemir group than the NPH group. MCR plotted against 
time is shown in figure 44. The difference was statistically significant in the hyperglycaemia period 
(ANOVA P=0.008) but not statistically significant in the euglycaemic clamp period. (ANOVA 
P=0.09)
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Figure 44. Metabolic clearance rate of glucose plotted against time in the euglycaemic and hyperglycaemic clamp 
protocol
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n=12
In summary, there were no significant differences on the effects of insulin detemir and NPH on 
glucose Ra and glucose Rd during the euglycaemic clamp period. However, there was a statistically 
significant difference in glucose Rd during the hyperglycaemic period. The glucose rate of 
disappearance was higher in the NPH group than the detemir group. A summary of the effects on 
glucose metabolism is shown in table 11.
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Table 11. A summary of the effect of insulin detemir and NPH insulin on glucose metabolism in the euglycaemic 
clamp and hyperglycaemic period.
Insulin
Detemir
NPH
Insulin
Mean difference 
(Cl)
P-value
Fasting plasma glucose (mmol/1) 10.8±1.7 11.4±1.8 -0.54 (-3.4 to 2.3) 0.68
Plasma glucose at isotopic equilibrium 
(mmol/1)
6.9±0.4 6.0±0.3 1.1 (-0.1 to 2.3) 0.07
Glucose Ra at subcutaneous injection 
(pmol/kg/min)
12.3 ±1.5 13.2 ±2.1 -1.0 (-6.9 to 4.9) 0.72
Glucose Ra at start o f euglycaemic clamp 
(pmol/kg/min)
8.4 ± 1.3 10.2 ± 2 .2 -1.8 (-7.9 to 4.2) 0.52
Glucose Ra at end o f euglycaemic clamp 
(pmol/kg/min)
5.3 ± 1.7 3.6 ±2.3 -1.7 (-3.1 to 6.4) 0.44
Glucose Ra at end o f hyperglycaemic 
period (pmol/kg/min)
4.0 ± 1.8 6.0 ± 1.4 -1.9 (-7.1 to 3.3) 0.43
Glucose Rd at subcutaneous injection 
(pmol/kg/min)
12.4 ± 1.5 13.4 ±2.1 -1.0 (-6.9 to 4.9) 0.72
Glucose Rd at start o f euglycaemic clamp 
(pmol/kg/min)
12.3 ± 0 .7 13.7=11.7 -1.5 (-5.5 to 2.5) 0.44
Glucose Rd at end o f euglycaemic clamp 
(pmol/kg/min)
9.1 ±1.0 10.2 ± 0 .6 -1.1 (-2.8 to 0.6) 0.18
Glucose Rd at end o f hyperglycaemic 
period (pmol/kg/min)
13.0 ±1.2 21.0 ±2.5 -9.0 (-15.9 to -2.0) *0.02
Values are mean±SEM. * = p value <0.05.
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6.4. Non esterified fatty acids (NEFA)
The NEFA concentration plotted against time is shown in figure 45. At the end of the euglycaemic 
clamp period, plasma NEFA eoncentration was stable at 0.62 ± 0.05 in the detemir group and 0.40 
± 0.06 mmol/1 in the NPH group. At the end of the hyperglycaemic clamp period, plasma NEFA 
concentration fell to 0.53 ± 0.05 in the detemir group and 0.44 ± 0.1 mmol/1 in the NPH group. 
When taking into account the difference in NEFA concentrations at time 0, there was no statistical 
difference in NEFA concentrations between the two insulin profiles. (ANOVA P= 0.09)
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Figure 45. Plasma NEFA concentration plotted against time in the clamp protocol.
Closed circles represent insulin detemir and closed squares represent NPH insulin. Values are mean±SEM, n=12
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6.5. Electroencephalograph (EEG)
6.5.1. DC-potential
The mean DC-potentials for all electrodes in the detemir group and NPH group showed a negative 
shift with time. This negative shift was more marked in the detemir group. (ANOVA P=0.03) The 
mean DC-potentials for all electrodes in the detemir group and NPH group plotted against time 
from subcutaneous injection is shown in figure 46.
During the euglycaemic clamp period there was a statistical difference in DC-potentials between the 
insulin detemir group and NPH group. (P=0.02) When comparing time points, the greatest 
difference in DC potential was seen at 210 minutes (the end of the euglycaemic clamp period). At 
this time point the values were -6.13 ± 1.34 in the detemir group and -1.86 ± 0.97 in the NPH group 
(mean difference -4.3mVolts Cl -8.0 to -0.5 P=0.03).
During the hyperglycaemia period there was a difference in DC-potentials between the insulin 
detemir group and NPH group but this did not reach statistical significance (P=0.08). At 300 
minutes (the end of the hyperglycaemic clamp period), the mean value was -6.54 ± 1.38 in the 
detemir group and -3.10 ± 1.01 in the NPH group (mean difference -3.4mVolts Cl -7.9 to 1.0 
P=0.10).
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Figure 46. The mean DC-potential for all subjects and all electrodes plotted against time from subcutaneous 
injection.
Plasma glucose concentration 6mmoFl ANOVA P value 0.3 and plasma glucose concentration 6-lOmmol/l 
ANOVA P value 0.8. n=12.
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Looking at the different electrodes in isolation. The mean DC-potentials for each electrode in the 
detemir and NPH group during the euglycaemic period (from 90 mins to 210 mins) are shown in 
table 12. There were statistically significant differences between the mean DC-potentials for each 
electrode position except electrode F3 (the left frontal electrode) in the detemir group when 
compared with the NPH group in the euglycaemic period. EGG DC-potentials show global low- 
grade voltage fluctuations and do not demonstrate differences in anatomical brain areas. If there 
were significant differences between the action of the two insulins, one would expect the 
differences to be present in all electrodes. The mean DC-potentials for each electrode in the detemir 
and NPH group in the hyperglycaemia period (from 210 mins to 270 mins) are shown in table 13. 
There were statistically significant differences between the mean DC-potentials for each electrode 
position.
Table 12. Mean DC potentials for each electrode during the euglycaemia period.
Electrode
position
Detemir NPH Mean difference 
(Cl)
P value
F3 -0.69 -0.37 0.33 (-0.56 to 1.2) >0.05
F4 -3.95 -0.82 3.13 (2.24 to 4.02) <0.001*
03 -7.13 -2.22 4.91 (4.02 to 5.79) <0.001*
04 -4.13 0.78 4.91 (4.03 to 5.80) <0.001*
F03 -5.91 -4.78 1.13 (0.24 to 2.02) <0.01*
F04 -8.05 -0.66 7.38 (6.50 to 8.27) <0.001*
F3 left frontal, F4 right frontal, FC3 left frontocentral, FC4 right frontocentral, C3 left central, C4 right central cortical 
areas. * p<0.05.
Table 13. Mean DC potentials for each electrode during the hyperglycaemia period.
Electrode
position
Detemir NPH Mean difference 
(Cl)
P value
F3 -0.29 -3.77 -3.48 (-5.03 to -1.92) <0.001*
F4 -5.88 -2.52 3.36 (1.80 to 4.91) <0.001*
03 -9.50 -6.07 3.43 (1.88 to 4.99) <0.001*
04 -7.27 -2.53 4.75 (3.19 to 6.30) <0.001*
F03 -7.12 -4.38 2.73 (1.18 to 4.29) <0.001*
F04 -6.52 0.68 7.21 (5.65 to 8.76) <0.001*
F3 left frontal, F4 right frontal, FC3 left frontocentral, FC4 right frontocentral, C3 left central, C4 right central cortical 
areas. * p<0.05.
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The mean DC-potentials in the detemir and NPH group for each electrode have been plotted against 
time and are shown in figure 47, figure 48 and figure 49.
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Figure 47. Mean DC potentials for each individual frontal electrode following subcutaneous injection. 
Detemir (solid line) and NPH (dashed lines), a. F3 left frontal electrode, b. F4 right frontal electrode, n=12.
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b. C4 right central electrode
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Figure 48. Mean DC potentials for each individual central electrode following subcutaneous injection.
Detemir (solid line) and NPH (dashed lines), a. C3 left central electrode, b. C4 right central cortical electrode 
n=12.
123
a. FC3 left frontocentral electrode
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b. FC4 right frontocentral electrode
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Figure 49. Mean DC potentials for each individual frontocentral electrode following subcutaneous injection. 
Detemir (solid line) and NPH (dashed lines), a. FC3 left frontocentral, b. FC4 right frontocentral, n=12.
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6.5.2. AC-potential
The EEG AC-potential data has been divided into a series of bands, which represent different 
ranges of frequencies. A description of each band frequency is shown in table 14.
Table 14. EGG AC potential band frequencies.
AC-Potential Band Frequency Frequency name
Band 1 0.5 Hz - 1 Hz Delta
Band 2 1 Hz - 5 Hz Delta
Band 3 5 Hz - 8 Hz Theta
Band 4 8 Hz - 12 Hz Alpha
Band 5 12 Hz - 15 Hz Beta
Band 6 15 Hz - 20 Hz Beta
Band 7 20 Hz - 25 Hz Beta
Band 8 25 Hz- 32 Hz Gamma
Differences in eyes open period
Comparisons between the two insulins were made during the euglycaemic time period (90 to 210 
minutes) and hyperglycaemic period (210 mins to 300 mins). The differences between the two 
insulins for all bands during the euglycaemic period and the hyperglycaemic period were not 
statistically significant, (ANOVA P= 0.18) and (ANOVA P=0.18) respectively.
Comparison between treatment and mean spectral power (uV^ per Hz) at each band frequency 
during the eyes open period is shown in table 15. A positive AC potential indicates that spectral 
power activity is increased compared to baseline, and negative potential means a decrease in 
spectral power activity. There was a statistical difference between insulin detemir and NPH in band 
1 and 2 in the euglycaemic period and band 1 in the hyperglycaemic period. Band 1 and 2 
represents the delta band.
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Table 15. Comparison between treatment group and mean spectral power (uV2 per Hz) at each band frequency 
during the eyes open period.
Spectral power 
uV^ per Hz in 
Detemir group
Spectral power
uV  ^per Hz in 
NPH group
Mean difference 
(Cl)
P value
Euglycaemic period (90 - 210 mins)
Band 1 83.7 -21.6 -105.2 (-155.6 t o -54.8) P<0.001*
Band 2 33.8 -33.9 -67.8 (-118.2 t o -17.4) P < 001*
Band 3 -7.7 -14.7 -6.9 (-57.3 to 43.5) P > 0.05
Band 4 -26.8 -27.1 -0.30 (-50.7 to 50.1) P > 0.05
Band 5 -5.6 -6.7 -1.1 (-51.5 to 49.3) P > 0.05
Band 6 -1.7 -3.9 -2.2 (-52.6 to 49.2) P > 0.05
Band 7 14.7 -2.5 -17.3 (-67.7 to 33.1) P > 0.05
Band 8 17.7 -2.2 -19.9 (-70.4 to 30.5) P > 0.05
Hyperglycaemic period (210-300  mins)
Band 1 35.1 -85.1 -120.1 (-189.8 to 50.5) P <0.001*
Band 2 60.8 - 5 j -66.6 (-136.3 to 3.0) P > 0.05
Band 3 -8.8 -5.9 2.9 (-66.7 to 72.6) P > 0.05
Band 4 -12.5 -20.7 -8.2 (-77.8 to 61.4) P > 0.05
Band 5 -7.8 -8.5 -0.7 (-70.3 to 68.9) P > 0.05
Band 6 -2.7 -6.5 -3.8 (-73.4 to 65.8) P > 0.05
Band 7 14.3 -2.7 -17.0 (-86.7 to 52.6) P > 0.05
Band 8 13.6 -5.7 -19.3 (-89.0 to 50.3) P > 0.05
* P<0.05 Statistically significant. A positive AC potential indicates that spectral power activity is increased compared 
to baseline, and negative potential means a decrease in spectral power activity
Difference in eyes closed period
Comparisons between insulin detemir and NPH were made during the euglycaemic time period (90
to 210 mins) and hyperglycaemic period (210 mins to 300 mins). The differences between insulin
detemir and NPH in all bands during the euglycaemic period were not significant (ANOVA P=
0.06) but they were significant during the hyperglycaemia period (ANOVA P= 0.03). Comparison
between treatment and mean spectral power (uV^ per Hz) at each band frequency during the eyes
closed period is shown in table 16. A positive AC potential indicates that spectral power activity is
increased compared to baseline, and negative potential means a decrease in spectral power activity
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There was a significant difference in spectral power between the two insulin insulin in band 1 
during the euglycaemic period and band 4 during the hyperglycaemic period.
Table 16. Comparison between treatment group and mean spectral power (uV2 per Hz) at each band frequency 
during the eyes closed period.
Spectral power 
uV  ^per Hz in 
Detemir group
Spectral power uV  ^
per Hz in NPH 
group
Mean difference 
(Cl)
P value
Euglycaemic period (90 - 210 mins)
Band 1 28.4 -48.5 -76.8 (-119.3. to 34.4) p <0.001*
Band 2 21.8 -19.2 -41.0 (-83.5 to 1.4) p > 0.05
Band 3 -17.7 -31.7 -14.0 (-56.4.0 to 28.5) p > 0.05
Band 4 -12.5 -51.9 -39.5 (-81.9 t o -3.0) p > 0.05
Band 5 -2.7 -4.7 -2.0 (-44.4 to 40.5) p > 0.05
Band 6 0.9 -3.2 -4.1 (-46.5 to 38.4) p > 0.05
Band 7 5.0 -1.3 -6.3 (-48.8 to 36.1) p > 0.05
Band 8 12.0 -1.4 -13.4 (-55.9 to 29.0) p > 0.05
Hyperglycaemic period (210 - 300 mins)
Band 1 -33.3 -51.5 -18.2 (-48.4. to 12.0) p > 0.05
Band 2 -14.4 -12.8 1.3 (-28.9 to 31.6) p > 0.05
Band 3 -21.4 -19.2 2.2 (-28.0 to 32.4) p > 0.05
Band 4 8.6 -77.3 -85.9 (-116.1 to -55.7) p <0.001*
Band 5 -1.4 -5.6 -4.2 (-34.4 to 26.0) p > 0.05
Band 6 0.5 -4.3 -4.8 (-35.0 to 25.4) p > 0.05
Band 7 4.2 1.4 -2.3 (-33.0 to 27.4) p > 0.05
Band 8 10.6 -0.30 -10.8 (-41.0 to 19.4) p > 0.05
* P<0.05 Statistically significant. A positive AC potential indicates that spectral power activity is increased compared 
to baseline, and negative potential means a decrease in spectral power activity
In summary, there were negative shifts in DC-potentials with time and the shifts were more marked 
with insulin detemir compared with NPH insulin. AC-potentials changed in every band frequency 
suggesting that EEG AC potentials were sensitive to insulin. However, significant differences 
between the insulins were only seen in band 1 and 2 during eyes open and band 4 during eyes 
closed. The relevance of this difference is still to be determined.
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Chapter 7. Discussion of euglycaemic / hyperglycaemic clamp protocol
7.1. Summary of main findings
While eliciting comparable effects on glucose flux and lipolysis as measured by NEFA 
concentrations during the euglycaemic clamp protocol, subcutaneous insulin detemir compared with 
NPH insulin triggered a distinct negative shift in EEG DC-potentials. During the hyperglycaemia 
period, the distinct negative shift in EEG DC-potentials seen with detemir remained significant 
although glucose Rd was higher with detemir when compared with NPH.
This supports the hypothesis that subcutaneous detemir may affect brain fiinction to a greater extent 
than NPH insulin. This enhanced insulin signalling to the brain may be an important mechanism 
behind the limitation of weight gain observed in patients with type 1 diabetes receiving 
subcutaneous detemir treatment.
7.2. Factors influencing results
Metabolic study protocol
The aim was to achieve euglycaemia at 5mmol/l followed by a period of hyperglycaemia clamped 
at lOmmol/1. To achieve a hyperglycaemia, the plasma glucose concentration had to rise acutely 
and be maintained at lOmmol/1 until the end of the metabolic protocol. This rapid rise in glucose 
concentration should have been achieved using a 15minute ‘priming dose’ and then maintained with 
a variable rate glucose infusion at 7minute intervals. This was particularly important as the 
hyperglycaemia period only lasted 90 minutes. A steady hyperglycaemic period was not achieved 
and the changing hyperglycaemic state may influence the EEG results measured during 
hyperglycaemia.
7.3. Discussion of clamp protocol results
Plasma glucose concentration
Following discontinuation of the intravenous insulin infusion the plasma glucose concentration 
profiles were similar for insulin detemir and NPH. There was a non-significant difference in
128
glucose concentration in participants at the point of subcutaneous injection. It was important that 
the blood glucose concentration was not allowed to rise above the euglycaemia range while waiting 
for the subcutaneous insulin to take effect. The intravenous insulin infusion was therefore continued 
for a short time period, following the insulin subcutaneous injection and gradually decreased in 
parallel with the initiation of the glucose lowering effects of the subcutaneous insulin. The glucose 
lowering effect should have occurred by 90 minutes and the intravenous insulin was not continued 
beyond this time point.
The other advantage of comparing the euglycaemia data after 90 minutes was that it eliminated any 
effect of overinsulinisation and underinsulinisation produced by the intravenous insulin period prior 
to the subcutaneous injection. For instance, “ overinsulinisation” during this phase could impact the 
glucose requirement during the first part of the clamp, influencing insulin sensitivity, and 
overestimating the subsequent insulin action, thereby making any difference in subcutaneous 
insulin action difficult to interpret. Conversely, an “ underinsulinisation” during the feedback 
phase would probably translate into an easy “ escape” of blood glucose from the target value during 
the first part of the clamp, before insulin action takes place.
Ideally, the plasma glucose target of a metabolic clamp has to be reached at least 1 hour before trial 
insulin administration. This period is frequently termed the ‘insulin feedback’ period. (Porcellati et 
al. 2011.) It is a period where the glucose concentration, insulin concentration and isotopes should 
be at a steady state. Due to the difference between whole blood and plasma glucose concentration, 
the euglycaemic clamp averaged at a plasma glucose concentration of 6mmol/l. This was slightly 
higher than in the study protocol but the glucose concentration was stable.
Glucose metabolism using stable isotopes
No significant differences were identified between the glucose lowering effects of detemir and NPH 
insulin on hepatic glucose production or peripheral glucose uptake during the euglycaemic period. 
However, there were significant differences in peripheral glucose uptake during the hyperglycaemic 
period. The glucose rate of disappearance was higher in the NPH group than the detemir group.
It was slightly surprising that there were no differences in glucose Rd during the euglycaemic clamp 
period. One reason may be related to the length of the euglycaemic clamp period. Euglycaemia was 
only maintained for 210 minutes following the subcutaneous insulin injection and this may have 
been too short to detect a significant difference. A similar study design investigating insulin detemir
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and NPH insulin in healthy subjects showed a significant difference in glucose Rd after only 240 
minutes (Hordern et al. 2005).
DC-potential
This study showed that insulin action on the brain occurred quicker than peripheral action, with 
changes in DC-potentials being seen as early as 30 minutes following the subcutaneous insulin 
injection. It seems likely that insulin may have a tissue selective action, with preference for the 
brain compared with peripheral tissues (Zachariah et al 2011). In the current study, this tissue 
selective action is greater with detemir perhaps due to its unique property of partial non-receptor 
mediated clearance, which results in higher circulating concentrations of detemir.
While eliciting comparable effects on glucose flux and lipolysis during euglycaemia, subcutaneous 
insulin detemir compared with NPH insulin triggered a distinct negative shift in EEG DC- 
potentials. The negative shift in DC-potential seemed to be of a global nature with every electrode 
except the left frontal electrode demonstrating a marked negative shift. Negative changes were seen 
with NPH insulin but not as marked. Insulin receptors are located globally having been 
demonstrated throughout the human brain, with particularly high concentrations in the 
hypothalamus, cerebellum, and cortex supporting a global effect (Hopkins & Williams. 1997).
It is difficult to establish what this marked negative DC-potential shift actually means. DC- 
potentials are recorded from the scalp and considered to be a reflection of general changes in 
cortical excitability and likely represent shifts in extracellular ionic concentrations stemming from 
potential shifts in the glial membranes that are endowed with insulin receptors (Hallschmid et al. 
2010). The negative DC-potential may therefore reflect the electrical potentials generated during 
receptor mediated transport across the blood brain barrier (Pardridge. 1993). Alternatively, insulin 
detemir and NPH insulin could cross the blood brain barrier equally but have different binding 
affinities to the insulin receptors located within the brain. Albumin is also very low in the 
cerebrospinal fluid so another possibility is that there may be more unbound active detemir 
available to bind to the insulin receptor in the brain.
Interpretation of the EEG DC-potentials during the hyperglycaemia period is difficult because 
glucose Ra was higher in the NPH group when compared with the detemir group. The difference in
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EEG DC-potentials between the two insulins may be as a result of the increased rate of peripheral 
glucose uptake in the NPH group.
AC-Potential
Insulin has been shown to induce activation of delta, theta, alpha and beta EGG activity although 
the exact significance remains unclear (Tschritter et al. 2007). Following the subcutaneous insulin 
injection, AC-potentials changed in every band frequency suggesting that EGG AC-potentials were 
sensitive to insulin. There were statistically significant differences between the two insulins in band 
1 and 2 while the subject was alert, indicating a possible difference in the activation of delta EGG 
activity during the euglycaemic clamp. During the hyperglycaemia period there were statistically 
significant differences between the two insulins in band 4 while the subject was resting, indicating a 
possible difference in the activation of alpha EGG activity.
The direct effect of insulin on EGG AC potential has rarely been studied and most studies involve 
animal models. In mice using epidural EEG AC-potential recording insulin has been shown to 
induce activation of delta, theta, alpha and beta EGG activity. This suggests that insulin signalling 
modulates electrical activity in the mouse cortex (Hennige et al. 2006). One of the only human 
studies has reported that insulin stimulates cerebrocortical beta and theta activity in lean humans 
and this effect is reduced in obese individuals (Tschritter et al. 2007). Subcutaneous insulin seems 
to affect AC-potential but its role and preference for specific fi*equencies remains unclear.
7.4. Comparison with similar work
The exact role of insulin signaling to the brain is not understood and the majority of data looking at 
the action of insulin in the brain has been obtained in animal models. However, it is well recognised 
that insulin action in the central nervous system inhibits food intake and reduces body fat in 
humans. It has been shown that peripherally injected insulin crosses the blood-brain barrier and 
contributes to the regulation of food intake and energy homeostasis (Tschritter et al 2007). 
Dysregulation of the CNS insulin receptor has also been associated with obesity and insulin 
resistance (Bruning et al. 2000). Importantly the specific role of insulin was further clarified 
following the brain specific deletion of the insulin receptor in mice. Deletion of the insulin receptor 
resulted in hyperphagia, obesity and metabolic insulin resistance (Tschritter et al. 2006).
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Increased brain responses to detemir when compared with human insulin have been studied in 
animals (Hennige et al. 2006) and humans (Tschritter et al. 2007; Rossetti et al. 2008; Tschritter et 
al. 2009). Insulin signalling in hypothalamic and cerebrocortical tissue as determined by tyrosine- 
phosphorylation of the IR and Irs2 proteins occurred faster with detemir when compared with 
human insulin in mice and higher concentrations of detemir than human insulin have been found in 
brain extracts indicating ease of transport across the blood brain barrier. Moreover, epidural EEG in 
mice also displayed increased cortical activity using insulin detemir when compared with human 
insulin (Hennige et al. 2006).
In 2010, Hallschmid investigated the relevance of enhanced central nervous detemir action in the 
regulation of food intake by assessing the effects of intravenous insulin detemir in comparison with 
human insulin on electroencephalography (EEG) direct current potentials during a euglycaemic 
clamp protocol. EEG direct current (DC) potentials are sensitive to changes in insulin concentration 
(Hallschmid et al. 2004). Differential effects on DC potential EEG were seen between insulin 
detemir and human insulin with an associated relative decrease in food consumption, supporting an 
enhanced anorexigenic effect from detemir (Hallschmid et al. 2010). In this study detemir was 
given intravenously. Intravenous insulin may act differently to subcutaneous insulin, which is the 
preferred method of insulin administration in people with type 1 diabetes. The study presented in 
this thesis shows that the marked negative shift in DC potential is still evident with clinically 
relevant doses of subcutaneous insulin. What this finding actually means with regards to human 
behaviour and weight is still uncertain.
The molecular mechanism underlying the greater action of insulin detemir in the brain is not 
understood but it is likely that it is related to the albumin binding or the novel method of protraction 
of insulin detemir. The capillary endothelial barrier in peripheral tissue may limit the transfer of 
detemir insulin from the circulation into the extravascular space. However, most studies have 
assumed that detemir would cross the blood brain barrier more easily than human insulin as when 
injected intravenously, insulin detemir has been shown to have a greater effect and more rapid 
effect on hypothalamic and cerebrocortical insulin receptor phosphorylation than human insulin 
(Hennige et al. 2006). Detemir is more lipophilic than human insulin and there is evidence that 
increasing lipophilicity can increase concentrations in the cerebrospinal fluid (Rossetti et al. 2008). 
It is also known that albumin easily penetrates the choroid plexus epithelial cells (Knott et al. 1997). 
Albumin is very low in the cerebrospinal fluid so there may be more unbound active detemir
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available to bind to the insulin receptor in the brain. Interestingly, a recent study in mice using 
radioactive iodine has suggested that detemir may in fact not cross the blood brain barrier (Banks et 
al. 2010). Suggesting that the brain effects seen with detemir could be due to lack of stimulation of 
the CNS insulin receptors rather than greater stimulation or detemir may simply block endogenous 
insulin from accessing the CNS. This has been disputed in the literature and what is evident is that 
further work in the field is still required to establish the exact mechanism.
Insulin detemir may also be more effective than human insulin in communicating satiety signals 
within the central nervous system. Interestingly, the negative shift in EEG DC potential observed 
by Hallschmid was also associated with reduced food intake suggesting that detemir had an 
enhanced anorexigenic impact on the central nervous system that controls nutrient uptake 
(Hallschmid et al. 2010). A lower intake of energy with detemir than with NPH has also been 
reported in patients with type 1 diabetes further supporting reduced food intake as a potential 
mechanism for the weight sparing effect (Zachariah et al. 2011). Detemir may mediate this effect 
directly in the brain or alternatively, by an indirect effect on satiety. Preliminary studies have also 
reported that the effect of human insulin on cerebrocortical activity is compromised in obese 
patients, whereas the effect of insulin detemir is enhanced (Hermansen and Davies. 2007).
It has also been postulated that insulin action in the brain plays an important role in the regulation 
of hepatic glucose production (Obici et al. 2002). The brain can sense circulating insulin levels 
(Davis et al. 1995). In addition, it provides neural input to the liver (La Fleur et al. 2000). The vagus 
nerve is the most important link between the gut, pancreas and liver to the brain and appears to be 
involved in the control of food intake (Berthoud 2008). The vagus nerve can modulate both insulin 
secretion from the pancreas and glucose metabolism in the liver following responses from the 
hypothalamus. The infusion of insulin in the third ventricle reduces hepatic glucose production 
independently of systemic concentrations of insulin (Obici et al. 2002). It is thought that the efferent 
neural pathway on the liver may be responsible for this reduction (Pocai et al. 2005). The efferent 
vagus nerves enhances hepatic glucose uptake directly by stimulating the parasympathetic 
innervation of the liver (Moore & Cherrington 1996) and reduces hepatic glucose production by 
inhibiting glycogenolysis rather than gluconeogenesis (Cardin et al. 2002) The indirect action of 
insulin on the hypothalamus and interaction with hepatic glucose production is of interest and 
warrants further investigation.
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7.5. Directions for the future
This is certainly an interesting field.
1. The study has shown that there is a marked difference in DC-potential using clinically relevant 
insulin but does this EEG DC-potential difference have a direct effect on human and behavioural 
activity? Incorporting FMRI or PET scanning into a protocol can be expensive but would provide 
direct information about behavioural activity.
2. It would also be of interest to further explore the relationship of EEG changes, satiety and 
glucose metabolism in patients with type 2 diabetes. People with type 2 diabetes have endogenous 
insulin production but are resistant to its actions. A hyperinsulinaemic euglycaemic clamp protocol 
with EGG monitoring plus functional MRI imaging in people with type 2 diabetes may add further 
information to this field of research and may be clinically helpful especially when deciding on the 
best treatment options for patients who are clinically obese and have type 2  diabetes.
It would also be interesting to observe changes in insulin action on the brain before and after weight 
loss following calorie restriction or weight loss intervention. There may be changes in glucose 
metabolism as well as brain fiinction.
3. The role of the vagus nerve is still uncertain but has a direct link between the brain and the 
periphery. Study the EGG differences seen with insulin detemir and NPH insulin in patient swho 
have undergone a vagotomy may provide further information into this complex relationship.
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Chapter 8. Conclusion
Identification of the pancreas as the origin of diabetes mellitus led eventually to the successful 
extraction and introduction of the active principle, insulin, in 1921. These developments have 
radically changed the management of type 1 diabetes. There have been major developments in 
insulin production, purification, pharmaceutical formulation, and methods of delivery. However, the 
persistence of microvascular and premature macrovascular complications as the main cause of 
morbidity and mortality in patients with diabetes is a constant reminder that our therapeutic and 
management strategies are for most patients inadequate.
Our current challenge in insulin treatment for diabetes, regardless of Type 1 and Type 2 diabetes, 
lies in the difficult balance between insufficient hyperglycemic control and the side effects of 
insulin treatment including hypoglycemia and weight gain.
Results from clinical trials have consistently shown insulin detemir to be associated with less 
weight gain and lower hypoglycaemic episodes compared with NPH insulin (Hollander 2012). 
Results presented here support evidence of a potential hepatoselective effect of insulin detemir. The 
decreased peripheral glucose uptake and reduced effects on adipose tissue shown with insuin 
detmeir when compared with NPH insulin may contribute to the reduction in hypoglycaemia and 
lower weight gain.
Another possible explanation of the lower weight gain is that insulin detemir facilitates the central 
nervous system mechanisms associated with satiety. The results highlight the rapid brain response 
to insulin detemir suggesting easier access across the blood brain barrier potentially enhancing the 
anorexigenic effects of insulin. Further potential clinical advantages of this phenomenon deserve 
exploration.
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1. Oral presentation Diabetes UK APC Manchester 14th March 2013.
The effects of subcutaneous insulin NPH on glucose metabolism following a period of insulin 
withdrawal in patients with type 1 diabetes.
Roselle Herring % Fariba Shojaee-Moradie^, Nieola Jackson^, Riehard Jones^, A.Margot Umpleby^ 
and David L Russell-Jones.^
1. C entre fo r Endocrino logy , D iabetes and  R esearch . R oyal Surrey  C ounty  H ospital. G uildford , U nited  K ingdom
2. D iabetes and M etabo lic  M edicine. U niversity  o f  Surrey, G uildford . U nited  K ingdom .
Aims:
The usual method for investigating the action of insulin on glucose metabolism is by a euglycaemic 
hyperinsulinaemic clamp. This serves to underestimate the vital physiological significance of 
hepatie insulin action. With the use of stable isotope technology we aimed to demonstrate the 
glucose lowering effect of subcutaneous NPH insulin following a period of insulin withdrawal in 
patients with type 1 diabetes.
Methods:
Twelve participants with type 1 diabetes were transferred to a soluble variable insulin infusion to 
maintain a blood glucose concentration of 5 mmol/1. A primed constant infusion of [6 ,6 -^H2 ]glucose 
was given. At isotopic steady state insulin was withdrawn and blood glucose allowed to increase to 
7mmol/l. Partieipants then received (0 minutes) a subcutaneous injection of NPH insulin at 0.5 
U/kg BW. Blood samples were taken for plasma glucose concentration and enriehment 
measurement at 20 minute intervals. The study was terminated when blood glueose level fell below 
5.0mmol/l or at 420 minutes after insulin administration.
Results:
Following NPH insulin plasma glucose eontinued to rise peaking at 10.25mmol/l±0.58 
(meaniSEM) at 62.27±7.76 minutes. As glucose concentration decreased endogenous glueose 
production declined rapidly firom 16.66±1.46 to 8.95±0.30 pmol/kg/min, and peripheral glucose 
uptake increased slightly before falling slowly from 12.09±0.74 to 11.47±0.26 pmol/kg/min.
Conclusions
The decline in plasma glueose following subeutaneous NPH resulted from suppression of 
endogenous glucose production and to a lesser extent from the stimulation of peripheral glucose 
uptake. Peripheral uptake of glucose was largely dependent on glucose eoncentration rather than 
stimulated by basal levels of peripheral plasma insulin.
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2. Poster Presentation. American Diabetes Association. Chicago. June 2013.
The effects of subcutaneous insulin NPH and detemir on glucose flux and lipolysis following a 
period of insulin withdrawal in patients with type 1 diabetes.
Roselle Herring\ Fariba Shojaee-Moradie^, Nicola Jackson^, Richard Jones^, A.Margot Umpleby^ 
and David L Russell-Jones.^
1. C en tre  fo r E ndocrinology, D iabetes and  R esearch . R oyal Surrey  C ounty  H ospital. G uildford , U nited  K ingdom
2. D iabetes and  M etabolic  M edicine. U niversity  o f  Surrey, G uildford . U nited  K ingdom .
Endogenous insulin secretion exposes the liver to insulin concentrations 2-3 times greater than 
peripheral tissues. Subcutaneous insulin delivery eliminates this gradient resulting in metabolic 
abnormalities. With the use of stable isotope technology we aimed to demonstrate the differential 
effeets of subcutaneous NPH and detemir on glueose flux and lipolysis following a period of insulin 
withdrawal in patients with type 1 diabetes.
Eleven participants were transferred to a soluble variable insulin infusion to maintain a blood 
glucose concentration of 5 mmol/1. A primed constant infusion of [6 ,6 -^H2 ]glucose was given. At 
isotopic steady state insulin was withdrawn and blood glucose allowed to increase to 7mmol/l. 
Participants were given in random order 0.5 Units/kg BW detemir or NPH. Blood samples were 
taken for plasma glucose eoneentration and enrichment and plasma NEFA concentrations. The 
study was terminated when blood glueose level fell below 5.0mmol/l or at 420 minutes after insulin 
administration.
Following administration of NPH or detemir plasma glucose eontinued to rise peaking at 
10.25mmol/l±0.58 (mean±SEM) at 62.27±7.76 minutes and 9.41±0.63 at_50.9±6.97 minutes, 
respeetively. As glucose concentration decreased suppression of endogenous glucose produetion 
was similar with NPH and detemir. Glucose Ra (pmol/kg/min;glucose concentration 9 to 6 mmol/l) 
was 8.20±0.48 to 6.27±0.62 and 8.2Ü0.86 to 5.79±0.46 respeetively. Stimulation of peripheral 
glucose uptake was greater with NPH insulin than with detemir. Glucose Rd (pmol/kg/min;glucose 
concentration 9 to 6 mmol/l) was 11.53±0.61 to 11.42±0.41 and 11.0±0.61 to 9.47±0.69 
respectively. Suppression of lipolysis was delayed with detemir compared to NPH, during the first 2 
hours plasma NEFA levels (mmol/1) decreased from 0.44±0.08 to 0.42±0.05 with NPH and 
increased from 0.35±0.05 to 0.68±0.08 with detemir. By 4 hours there was no differenee.
Detemir had a lesser effect on peripheral glucose uptake and delayed suppression of lipolysis 
providing evidenee that it acts preferentially in the liver when compared to NPH.
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